
<html lang="en"     class="pb-page"  data-request-id="4160ecc1-dad6-4873-82f3-1f4c74dbf3dd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00507;issue:issue:10.1021/jmcmar.2020.63.issue-19;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Creator" content="Jeff B.  Smaill" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="Clinically acquired resistance to small molecule kinase inhibitors (SMKIs) has become a major “unmet clinical need” in cancer therapy. To date, there are six SMKIs to be approved for the treatment ..." /></meta><meta name="Description" content="Clinically acquired resistance to small molecule kinase inhibitors (SMKIs) has become a major “unmet clinical need” in cancer therapy. To date, there are six SMKIs to be approved for the treatment ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 20, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00507" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00507" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00507" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00507" /></link>
        
    
    

<title>Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00507" /></meta><meta property="og:title" content="Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0013.jpeg" /></meta><meta property="og:description" content="Clinically acquired resistance to small molecule kinase inhibitors (SMKIs) has become a major “unmet clinical need” in cancer therapy. To date, there are six SMKIs to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations. These are mainly focused on the mutant kinases Bcr-Abl T315I, EGFR T790M, and ALK L1196M. Herein, we summarize the major medicinal chemistry strategies employed in the discovery of these representative SMKIs, such as avoiding steric hindrance, making additional interactions with mutated residues, and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors. Additionally, we also briefly describe allosteric kinase inhibitors and proteolysis targeting chimera (PROTAC) as two other potential strategies while addressing future opportunities in this area." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00507"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00507">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00507&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00507&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00507&amp;href=/doi/10.1021/acs.jmedchem.0c00507" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 10726-10741</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00352" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00523" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaoyun Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyun Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>X.L.: email, <a href="/cdn-cgi/l/email-protection#29455c51501b19181f6943475c074c4d5c074a47"><span class="__cf_email__" data-cfemail="92fee7eaeba0a2a3a4d2f8fce7bcf7f6e7bcf1fc">[email protected]</span></a>; phone, <a href="/cdn-cgi/l/email-protection#95beada3b8a7a5b8ada0a7a7a6a7a0ac">+86-20-85223259</a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeff B. Smaill</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeff B. Smaill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeff+B.++Smaill">Jeff B. Smaill</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ke Ding</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ke Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>K.D.: email, <a href="/cdn-cgi/l/email-protection#cca8a5a2aba7a98ca6a2b9e2a9a8b9e2afa2"><span class="__cf_email__" data-cfemail="5a3e33343d313f1a30342f743f3e2f743934">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00507&amp;href=/doi/10.1021%2Facs.jmedchem.0c00507" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 10726–10741</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 20, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 March 2020</li><li><span class="item_label"><b>Published</b> online</span>20 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10726%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaoyun%2BLu%252C%2BJeff%2BB.%2BSmaill%252C%2BKe%2BDing%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D19%26contentID%3Dacs.jmedchem.0c00507%26title%3DMedicinal%2BChemistry%2BStrategies%2Bfor%2Bthe%2BDevelopment%2Bof%2BKinase%2BInhibitors%2BTargeting%2BPoint%2BMutations%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10741%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00507"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4896</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00507" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;B. Smaill&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10726-10741&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00507&quot;},&quot;abstract&quot;:&quot;Clinically acquired resistance to small molecule kinase inhibitors (SMKIs) has become a major “unmet clinical need” in cancer therapy. To date, there are six SMKIs to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations. These are mainly focused on the mutant kinases Bcr-Abl T315I, EGFR T790M, and ALK L1196M. Herein, we summarize the major medicinal chemistry strategies employed in the discovery of these representative SMKIs, such as avoiding steric hindrance, making additional interactions with mutated residues, and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors. Additionally, we also briefly describe allosteric kinase inhibitors and proteolysis targeting chimera (PROTAC) as two other potential strategies while addressing future opportunities in this area.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00507&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00507" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00507&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00507" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00507&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00507" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00507&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00507&amp;href=/doi/10.1021/acs.jmedchem.0c00507" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00507" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00507" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26pmid%3D32432477%26genre%3Darticle%26aulast%3DLu%26date%3D2020%26atitle%3DMedicinal%2BChemistry%2BStrategies%2Bfor%2Bthe%2BDevelopment%2Bof%2BKinase%2BInhibitors%2BTargeting%2BPoint%2BMutations%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/jmcmar.2020.63.issue-19/20201008/jmcmar.2020.63.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Clinically acquired resistance to small molecule kinase inhibitors (SMKIs) has become a major “unmet clinical need” in cancer therapy. To date, there are six SMKIs to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations. These are mainly focused on the mutant kinases Bcr-Abl T315I, EGFR T790M, and ALK L1196M. Herein, we summarize the major medicinal chemistry strategies employed in the discovery of these representative SMKIs, such as avoiding steric hindrance, making additional interactions with mutated residues, and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors. Additionally, we also briefly describe allosteric kinase inhibitors and proteolysis targeting chimera (PROTAC) as two other potential strategies while addressing future opportunities in this area.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein kinases (simply referred to herein as kinases) are enzymes that transfer the terminal phosphate group of ATP to tyrosine, threonine, or serine residues of proteins. Such protein phosphorylation drives signal transduction in cells regulating a series of biological process, such as cell growth, differentiation, metastasis, homeostasis, and death.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Kinases have been intensively investigated as a major class of targets for drug discovery, accounting for 25–30% of all targets screened in the pharmaceutical industry. Since 2001, the FDA has approved 59 small molecule kinase inhibitors (SMKIs) leading to the emergence of the field of targeted drug therapy for cancer and other diseases (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00507/suppl_file/jm0c00507_si_001.pdf" class="ext-link">Table S1</a>),<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> resulting in greatly improved clinical outcomes for patients. Despite these encouraging clinical benefits, SMKIs are still faced with two critical challenges in both the clinical and experimental oncology settings.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> First, type I and type II SMKIs bind at the conserved ATP-binding pocket of the target kinase and therefore lack selectivity against other targets in the human kinome. Second, clinically acquired resistance to SMKIs generally occurs after 1–2 years of clinical use driven by secondary or tertiary kinase mutations (on-target mutations) or kinase bypass signaling (off-target resistance). This second phenomenon has become one of the most serious problems in cancer therapy.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Kinase on-target mutations have been found to most frequently occur at the so-called oncogene “gatekeeper” residue (e.g., Bcr-Abl T315I, EGFR T790M, and ALK L1196M mutations), a covalent binding site that drives inhibitor potency (e.g., EGFR C797S and BTK C481S mutations), and at residues on the “solvent-front” (e.g., ALK G1202R and ROS G2032R mutations). Among secondary mutations, the gatekeeper mutation is the most common, typically resulting in resistance by sterically impeding the binding of SMKIs. The challenges derived from on-target mutations have prompted medicinal chemists to design new generations of SMKIs that can override treatment-related drug resistance observed for existing agents.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SMKIs approved by the FDA from 2001 to May 2020. Examples that target kinase point mutations driving acquired resistance are colored in orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An analysis of the FDA-approved SMKIs indicates that there are currently six examples registered for the treatment of cancer that target clinically acquired resistance caused by kinase point mutations (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, colored orange). Ponatinib, first approved in 2012, has been shown to overcome clinically acquired resistance in chronic myeloid leukemia (CML) patients treated with imatinib induced by the Bcr-Abl T315I gatekeeper mutation.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Ceritinib was approved in 2014 as a second-generation ALK inhibitor for the treatment of non-small-cell lung cancer (NSCLC) patients who have developed acquired resistance to crizotinib through a number of resistance mutations, especially the ALK L1196M gatekeeper mutation. However, ceritinib does not overcome the ALK G1202R mutation, another common crizotinib resistance mutation observed in patients.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Lorlatinib, a macrocyclic third-generation ALK inhibitor, was discovered to overcome the ALK G1202R mutation and similarly positioned ROS1 G2032R resistance mutation detected in NSCLC patients treated with crizotinib, resulting in FDA approval in 2018.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Osimertinib, approved in 2015, is a third-generation wild type EGFR-sparing irreversible inhibitor of mutant forms of EGFR that overcomes acquired resistance observed in NSCLC patients caused by the EGFR T790M gatekeeper mutation.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, in EGFR-mutant NSCLC and BTK-mutant chronic lymphocytic leukemia (CLL), no drugs have been marketed for the treatment of osimertinib-resistant EGFR T790M/C797S mutations and ibrutinib-resistant BTK C481S mutation. Indeed, acquired drug resistance to SMKIs caused by on-target mutations like these is a very common paradigm and remains a major clinical challenge in cancer therapy.</div><div class="NLM_p last">The main mechanisms by which point mutations lead to drug resistance include (i) causing steric hindrance or electrical mismatch to decrease drug binding capability, (ii) increasing affinity of ATP for the ATP-binding domain, making it harder for the drug to compete for active site occupancy, (iii) disturbing a covalent bond formed between the inhibitor and the active site of the protein. In this review we summarized the major medicinal chemistry strategies for discovery of representative SMKIs which can overcome on-target point mutations that drive acquired resistance. Herein, we focus mainly on the successful clinically approved drugs that have addressed acquired resistance through optimization of existing drug classes using ingenious strategies including avoiding steric hindrance with mutated residues, making interactions with mutated residues, and forming covalent bonds with active site cysteines to override resistance observed for reversible inhibitor counterparts. Additionally, we also briefly describe allosteric kinase inhibitors and proteolysis targeting chimera (PROTAC) as two other potential strategies while addressing future opportunities in this area.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Medicinal Chemistry Strategies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Avoiding Steric Hindrance with the Mutated Residue</h3><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5">2.1.1.  Abl T315I</h4><div class="NLM_p">The Bcr-Abl fusion oncogene is constitutively active and crucial for malignant transformation in CML.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Abl tyrosine kinase inhibitors were subsequently developed as effective therapy for CML. Imatinib (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was the first approved SMKI for the treatment of CML,<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> pioneering the era of targeted drug therapy in oncology. However, emerging acquired resistance to imatinib has become a major challenge in the clinic. It has been observed that the occurrence of point mutations in the kinase domain of Abl is the primary mechanism for clinical resistance to imatinib.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Over 50 different Bcr-Abl point mutations have been reported from the genetic sequencing of clinical samples, among which the most common T315I gatekeeper mutation accounts for 15–20% of all acquired resistance.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> In this mutation, threonine is replaced by the larger and more lipophilic isoleucine residue. A protein X-ray crystal structure indicates that the T315I mutation leads to the loss of a fundamental hydrogen bond with the aminopyrimidine hinge-binding scaffold of imatinib and a steric clash with the imatinib methyl-substituted phenyl ring, diminishing the inhibitory potency of imatinib against this mutant variant (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref20">(18,20)</a> Unfortunately, the second generation of approved Bcr-Abl inhibitors, dasatinib, nilotinib and bosutinib, suffer from the same liability, having been found to be incapable of inhibiting the T315I gatekeeper mutation due to similar steric hindrance.<a onclick="showRef(event, 'ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref21">(19,21)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ponatinib was developed to avoid steric hindrance with gatekeeper Ile315 of Bcr-Abl T315I and overcome acquired resistance to imatinib. The T315I mutation leading to steric hindrance with imatinib is highlighted in blue spheres (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYY">2HYY</a>). The alkyne of ponatinib minimizes steric clash with Ile315 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3">3IK3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ponatinib (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), a third-generation Bcr-Abl inhibitor approved in 2012, was developed to overcome Bcr-Abl T315I resistance by using an alkyne linker connected to an imidazo[1,2-<i>b</i>]pyridazine core.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The detailed optimization process to develop this agent has been reviewed by our group.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Ponatinib exhibits excellent potency against the Bcr-Abl wild type kinase (IC<sub>50</sub> = 0.37 nM) and the T315I mutant (IC<sub>50</sub> = 2 nM), as well as other clinically relevant mutants in the Bcr-Abl kinase domain (IC<sub>50</sub> = 0.30–0.44 nM).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The key factor contributing to the high T315I mutant potency of ponatinib is the ability of the alkyne to avoid steric clash with Ile315 while maintaining the crucial remaining interactions with the Abl kinase domain.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> But it is also suggested that the small volume of alkyne leads to the kinase selectivity of ponatinib (selectivity entropy <i>S</i><sub>sel</sub> = 4) far worse than that of imatinib (<i>S</i><sub>sel</sub> = 0.8) in a panel of more than 300 kinase activity assays.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> To date, ponatinib is the only approved drug for the treatment of CML patients harboring a Bcr-Abl T315I mutation, although it was temporarily suspended in 2013 with noted occurrence of cardiovascular thrombotic side effects.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6">2.1.2.  ALK L1196M or G1202R</h4><div class="NLM_p">Anaplastic lymphoma kinase (ALK) has been identified as a validated target in oncology drug development after the discovery that two main fusion genes encoding the proteins EML4-ALK and NPM-ALK result in constitutively active ALK kinase activity driving oncogenic signaling in NSCLC and anaplastic large cell lymphoma (ALCL), respectively.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Significant efforts have been made over the past two decades to develop ALK inhibitors for the treatment of cancer. Crizotinib (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), a first-generation ALK, c-Met, and ROS1 inhibitor developed by Pfizer,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> gained FDA approval for the treatment of ALK-positive and ROS1-positive NSCLC in 2011 and 2016, respectively, bringing significant clinical benefit to patients.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Like imatinib, acquired resistance mediated by on-target mutations inevitably emerged during the clinical use of crizotinib. For ALK, the most frequent mutations appear at the gatekeeper L1196M, the solvent-front G1202R, the regulatory αC helix C1156Y and around the DFG motif G1269A.<a onclick="showRef(event, 'ref31 ref9'); return false;" href="javascript:void(0);" class="ref ref31 ref9">(31,9)</a> Second- and third-generation ALK inhibitors have been developed to overcome these resistance mutations.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Among them, ceritinib, alectinib, brigatinib, and lorlatinib have been successively approved by the FDA for the treatment of metastatic NSCLC harboring mutant forms of ALK (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The second-generation inhibitors ceritinib and alectinib effectively inhibit the majority of crizotinib-resistant mutations, especially the gatekeeper ALK L1196M mutation. The strategies used to optimize these second-generation ALK inhibitors will be described in further detail below. However, it has been demonstrated that they unfortunately cannot overcome the clinically important crizotinib-resistant G1202R solvent-front mutation.<a onclick="showRef(event, 'ref9 ref34'); return false;" href="javascript:void(0);" class="ref ref9 ref34">(9,34)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Lorlatinib is designed to avoid steric hindrance with gatekeeper Met1196 and solvent-front Arg1202 of ALK to overcome acquired resistance to crizotinib. The L1196M and G1202R mutations leading to steric hindrance with crizotinib are highlighted in blue spheres (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ANS">4ANS</a>). Lorlatinib demonstrates no steric clash with Met1196 and Gly1202 (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLJ">4CLJ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the ALK gatekeeper L1196M mutation, leucine is replaced by the more polar and sterically hindered methionine residue, leading to a loss of nonpolar van der Vaals interactions between the methyl substituent of crizotinib and the leucine residue while introducing a steric clash that interferes with crizotinib binding.<a onclick="showRef(event, 'ref31 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref35">(31,35)</a> The solvent-front G1202R mutation also causes a steric clash with the piperidine ring of crizotinib due to the increased bulk of the arginine residue of the mutant. In 2018, a third-generation macrocyclic ALK inhibitor, lorlatinib (<b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), was approved for the treatment of ALK-positive metastatic NSCLC resistant to crizotinib, ceritinib, and alectinib.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Lorlatinib was designed with a rigid amide-linked 12-membered macrocycle instead of the more linear crizotinib scaffold. It is a structural modification that eliminates steric hindrance with Met1196 and Arg1202 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref38 ref32'); return false;" href="javascript:void(0);" class="ref ref38 ref32">(38,32)</a> As expected, lorlatinib displays superior potency against all known clinically acquired ALK mutations, including the G1202R mutation, demonstrating an antiproliferative IC<sub>50</sub> of 77 nM against Ba/F3 cells expressing ALK G1202R. Moreover, lorlatinib shows excellent kinase selectivity and remarkable activity against ROS1 and the clinically acquired resistance mutations ROS1 G2032R and ROS1 L2026M.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Of note, lorlatinib has good blood–brain barrier (BBB) penetration and central nerve system (CNS) exposure leading to its use as an effective agent against neuroblastoma and metastatic brain cancer.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> An X-ray crystal structure of lorlatinib with ALK demonstrates that it forms two fundamental hydrogen bonds with Glu1197 and Met1199 and that the constrained macrocycle fits well in the ATP-binding site without any steric clashes (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">2.1.3.  TRKA G595R or G677C</h4><div class="NLM_p">Tropomyosin receptor kinases (TRKA, TRKB, and TRKC), activated by the neurotrophin family of growth factors, have been identified as effective therapeutic targets for a diverse but rare set of cancers harboring NTRK fusions or rearrangements.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Numerous TRK inhibitors have been developed,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> with larotrectinib (<b>5</b> [LOXO-101], <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) in particular being notable as the first SMKI to gain approval in a “tissue-agnostic” setting in 2018 (i.e., approval for the treatment of multiple different cancer indications that contain NTRK fusions).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In 2019, another multikinase inhibitor, entrectinib, also gained FDA approval for the treatment of ROS1-positive metastatic NSCLC and NTRK gene fusion-positive solid tumors.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. LOXO-195 and TPX-0005 are designed to avoid steric hindrance with Arg595 and Cys677 of TRKA and overcome acquired resistance to larotrectinib. The G595R and G667C mutations leading to steric hindrance with larotrectinib are highlighted in blue spheres (docking based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE">4YNE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the first-generation TRK inhibitors exhibit profound efficacy, acquired resistance invariably develops due to secondary mutations in the TRK kinase domain.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Like ALK and ROS1, it has been reported that the most frequent mutations in TRK are located at the solvent-front and near the DFG motif (G595R and G667C, respectively, for TRKA; G623R and G696A, respectively, for TRKC).<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Molecular modeling suggests that mutation of Gly595 to arginine (G595R) at the solvent-front introduces steric hindrance with the hydroxypyrrolidine group of larotrectinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Similarly, the glycine to cysteine G667C mutation close to the DFG motif increases steric hindrance with the difluorophenyl group of larotrectinib.</div><div class="NLM_p last">To overcome the aforementioned TRK resistance mutations, two macrocyclic compounds LOXO-195 (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) and TPX-0005 (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) were developed to introduce increased conformation rigidity compared to the larotrectinib scaffold and avoid steric clashes with Arg595 and Cys667.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> Molecular modeling indicated that LOXO-195 and TPX-0005 can occupy the ATP-binding site of mutated TRK without any steric impediments (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). LOXO-195 (selitrectinib) demonstrated low nanomolar inhibitory activity against TRK WT, G595R, and G667C mutants (IC<sub>50</sub> = 0.6–9.8 nM) and significant in vitro and in vivo efficacy in a range of cancer models dependent on wild type and mutant variants of TRKA. TPX-0005 (repotrectinib) can effectively inhibit the activity of ROS1 and ALK solvent-front and near-DFG mutants in addition to TRK and its mutant forms in vitro and in vivo. Both agents are under clinical evaluation as second generation TRK inhibitors for patients with advanced TRK fusion-positive cancers.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.2.  Making Interactions with the Mutated Residue</h3><div class="NLM_p">As described above, the second-generation ALK inhibitor ceritinib developed by Novartis was approved in 2014 for the treatment of ALK-positive NSCLC patients following progression on crizotinib.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Many of these patients present with acquired resistance due to the gatekeeper ALK L1196M mutation. Ceritinib was discovered following optimization of a 2,4-diaminopyrimidine-based high-throughput screening (HTS) hit with the purpose of improving the kinome selectivity and ADME properties of the class.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> It demonstrates potent biochemical inhibition of ALK and excellent antiproliferative activity against NSCLC cells harboring EML4-ALK L1196M and G1269A mutants (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref51 ref9'); return false;" href="javascript:void(0);" class="ref ref51 ref9">(51,9)</a> Of note, profiling of 280 kinases showed that ceritinib inhibits 16 kinases with a <i>S</i><sub>sel</sub> value of 2.6, indicating its selectivity is slightly better than that of crizotinib (<i>S</i><sub>sel</sub> = 2.7).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The cocrystal structure of ceritinib and ALK L1196M offers an explanation for the ability of ceritinib to maintain activity against this gatekeeper mutant. The chlorine substituent of the central aminopyrimidine ring of ceritinib is directed toward the small back pocket of the ATP-binding domain forming a hydrophobic interaction with Met1196 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). This differs significantly from crizotinib where the methyl group adjacent to the alkoxy linker suffers from steric interference with the Met1196 side chain. In contrast with lorlatinib, ceritinib is inactive against the solvent-front G1202R crizotinib-resistance mutation as it also experiences steric hindrance between the bulky and rigid tetrasubstituted phenyl group and Arg1202.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Ceritinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKC">4MKC</a>) is designed to make hydrophobic interactions with the ALK gatekeeper mutation Met1196 to overcome acquired resistance to crizotinib. Brigatinib is designed to make interactions with Met1196 and avoid steric hindrance with Arg1202 of ALK (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MX8">6MX8</a>). The ALK L1196M and G1202R mutations leading to steric hindrance with crizotinib are highlighted in blue spheres (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ANS">4ANS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ariad Pharmaceuticals has reported a third-generation ALK inhibitor, brigatinib (<b>9</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), a phosphine oxide-containing 2,4-diarylaminopyrimidine compound that exhibits greater potency than ceritinib against a broader range of acquired ALK mutants.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> Brigatinib is highly active against the ALK L1196M gatekeeper mutation with a biochemical IC<sub>50</sub> value of 1.7 nM. Further to this, it demonstrates potent antiproliferative activity against Ba/F3 cells harboring EML4-ALK L1196M with an IC<sub>50</sub> value of 41 nM. The chlorine substituent at the pyrimidine ring C5-position is predicted to form a hydrophobic interaction with Met1196 in a similar manner to that of ceritinib (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Unlike ceritinib, brigatinib maintains substantial activity against the ALK G1202R mutant with a biochemical IC<sub>5O</sub> value of 4.9 nM, although its antiproliferative potency in Ba/F3 EML4-ALK G1202R cells is less favorable (IC<sub>50</sub> = 184 nM).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> A comparison of the ceritinib and brigatinib ALK cocrystal structures suggests that the rotational flexibility of the brigatinib piperidinyl-piperazine hydrophilic moiety greatly reduces a steric clash with Arg1202, unlike the substituted phenyl group of ceritinib. The unique dimethylphosphine oxide and methoxy groups of brigatinib largely contribute to its improved potency and selectivity. In spite of this, its selectivity (<i>S</i><sub>sel</sub> = 3.3) is still worse than crizotinib (<i>S</i><sub>sel</sub> = 2.7) in 280 kinases profiling assay.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Brigatinib shows remarkable in vivo efficacy in mice against multiple NSCLC models driven by ALK wild type (WT) and mutant variants. It further demonstrates good CNS penetration. In 2017, brigatinib received accelerated approval from the FDA as a third-generation ALK inhibitor for the treatment of patients with ALK-positive metastatic NSCLC who are resistant or intolerant to crizotinib.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.3.  Forming a Covalent Bond with an Active Site Cysteine</h3><div class="NLM_p">Activating mutations in the epidermal growth factor receptor (EGFR) kinase domain (exon-21 L858R point mutation and exon-19 deletions) have been identified as oncogenic drivers for NSCLC.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> The first-generation small molecule EGFR inhibitors, gefitinib (<b>10</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and erlotinib, were approved by the FDA in 2003 and 2004 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), respectively, and have achieved significant clinical benefit for NSCLC patients with EGFR activating mutations.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> Unfortunately, the vast majority of patients progress after 9–14 months of treatment due to acquired point mutations in the EGFR kinase domain or up-regulation of bypass signaling pathways. Of note, the EGFR T790M gatekeeper mutation is one of the primary mechanisms of resistance identified in 55–70% of mutant EGFR NSCLC patients progressing on first-generation EGFR inhibitors.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> EGFR T790M mutation causes some loss of affinity of the inhibitors for the ATP-binding domain; however the dominant paradigm is an increase in affinity of ATP for the EGFR T790M active site (relative to the activating mutations) such that the first-generation reversible SMKIs are unable to compete with ATP efficiently at physiologically achievable concentrations.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> To overcome acquired resistance caused by the EGFR T790M mutation, second-generation irreversible EGFR inhibitors such as canertinib, pelitinib, neratinib, afatinib (<b>11</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), and dacomitinib were developed.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> These irreversible inhibitors contain a Michael acceptor group positioned to form a covalent bond with a cysteine (Cys797) at the solvent-front of the EGFR ATP-binding domain. This approach was anticipated to be less sensitive to ATP affinity and achieve greater ligand occupancy and suppression of kinase signaling than the first-generation reversible inhibitors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The second-generation inhibitors afatinib and dacomitinib were approved by the FDA in 2013 and 2018, respectively, for the treatment of NSCLC patients with EGFR activating mutations. The latter agent demonstrated superiority over gefitinib in this setting following a randomized phase III trial (ARCHER 1050).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Afatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P">4G5P</a>), WZ4002 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>), and osimertinib (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) are designed to form a covalent bond with cysteine 797 to overcome acquired resistance to gefitinib caused by the gatekeeper T790M mutation. The T790M mutation leading to gefitinib resistance is highlighted in blue spheres (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Cys797-chelating second-generation irreversible inhibitors displayed promising efficacy in overcoming the EGFR T790M gatekeeper mutation in preclinical models. However, it is now widely accepted that this activity can only be achieved at supraphysiological concentrations that are not possible in patients due to dose-limiting toxicities (DLTs) derived from potent inhibition of wild type EGFR in skin and gastrointestinal tissues.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> Indeed, recent reports indicate that EGFR T790M mutation is the major mechanism of acquired resistance to afatinib in NSCLC patients with EGFR activating mutations.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> To avoid “on-target” toxicity, third-generation EGFR inhibitors have been developed that irreversibly inhibit mutant forms of EGFR including the EGFR T790M variant while sparing wild type EGFR. The 4-aminopyrimidine WZ4002 (<b>12</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) was the first example reported, demonstrating good efficacy against EGFR L858R/T790M and EGFR Del19/T790M NSCLC models while being less potent against EGFR WT in vitro and in vivo.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> A crystal structure of WZ4002 bound to EGFR T790M indicates its T790M mutant-selectivity derives from its “U-shaped” binding conformation, lack of occupancy of the hydrophobic back-pocket, and a lipophilic interaction between the pyrimidine ring chorine substituent and the gatekeeper Met790 residue (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Unfortunately, WZ4002 failed to enter clinical development due to legal issues around the commercialization of the compound.</div><div class="NLM_p last">In 2015, osimertinib (<b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), with a similar aminopyrimidine scaffold to WZ4002, gained accelerated approved by the FDA for the treatment of NSCLC patients progressing on a first-generation EGFR inhibitor whose disease is positive for the EGFR T790M mutation. In 2018, osimertinib gained FDA approval as a first-line treatment for metastatic NSCLC patients harboring EGFR activating mutations.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Osimertinib displayed low nanomolar potency against PC9 NSCLC cells harboring the EGFR Del19 mutation (IC<sub>50</sub> = 17 nM) and H1975 NSCLC cells harboring the EGFR L858R/T790M mutation (IC<sub>50</sub> = 15 nM) while sparing LoVo cells expressing EGFR WT (IC<sub>50</sub> = 480 nM).<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a> Modeling studies suggested osimertinib also bound EGFR T790M in a “U-shaped” conformation with the acrylamide forming a covalent bond with Cys797 and the aminopyrimidine core forming two conserved hydrogen bonds with Met793 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The <i>N</i>-methylindole of osimertinib forms hydrophobic interactions with the gatekeeper Met790 residue, which may help explain the selectivity of osimertinib for EGFR L858R/T790M over EGFR WT. Additionally, chemical proteomics studies indicated that osimertinib achieves good selectivity within the kinome.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.4.  Overriding Resistance to Irreversible Inhibitors with Reversible Inhibitors</h3><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.4.1.  BTK C481S</h4><div class="NLM_p">Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase in the Tec family, is a critical effector molecule for B-cell development that has been identified as a validated target for B-cell lymphoproliferative disorders,<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> such as hematologic malignancies and chronic inflammatory diseases.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> More than a decade of research and development has seen several BTK inhibitors advance to clinical evaluation.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> Ibrutinib (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) is notable as a first-in-class example that was approved in 2013 by the FDA for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> Similar to the irreversible EGFR inhibitors that target EGFR Cys797, ibrutinib covalently binds the analogous Cys481 in the kinase domain of BTK.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Despite the remarkable efficacy of ibrutinib in the clinic, acquired resistance inevitably occurs, with the major cause of resistance having been identified as mutation of Cys481 to serine (C481S) resulting in disruption of inhibitor covalent binding.<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> Overcoming this resistance remains an unmet clinical need; however reversible ATP-competitive BTK inhibitors display promising potential to address acquired ibrutinib BTK C481S resistance.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Vecabrutinib, ARQ 531 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E4F">6E4F</a>), and GDC-0583 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI">5VFI</a>) are designed as reversible inhibitors of BTK to overcome acquired resistance to ibrutinib caused by the BTK C481S mutation. The BTK C481S resistance mutation is highlighted in blue ball and stick structures (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Currently available reversible BTK inhibitors, such as vecabrutinib, ARQ 531, and GDC-0583, do not rely upon covalent binding with Cys481 of BTK for inhibitory potency and therefore effectively retain potency against the acquired BTK C481S resistance mutation.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Vecabrutinib (<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), developed by Sunesis Pharmaceuticals, is a reversible inhibitor of BTK WT and the BTK C481S mutant with biochemical IC<sub>50</sub> values of 2.9 and 4.5 nM, respectively. Unlike ibrutinib, vecabrutinib has a good selectivity profile against the human kinome with off-target activity against only six other kinases including two Tec family members (ITK and TEC) and four non-Tec kinases. Of particular note, vecabrutinib does not inhibit EGFR, a common off-target hit for many BTK inhibitors. Vecabrutinib demonstrates favorable pharmacokinetic and toxicology profiles supporting sustained inhibition of BTK in vivo. It is currently under phase 1b/2 clinical investigation in patients with advanced B-cell malignancies, including those with a BTK C481S mutation (NCT03037645). ARQ 531 (<b>16</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), with a similar structural skeleton to ibrutinib, is an orally bioavailable ATP-competitive reversible inhibitor of BTK.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> ARQ 531 exhibits biochemical inhibition of BTK and BTK C481S with IC<sub>50</sub> values of 0.85 and 0.39 nM. However, in addition to inhibiting BTK, ARQ 531 also inhibits Src, TEK, and the TRK family of kinases. Preclinical studies demonstrate that ARQ 531 significantly inhibits CLL cell survival and suppresses BCR-mediated activation of the BTK C481S and PLCγ2 mutations. It is currently in phase 1/2 clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies (NCT03162536). A crystal structure of ARQ 531 bound to BTK demonstrates that it occupies the ATP-binding site of BTK without interacting with Cys481 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), which suggests that the BTK C481S mutation will not affect its binding. Similar to ibrutinib, the pyrrolopyrimidine scaffold of ARQ 531 forms hydrogen bonds with Glu475 and Met477 in the hinge region of BTK, while the phenoxyphenyl group occupies the back pocket of the ATP-binding site. Notably, the tetrahydropyranyl methanol group forms a hydrogen bond network with Asn484 mediated by one water molecule, which directs it toward solvent accessible space.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> GDC-0583 (<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), an aminopyridone-based compound developed by Genentech, is an orally bioavailable and highly selective reversible BTK inhibitor that binds to the ATP-binding site of BTK without interacting with Cys481.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Preclinical studies suggested GDC-0853 possesses a favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile and effectively suppresses B-cell and myeloid cell-mediated disease models in vitro and in vivo.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Currently, GDC-0853 (fenebrutinib) is under phase 1 clinical investigation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma or chronic lymphocytic leukemia, including patients with a BTK C481S mutation (NCT01991184). GDC-0853 is in phase 2 clinical trial for patients with rheumatoid arthritis (NCT02833350). In addition, it has been suggested that GDC-0853 may have potential to overcome acquired resistance to ibrutinib caused by common BTK gatekeeper mutations (e.g., T474I and T474M) because its binding mode does not generate any steric hindrance with the gatekeeper residue.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div></div><div id="sec2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.4.2.  EGFR C797S</h4><div class="NLM_p">The Cys797-chelating third-generation irreversible EGFR inhibitors effectively overcome the gatekeeper T790M mutation and demonstrate great clinical benefit. Unfortunately, acquired resistance ultimately emerges in NSCLC patients through a tertiary Cys797 to serine (C797S) point mutation that disturbs covalent binding between the irreversible inhibitor and EGFR.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Indeed, the C797S mutation has become a leading mechanism of clinically acquired resistance in about 40% of patients treated with osimertinib.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Similar to the strategy outlined for BTK C481S mutation, selective ATP-competitive reversible EGFR inhibitors (defined as fourth-generation EGFR inhibitors) display promising potential to overcome acquired C797S resistance.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> However, most current candidates are in the early preclinical phase and either lack selectivity over wild-type EGFR or lack in vivo potency. Recently, Boehringer Ingelheim reported a rigid macrocyclic compound, BI-4020 (<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), based on the lead compound <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), employing a restricted conformation strategy similar to that described above for LOXO-195 and TPX-0005 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Although it is reported that the lead compound <b>19</b> was identified from an HTS approach, based on structural similarities, it could be argued that conceptually it represents a reversible analog of the third-generation EGFR inhibitor nazartinib (<b>18</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Biochemical and cellular assays demonstrate that BI-4020 effectively inhibits the EGFR T790M and C797S mutations and shows good efficacy in an osimertinib-resistant PC9 NSCLC xenograft model harboring the EGFR Del19/T790M/C797S triple mutant. Most recently, Eck et al. revealed that the noncovalent inhibitors of EGFR L858R/T790M/C797S, such as trisubstituted imidazoles or <b>19</b>, overcome the C797S mutation through stabilization of the inactive kinase state anchored by forming a direct hydrogen bond with Lys745.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> BI-4020 restricted its conformational space to the “active conformation” by means of macrocyclization, thus obtaining strong potency against EGFR L858R/T790M/C797S. Although BI-4020 has not entered clinical studies, its discovery demonstrates that reversible binding inhibitors may serve as a potential strategy to overcome EGFR C797S resistance mutations.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. BI-4020 is designed as a reversible fourth-generation EGFR inhibitor to overcome osimertinib/nazartinib acquired resistance caused by the EGFR C797S mutation based on the lead <b>19</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a>). The binding mode of nazartinib and BI-4020 with EGFR T790M is demonstrated with crystal structures of close nazartinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FEE">5FEE</a>) and BI-4020 analogs (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D">6S9D</a>), respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To overcome acquired resistance to osimertinib, our group has reported a series of 5-methylpyrimidopyridone derivatives as selective reversible EGFR L858R/T790M/C797S inhibitors based on the irreversible EGFR L858R/T790M inhibitor <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The representative compound <b>23</b> exhibited a biochemical IC<sub>50</sub> of 27.5 nM against the EGFR L858R/T790M/C797S mutant while sparing EGFR WT with an IC<sub>50</sub> value of greater than 1.0 μM. The X-ray crystal structure of <b>23</b> and EGFR T790M/C797S demonstrated that it binds reversibly at the ATP-binding site of EGFR with a U-shaped configuration. Notably, the 5-methyl substituent of <b>23</b> is directed toward Met790 forming a hydrophobic interaction, contributing greatly to the EGFR T790M/C797S selectivity (over EGFR WT).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>23</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ">6JRJ</a>) is designed as a reversible EGFR T790M/C797S inhibitor, based on the reported irreversible EGFR T790M inhibitor <b>22</b>, to overcome acquired resistance to osimertinib caused by the C797S mutation. The ability of the C797S mutation to disturb covalent binding of osimertinib is highlighted in blue ball and stick structures (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">3.  Alternative Approaches</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.1.  Override ATP-Binding Site Mutations with Allosteric Inhibitors</h3><div class="NLM_p">Allosteric kinase inhibitors, such as type III and type IV, are defined as inhibitors that bind to an allosteric site outside the conserved ATP-binding pocket that demonstrate no direct interaction with the hinge region of a kinase. In addition to the aforementioned specifically designed ATP-competitive inhibitors, allosteric kinase inhibitors have also become an effective strategy to overcome acquired resistance of traditional ATP-competitive inhibitors.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> Two examples of clinically important targets with well-researched allosteric inhibitors, Bcr-Abl and EGFR, are discussed in this review. The development of allosteric inhibitors (type IV) that bind to the myristoyl pocket of Abl kinase in the C-terminal domain represents a promising strategy to overcome clinically acquired resistance to imatinib caused by mutations in the ATP-binding site. ABL001 (<b>26</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), a potent and specific allosteric Abl kinase inhibitor discovered through hit-to-lead optimization of the GNF-2 and GNF-5 series (<b>24</b> and <b>25</b>, respectively, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>),<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> mimics the myristate substrate, binding to Abl kinase with a <i>K</i><sub>d</sub> value of 0.5–0.8 nM.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> ABL001 exhibits low nanomolar inhibition of all catalytic ATP-binding site mutations in Bcr-Abl including the gatekeeper T315I mutation. Notably, combination of ABL001 with ATP-competitive Abl inhibitors (such as nilotinib and ponatinib) not only effectively suppresses the emergence of resistance caused by secondary mutations in the ATP-binding site but also overcomes resistance observed to ABL001 caused by mutations within or near the allosteric myristoyl-binding pocket.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a> ABL001 (asciminib) is currently in clinical trials for the treatment of CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) as a single-agent and in combination with imatinib (NCT03106779 and NCT03578367, respectively).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Allosteric Abl kinase inhibitors <b>24</b>–<b>26</b> bind to the myristoyl pocket of Abl kinase and are considered as an effective strategy to overcome acquired resistance to imatinib caused by mutations in the ATP-binding domain of Bcr-Abl. An X-ray crystal structure of ABL001 (orange) and imatinib (pink) bound with Abl kinase is shown (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MO4">5MO4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similar to the strategy described for Bcr-Abl, the development of allosteric inhibitors that bind to a site adjacent to the ATP-binding pocket of EGFR, known as the MEK1/2 type III inhibitor (MT3) site (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), represents another potential solution to overcome acquired resistance to osimertinib caused by the EGFR T790M/C797S mutation. Two representative compounds, JBJ-04-125-02 (<b>27</b>)<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100,101)</a> and dibenzodiazepinone <b>28</b>,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> discovered as allosteric EGFR inhibitors following HTS approaches, exhibit subnanomolar to single-digit nanomolar potency against the EGFR L858R/T790M and EGFR L858R/T790M/C797S mutants in biochemical assays. Notably, JBJ-04-125-02 potently inhibits cell proliferation and EGFR L858R/T790M/C797S signaling in vitro and in vivo as a single agent. In addition, combination of osimertinib and JBJ-04-125-02 provides a significant increase in efficacy when compared with either single-agent treatment.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> However, JBJ-04-125-02 is not active against EGFR Del19/T790M/C797S mutants. Dibenzodiazepinone <b>28</b> exhibits high selectivity in kinome profiling assays but weak cellular activity that can be improved through combination with the EGFR-targeted antibody cetuximab. Further optimization of this class is required to produce an allosteric inhibitor with improved single-agent cellular activity and ideal physicochemical properties. Nevertheless, these studies demonstrate that allosteric inhibitors of EGFR represent a promising potential strategy to combat clinically acquired osimertinib EGFR resistance mutations.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Allosteric EGFR inhibitors <b>27</b> and <b>28</b> bind to the MT3 pocket of EGFR and represent promising strategies to overcome acquired resistance to osimertinib. An X-ray crystal structure of JBJ-04-125-02 (orange) and ATP (pink) bound with EGFR T790M is shown (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUK">6DUK</a>). The ability of the C797S mutation to disturb covalent binding of osimertinib is highlighted in blue ball and stick structures (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.2.  Induced Degradation of Mutant Kinase Variants</h3><div class="NLM_p">Unlike traditional small molecule inhibitors, PROTACs function by directly degrading a target protein of interest (POI) via the ubiquitin-proteasome system (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). PROTACs featured a bifunctional small molecule that can bind a POI and then recruit an E3-ligase. PROTAC-induced degradation is iterative and therefore less susceptible to increases in target expression or mutations than traditional small molecules, providing a new strategy to overcome acquired resistance due to on-target mutations.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> Among the reported kinase PROTACs, only BTK degraders demonstrate high efficiency for drug-resistant mutant targets. The representative BTK degrader, L181 (<b>29</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), reported in 2018,<a onclick="showRef(event, 'ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref105 ref106">(105,106)</a> comprising an ibrutinib BTK-binding scaffold and a lenalidomide E3-ligase recruiting ligand connected by a polyethylene glycol (PEG) linker, efficiently degrades wild type and clinically relevant BTK mutants (C481S/T/G/W/A) with DC<sub>50</sub> values ranging from 18 to 41 nM. L181 potently inhibits the proliferation of ibrutinib-resistant diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells expressing the BTK C481S mutant. More importantly, L181 with a favorable toxicity profile and improved solubility over earlier examples showed potent in vivo antitumor efficacy in mice bearing HBL-1 xenografts that express the BTK C481S mutant. In the same year, a BTK degrader closely related in structure to L181, termed MT-802 (<b>30</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>),<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> was reported by Craig Crews’ laboratory to effectively degrade wild type and C481S mutant BTK with DC<sub>50</sub> values of 14.6 and 14.9 nM, respectively. Moreover, MT-802 effectively inhibited the phosphorylated form of the BTK C481S mutant in primary cells derived from CLL patients. However, MT-802 has not undergone in-depth in vivo studies due to poor pharmacokinetic properties. Structurally more distinct than the aforementioned BTK degraders, Nathanael Gray’s group has reported DD-03-171 (<b>31</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) as a potential BTK PROTAC.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The design of DD-03-171 is based on the reversible BTK inhibitor CGI1746 linked to the E3-ligase ligand, thalidomide, through a hydrocarbon chain.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> DD-03-171 efficiently induced BTK C481S degradation and inhibited the proliferation of MCL cells with an IC<sub>50</sub> value of 5.1 nM. Further, DD-03-171 effectively reduced tumor burden and extended survival in mice bearing PDX models of lymphoma. Outside the field of BTK, a Bcr-Abl PROTAC known as SIAIS178 has also been reported to degrade some clinically relevant mutants, such as the Bcr-Abl G250E/V299L/F317L(V) mutants. This agent however could not induce degradation of the common Bcr-Abl T315I gatekeeper mutation.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Nevertheless, the use of PROTACs to catalyze degradation of clinically acquired kinase mutant-variants may indeed provide an effective approach to overcome drug resistance caused by on-target point mutations.<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111,112)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Representative BTK PROTACs <b>29</b>–<b>31</b> targeting the BTK C481S mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">4.  Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Clinically acquired resistance to SMKIs represents a major challenge for current targeted cancer therapy. This has prompted medicinal chemists to design new generations of SMKI to override this resistance. On the basis of an understanding of the mechanism of acquired resistance induced by on-target mutations in the kinase domain, like common gatekeeper mutations, covalent binding site mutations, and solvent-front mutations, there are six SMKIs that have seen FDA approval with many other examples currently under clinical evaluation. The major medicinal chemistry approaches employed for the discovery of these representative SMKIs focused largely on optimization of existing drug scaffolds. Strategies include avoiding steric hindrance with the mutated residue, making interactions with the mutated residue, and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors. Briefly, ponatinib and lorlatinib, designed based on the respective first-generation inhibitors imatinib and crizotinib, avoid steric hindrance with gatekeeper mutations in Bcr-Abl and ALK. Ceritinib and brigatinib are designed to form hydrophobic interactions specifically with the ALK Met1196 gatekeeper mutation to overcome resistance to crizotinib. Osimertinib is designed to form a covalent bond with EGFR Cys797 to overcome acquired resistance to gefitinib and erlotinib caused by the EGFR T790M gatekeeper mutation. The BTK inhibitors vecabrutinib, ARQ 531, and GDC-0583 and the representative EGFR inhibitor BI-4020 are reversible inhibitors designed to overcome ibrutinib and osimertinib acquired resistance, respectively, induced through a cysteine to serine mutation. Although these latter inhibitors are still in clinical studies, they provide a very promising and powerful approach to overcome active site cysteine mutation.</div><div class="NLM_p last">Despite tremendous progress, some opportunities and challenges remain to be addressed. First, with the increasing number of approved SMKIs, many other kinase point mutations have been identified as common causes of clinically acquired drug resistance. For many of these, such as FLT3 F691L/I and C-Kit T670I,<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113,114)</a> there are no effective drugs reported to be in clinical trial. The medicinal chemistry strategies described herein may warrant consideration for their potential to be extended to these mutant kinases enabling the discovery of new generations of inhibitor. Second, each generation of kinase inhibitor inevitably demonstrates acquired resistance induced by point mutations, and these mutations are usually centralized around the ATP-binding pocket. Therefore, it is suggested that the use of an allosteric kinase inhibitor in combination with an ATP-binding site inhibitor (of the same kinase) or the use of a PROTAC strategy may effectively overcome or reduce acquired resistance due to on-target mutations. However, on-target mutation is not the only mechanism of clinically acquired SMKI resistance. Other mechanisms include the activation of alternative signaling pathways (bypass signaling), phenotypic alterations, and target amplification or overexpression. Combination of SMKIs with other kinase inhibitors and conventional chemotherapeutic agents is also a promising strategy for combating drug resistance. Nevertheless, the strategies reviewed herein provide a solid foundation for the discovery of new generations of kinase inhibitor to overcome resistance caused by on-target mutations.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00507" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14467" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14467" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00507?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00507</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Approved SMKIs including chemical structures, targets, indications, companies, and registered years (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00507/suppl_file/jm0c00507_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00507/suppl_file/jm0c00507_si_001.pdf">jm0c00507_si_001.pdf (174.51 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00507" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7931-6873" title="Orcid link">http://orcid.org/0000-0001-7931-6873</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5f332a27266d6f6e691f35312a713a3b2a713c317f746769726d6f72676a6d6d6c6d6a66"><span class="__cf_email__" data-cfemail="e08c959899d2d0d1d6a08a8e95ce858495ce838e">[email protected]</span> +86-20-85223259</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Discovery of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9df9f4f3faf6f8ddf7f3e8b3f8f9e8b3fef3"><span class="__cf_email__" data-cfemail="57333e39303c32173d392279323322793439">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff B. Smaill</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Xiaoyun Lu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=BIO-d7e1189-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiaoyun Lu</b> is a Professor of Medicinal Chemistry at Jinan University in Guangzhou. She studied Medicinal Chemistry at China Pharmaceutical University and received her Ph.D. in 2010. After working 6 years at GIBH, she moved to the School of Pharmacy at Jinan University in 2016. Her research interests include the design of novel inhibitors of protein kinase involved in targeting lung disease. She has been involved in the design and development of Bcr-Abl, EGFR, and DDRs inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Jeff B. Smaill</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=BIO-d7e1194-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jeff B. Smaill</b> is an Associate Professor at the University of Auckland and an Associate Investigator of the Maurice Wilkins Centre (a New Zealand CoRE). He completed his Ph.D. in Organic Chemistry at the University of Otago in 1992 and conducted his postdoctoral training at the University of Cambridge. His research interests include the discovery of novel small molecule covalent kinase inhibitors and hypoxia-activated prodrugs. He has been involved in the design and development of canertinib, dacomitinib, and tarloxotinib.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Ke Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=BIO-d7e1199-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ke Ding</b> is a Professor of Medicinal Chemistry at Jinan University in Guangzhou. He studied Organic Chemistry at Fudan University and received his Ph.D. in 2001. He worked as a postdoctoral fellow at University of Michigan, Ann Arbor. After working for 5 years, he joined GIBH. In 2016, he moved to the School of Pharmacy at Jinan University. His research focuses on design and synthesis of bioactive inhibitors of kinase for novel drug discovery. He has successfully developed two drug-like inhibitors of kinase into clinic.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors appreciate the financial support from National Natural Science Foundation of China (Grants 81922062 and 81874285), National Key Research and Development Program of China (Grant 2018YFE0105800), Guangdong Provincial Science and Technology program (Grant 2018A050506043), Jinan University, Health Research Council of New Zealand (Grant 18/1016), and Cancer Society Auckland Northland.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">SMKI</td><td class="NLM_def"><p class="first last">small molecule kinase inhibitor</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large cell lymphoma</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nerve system</p></td></tr><tr><td class="NLM_term">TRK</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">Ph+</td><td class="NLM_def"><p class="first last">Philadelphia chromosome-positive</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">MT3</td><td class="NLM_def"><p class="first last">MEK1/2 type III inhibitor</p></td></tr><tr><td class="NLM_term">POI</td><td class="NLM_def"><p class="first last">protein of interest</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 114 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudarsanam, S.</span></span> <span> </span><span class="NLM_article-title">The Protein Kinase Complement of the Human Genome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5600</span>),  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1126/science.1075762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&issue=5600&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+Protein+Kinase+Complement+of+the+Human+Genome&doi=10.1126%2Fscience.1075762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0li7yuq8HnsDnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520Protein%2520Kinase%2520Complement%2520of%2520the%2520Human%2520Genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5600%26spage%3D1912%26epage%3D1934%26doi%3D10.1126%2Fscience.1075762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span> <span> </span><span class="NLM_article-title">Catalytic Mechanisms and Regulation of Protein Kinases</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>548</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-397918-6.00001-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2FB978-0-12-397918-6.00001-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25399640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Onu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2014&pages=1-21&author=Z.+Wangauthor=P.+A.+Cole&title=Catalytic+Mechanisms+and+Regulation+of+Protein+Kinases&doi=10.1016%2FB978-0-12-397918-6.00001-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic mechanisms and regulation of protein kinases</span></div><div class="casAuthors">Wang, Zhihong; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">Protein Kinase Inhibitors in Research and Medicine</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Protein kinases transfer a phosphoryl group from ATP onto target proteins and play a crit. role in signal transduction and other cellular processes.  Here, we review the kinase kinetic and chem. mechanisms and their application in understanding kinase structure and function.  Aberrant kinase activity has been implicated in many human diseases, in particular cancer.  We highlight applications of technologies and concepts derived from kinase mechanistic studies that have helped illuminate how kinases are regulated and contribute to pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHXE76kfXQ4LVg90H21EOLACvtfcHk0li7yuq8HnsDnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Onu7nJ&md5=1f9dfeabf33b69658eb0eadaad6606c3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-397918-6.00001-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-397918-6.00001-X%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DCatalytic%2520Mechanisms%2520and%2520Regulation%2520of%2520Protein%2520Kinases%26jtitle%3DMethods%2520Enzymol.%26date%3D2014%26volume%3D548%26spage%3D1%26epage%3D21%26doi%3D10.1016%2FB978-0-12-397918-6.00001-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Kinase Inhibitors: an Analysis of FDA-Approved Drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&issue=1&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small+Molecule+Kinase+Inhibitors%3A+an+Analysis+of+FDA-Approved+Drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0lhXWxeHJhX3jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall%2520Molecule%2520Kinase%2520Inhibitors%253A%2520an%2520Analysis%2520of%2520FDA-Approved%2520Drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D1%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-Approved Small-Molecule Kinase Inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&issue=7&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-Approved+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lhXWxeHJhX3jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-Approved%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26issue%3D7%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caivano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>351</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&issue=1&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+Mechanism+of+Action+of+Some+Commonly+Used+Protein+Kinase+Inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0lgh5LZg7pxAEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520Mechanism%2520of%2520Action%2520of%2520Some%2520Commonly%2520Used%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26issue%3D1%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Understanding and Targeting Resistance Mechanisms in NSCLC</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc.2017.84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29068003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtl2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=637-658&issue=11&author=J.+Rotowauthor=T.+G.+Bivona&title=Understanding+and+Targeting+Resistance+Mechanisms+in+NSCLC&doi=10.1038%2Fnrc.2017.84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding and targeting resistance mechanisms in NSCLC</span></div><div class="casAuthors">Rotow, Julia; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">637-658</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  In this Review, we discuss alterations in the targeted oncogene ('on-target' resistance) and in other downstream and parallel pathways ('off-target' resistance) leading to resistance to targeted therapies in NSCLC, and we provide an overview of the current understanding of the bidirectional interactions with the tumor microenvironment that promote therapeutic resistance.  We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins.  Finally, we discuss how understanding these themes can inform therapeutic strategies, including combination therapy approaches, and overcome the challenge of tumor heterogeneity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDDpt7GHS9PbVg90H21EOLACvtfcHk0lgh5LZg7pxAEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtl2rtw%253D%253D&md5=f8ee7b5e94a150d4f14d3d243954ce34</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.84%26sid%3Dliteratum%253Aachs%26aulast%3DRotow%26aufirst%3DJ.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DUnderstanding%2520and%2520Targeting%2520Resistance%2520Mechanisms%2520in%2520NSCLC%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D11%26spage%3D637%26epage%3D658%26doi%3D10.1038%2Fnrc.2017.84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1002/anie.201710398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fanie.201710398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2307-2313&issue=9&author=J.+Lategahnauthor=M.+Keulauthor=D.+Rauh&title=Lessons+To+Be+Learned%3A+The+Molecular+Basis+of+Kinase-Targeted+Therapies+and+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1002%2Fanie.201710398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2313</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The treatment of non-small cell lung cancer (NSCLC) is currently experiencing a revolution.  Over the last decade, the knowledge gained about the biochem. features of biomarkers and their predictive abilities has led to the development of targeted small-mol. inhibitors that present an alternative to harsh chemotherapy.  The use of these new therapies has improved the quality of life and increased the survival of patients.  The occurrence of inevitable drug resistance requires the const. development of precision medicine.  The detailed understanding of the target biol. and the search for innovative chem. approaches has encouraged investigations in this field.  Herein, the authors review selected aspects of the mol. targets and present an overview of current topics and challenges in the rational development of small mols. to target NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowadpmmNyvGbVg90H21EOLACvtfcHk0lgh5LZg7pxAEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D&md5=78d3ce523d076c820cb7fcbf9a321e63</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710398%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DLessons%2520To%2520Be%2520Learned%253A%2520The%2520Molecular%2520Basis%2520of%2520Kinase-Targeted%2520Therapies%2520and%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26issue%3D9%26spage%3D2307%26epage%3D2313%26doi%3D10.1002%2Fanie.201710398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span> <span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0ljpX2jQzMS_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagitani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&issue=6&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.-Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+Inhibitor+Ceritinib+Overcomes+Crizotinib+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0li_hPp2KU6DfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520Inhibitor%2520Ceritinib%2520Overcomes%2520Crizotinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D6%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span> <span> </span><span class="NLM_article-title">PF-06463922 is a Potent and Selective Next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib Resistant ROS1 Mutations</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3498</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420785112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1073%2Fpnas.1420785112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25733882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3493-3498&issue=11&author=H.+Y.+Zouauthor=Q.+Liauthor=L.+D.+Engstromauthor=M.+Westauthor=V.+Applemanauthor=K.+A.+Wongauthor=M.+McTigueauthor=Y.-L.+Dengauthor=W.+Liuauthor=A.+Broounauthor=S.+Timofeevskiauthor=S.+R.+P.+McDonnellauthor=P.+Jiangauthor=M.+D.+Falkauthor=P.+B.+Lappinauthor=T.+Affolterauthor=T.+Nicholsauthor=W.+Huauthor=J.+Lamauthor=T.+W.+Johnsonauthor=T.+Smealauthor=A.+Charestauthor=V.+R.+Fantin&title=PF-06463922+is+a+Potent+and+Selective+Next-Generation+ROS1%2FALK+Inhibitor+Capable+of+Blocking+Crizotinib+Resistant+ROS1+Mutations&doi=10.1073%2Fpnas.1420785112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Engstrom, Lars D.; West, Melissa; Appleman, Vicky; Wong, Katy A.; McTigue, Michele; Deng, Ya-Li; Liu, Wei; Brooun, Alexei; Timofeevski, Sergei; McDonnell, Scott R. P.; Jiang, Ping; Falk, Matthew D.; Lappin, Patrick B.; Affolter, Timothy; Nichols, Tim; Hu, Wenyue; Lam, Justine; Johnson, Ted W.; Smeal, Tod; Charest, Al; Fantin, Valeria R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3493-3498</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Oncogenic c-ros oncogene 1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy.  The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clin. activity in ROS1 fusion-pos. non-small cell lung cancer.  However, emerging clin. evidence has shown that patients can develop resistance by acquiring secondary point mutations in ROS1 kinase.  In this study the authors characterized the ROS1 activity of PF-06463922, a novel, orally available, CNS-penetrant, ATP-competitive small-mol. inhibitor of ALK/ROS1.  In vitro, PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1G2032R mutation and the ROS1G2026M gatekeeper mutation.  Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase.  A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable interactions contributing to the high-affinity binding.  In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1G2032R mutation.  Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.  Taken together, the authors' results indicate that PF-06463922 has potential for treating ROS1 fusion-pos. cancers, including those requiring agents with CNS-penetrating properties, as well as for overcoming crizotinib resistance driven by ROS1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5t2o5BKPhK7Vg90H21EOLACvtfcHk0li_hPp2KU6DfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D&md5=8f549572dfac12c74b88705d57979c09</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420785112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420785112%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%2BP.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DCharest%26aufirst%3DA.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26atitle%3DPF-06463922%2520is%2520a%2520Potent%2520and%2520Selective%2520Next-Generation%2520ROS1%252FALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520Crizotinib%2520Resistant%2520ROS1%2520Mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26issue%3D11%26spage%3D3493%26epage%3D3498%26doi%3D10.1073%2Fpnas.1420785112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgzwE43rb17Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Etten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltimore, D.</span></span> <span> </span><span class="NLM_article-title">Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr/abl Gene of the Philadelphia Chromosome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>247</i></span> (<span class="NLM_issue">4944</span>),  <span class="NLM_fpage">824</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1126/science.2406902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.2406902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=2406902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFaqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=824-830&issue=4944&author=G.+Daleyauthor=R.+Van+Ettenauthor=D.+Baltimore&title=Induction+of+Chronic+Myelogenous+Leukemia+in+Mice+by+the+P210bcr%2Fabl+Gene+of+the+Philadelphia+Chromosome&doi=10.1126%2Fscience.2406902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Phildelphia chromosome</span></div><div class="casAuthors">Daley, George Q.; Van Etten, Richard A.; Baltimore, David</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">4944</span>),
    <span class="NLM_cas:pages">824-30</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">In tumor cells from virtually all patients with chronic myelogenous leukemia, the Philadelphia chromosome, a fusion of chromosomes 9 and 22, directs the synthesis of the P210bcr/abl protein.  The protein-tyrosine kinase activity and hybrid structure of P210bcr/abl are similar to the oncogene product of the Abelson murine leukemia virus, P160gag/v-abl, which induces acute lymphomas.  To det. whether P210bcr/abl can induce chronic myelogenous leukemia, murine bone marrow was infected with a retrovirus encoding P210bcr/abl and transplanted into irradiated syngeneic recipients.  Transplant recipients developed several hematol. malignancies; prominent among them was a myeloproliferative syndrome closely resembling the chronic phase of human chronic myelogenous leukemia.  Tumor tissue from diseased mice harbored the provirus encoding P210bcr/abl.  These results demonstrate that P210bcr/abl expression can induce chronic myelogenous leukemia.  Retrovirus-mediated expression of the protein provides a murine model system for further anal. of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsvVgj_mQk5rVg90H21EOLACvtfcHk0liFf4K2CYO0Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFaqs7c%253D&md5=6f36223545c27d509c8ff075de8eb4ca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.2406902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2406902%26sid%3Dliteratum%253Aachs%26aulast%3DDaley%26aufirst%3DG.%26aulast%3DVan%2BEtten%26aufirst%3DR.%26aulast%3DBaltimore%26aufirst%3DD.%26atitle%3DInduction%2520of%2520Chronic%2520Myelogenous%2520Leukemia%2520in%2520Mice%2520by%2520the%2520P210bcr%252Fabl%2520Gene%2520of%2520the%2520Philadelphia%2520Chromosome%26jtitle%3DScience%26date%3D1990%26volume%3D247%26issue%3D4944%26spage%3D824%26epage%3D830%26doi%3D10.1126%2Fscience.2406902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWhirter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span> <span> </span><span class="NLM_article-title">The Human Leukemia Oncogene bcr-abl Abrogates the Anchorage Requirement But Not the Growth Factor Requirement for Proliferation</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1128/MCB.15.3.1286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1128%2FMCB.15.3.1286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=7862122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADyaK2MXjsl2rtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=1286-1293&issue=3&author=M.+W.+Renshawauthor=J.+R.+McWhirterauthor=J.+Y.+Wang&title=The+Human+Leukemia+Oncogene+bcr-abl+Abrogates+the+Anchorage+Requirement+But+Not+the+Growth+Factor+Requirement+for+Proliferation&doi=10.1128%2FMCB.15.3.1286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation</span></div><div class="casAuthors">Renshaw, Mark W.; McWhirter, John R.; Wang, Jean Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1286-93</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Proliferation of normal cells in a multicellular organism requires not only growth factors but also the proper attachment to the extracellular matrix.  A hallmark of neoplastic transformation is the loss of anchorage dependence which usually accompanies the loss of growth factor requirement.  The Bcr-Abl tyrosine kinase of human leukemias is shown here to abrogate only the anchorage, not the growth factor, requirement.  Bcr-Abl-transformed cells grow in soft agar but do not proliferate in serum-free media.  Bcr-Abl does not activate the tetradecanoyl phorbol acetate response element (TRE).  However, Bcr-Abl can alleviate the anchorage requirement for the induction of the TRE enhancer; i.e., it allows serum to activate the TRE in detached cells.  This activity is dependent on the assocn. of an active Bcr-Abl tyrosine kinase with the actin filaments.  Despite its assocn. with the adapter protein Grb2, Bcr-Abl's effect on the TRE enhancer is not blocked by dominant neg. Ras or Raf.  The finding that Bcr-Abl tyrosine kinase abrogates only anchorage dependence may have important implications on the pathogenesis of chronic myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0gyI1Wh9CvrVg90H21EOLACvtfcHk0liFf4K2CYO0Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsl2rtr4%253D&md5=eb67facca4fedf9e1204994636d208ae</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.3.1286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.3.1286%26sid%3Dliteratum%253Aachs%26aulast%3DRenshaw%26aufirst%3DM.%2BW.%26aulast%3DMcWhirter%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26atitle%3DThe%2520Human%2520Leukemia%2520Oncogene%2520bcr-abl%2520Abrogates%2520the%2520Anchorage%2520Requirement%2520But%2520Not%2520the%2520Growth%2520Factor%2520Requirement%2520for%2520Proliferation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26issue%3D3%26spage%3D1286%26epage%3D1293%26doi%3D10.1128%2FMCB.15.3.1286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">5486</span>),  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&issue=5486&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+Mechanism+for+STI-571+Inhibition+of+Abelson+Tyrosine+Kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0liFf4K2CYO0Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520Mechanism%2520for%2520STI-571%2520Inhibition%2520of%2520Abelson%2520Tyrosine%2520Kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26issue%3D5486%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4236</span>– <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+Structures+of+the+Kinase+Domain+of+c-Abl+in+Complex+with+the+Small+Molecule+Inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lhnri8hkI2lgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520Kinase%2520Domain%2520of%2520c-Abl%2520in%2520Complex%2520with%2520the%2520Small%2520Molecule%2520Inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W. N.</span></span> <span> </span><span class="NLM_article-title">Bcr-Abl Kinase Domain Mutations, Drug Resistance, and the Road to a Ccure For Chronic Myeloid Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2242</span>– <span class="NLM_lpage">2249</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-03-066936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2007-03-066936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17496200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCnsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&issue=7&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+N.+Deininger&title=Bcr-Abl+Kinase+Domain+Mutations%2C+Drug+Resistance%2C+and+the+Road+to+a+Ccure+For+Chronic+Myeloid+Leukemia&doi=10.1182%2Fblood-2007-03-066936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span></div><div class="casAuthors">O'Hare, Thomas; Eide, Christopher A.; Deininger, Michael W. N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2242-2249</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML).  Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance.  We also provide a perspective on how the secondline Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, esp. in relation to specific KD mutations.  We discuss the growing importance of the multi-inhibitor-resistant 315T>I mutant and the therapeutic potential that a 315T>I inhibitor would have.  Last, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodEKBGc_yDbLVg90H21EOLACvtfcHk0lhnri8hkI2lgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCnsb%252FE&md5=8a46ac53b7de9fe81e9508015f5b347b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-03-066936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-03-066936%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26atitle%3DBcr-Abl%2520Kinase%2520Domain%2520Mutations%252C%2520Drug%2520Resistance%252C%2520and%2520the%2520Road%2520to%2520a%2520Ccure%2520For%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26issue%3D7%26spage%3D2242%26epage%3D2249%26doi%3D10.1182%2Fblood-2007-03-066936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorre, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&issue=2&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+Kinase+Domain+Mutations+Confer+Polyclonal+Resistance+to+the+Tyrosine+Kinase+Inhibitor+Imatinib+%28STI571%29+in+Chronic+Phase+and+Blast+Crisis+Chronic+Myeloid+Leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0lgGVBtWVwQWpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520Kinase%2520Domain%2520Mutations%2520Confer%2520Polyclonal%2520Resistance%2520to%2520the%2520Tyrosine%2520Kinase%2520Inhibitor%2520Imatinib%2520%2528STI571%2529%2520in%2520Chronic%2520Phase%2520and%2520Blast%2520Crisis%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26issue%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorre, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwood, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span> (<span class="NLM_issue">5531</span>),  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1126/science.1062538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.1062538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=11423618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVKrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=876-880&issue=5531&author=M.+E.+Gorreauthor=M.+Mohammedauthor=K.+Ellwoodauthor=N.+Hsuauthor=R.+Paquetteauthor=P.+N.+Raoauthor=C.+L.+Sawyers&title=Clinical+Resistance+to+STI-571+Cancer+Therapy+Caused+by+BCR-ABL+Gene+Mutation+or+Amplification&doi=10.1126%2Fscience.1062538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification</span></div><div class="casAuthors">Gorre, Mercedes E.; Mohammed, Mansoor; Ellwood, Katharine; Hsu, Nicholas; Paquette, Ron; Rao, P. Nagesh; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5531</span>),
    <span class="NLM_cas:pages">876-880</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Clin. studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse.  Through biochem. and mol. anal. of clin. material, we find that drug resistance is assocd. with the reactivation of BCR-ABL signal transduction in all cases examd.  In six of nine patients, resistance was assocd. with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a crit. hydrogen bond with the drug.  This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution expt.  In three patients, resistance was assocd. with progressive BCR-ABL gene amplification.  These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest STI-571 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGNMgCA30skrVg90H21EOLACvtfcHk0lgGVBtWVwQWpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVKrsbs%253D&md5=6aad1d55ff37d879c992968ddf5eaf20</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscience.1062538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1062538%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DMohammed%26aufirst%3DM.%26aulast%3DEllwood%26aufirst%3DK.%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DClinical%2520Resistance%2520to%2520STI-571%2520Cancer%2520Therapy%2520Caused%2520by%2520BCR-ABL%2520Gene%2520Mutation%2520or%2520Amplification%26jtitle%3DScience%26date%3D2001%26volume%3D293%26issue%3D5531%26spage%3D876%26epage%3D880%26doi%3D10.1126%2Fscience.1062538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Second Generation Inhibitors of BCR-ABL for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nrc2126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=345-356&issue=5&author=E.+Weisbergauthor=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=A.+Hochhausauthor=J.+D.+Griffin&title=Second+Generation+Inhibitors+of+BCR-ABL+for+the+Treatment+of+Imatinib-Resistant+Chronic+Myeloid+Leukaemia&doi=10.1038%2Fnrc2126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a small-mol. ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein.  However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance.  Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib-resistant CML.  Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlco2ZKndcbVg90H21EOLACvtfcHk0liqleJgWIQytA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D&md5=36735dff94df075862a60b26d3f358e5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2126%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DSecond%2520Generation%2520Inhibitors%2520of%2520BCR-ABL%2520for%2520the%2520Treatment%2520of%2520Imatinib-Resistant%2520Chronic%2520Myeloid%2520Leukaemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D5%26spage%3D345%26epage%3D356%26doi%3D10.1038%2Fnrc2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">32214</span>– <span class="NLM_lpage">32219</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111525200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1074%2Fjbc.M111525200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12077114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32214-32219&issue=35&author=A.+S.+Corbinauthor=E.+Buchdungerauthor=F.+Pascalauthor=B.+J.+Druker&title=Analysis+of+the+Structural+Basis+of+Specificity+of+Inhibition+of+the+Abl+Kinase+by+STI571&doi=10.1074%2Fjbc.M111525200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571</span></div><div class="casAuthors">Corbin, Amie S.; Buchdunger, Elisabeth; Pascal, Furet; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">32214-32219</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">STI571, a selective inhibitor of Bcr-Abl, has been a successful therapeutic agent in clin. trials for chronic myelogenous leukemia.  Chronic phase chronic myelogenous leukemia patients treated with STI571 have durable responses; however, most responding blast phase patients relapse despite continued therapy.  Co-crystn. studies of Abl kinase and an STI571-related compd. identify specific amino acid residues as crit. to STI571 binding, one of which, T315, has been characterized as an acquired Thr to Ile mutation in relapsed patients.  Other studies, however, suggest that mutations other than these predicted contact points are capable of conferring STI571 resistance in relapsed patients.  Using a variety of models of STI571 binding to the Abl kinase, we have performed an extensive mutational anal. of sites that might alter the sensitivity of the Abl kinase to STI571.  Although mutation of many of the predicted contact points between Abl and STI571 result in a kinase-inactive protein, addnl. mutations that render the Abl kinase less sensitive to STI571 demonstrate a broad range of possibilities for clin. resistance that are now becoming evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1BukCe_64-LVg90H21EOLACvtfcHk0liqleJgWIQytA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslyjs7c%253D&md5=abc06de1a8f2889b4674423d76d23d30</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111525200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111525200%26sid%3Dliteratum%253Aachs%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DPascal%26aufirst%3DF.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAnalysis%2520of%2520the%2520Structural%2520Basis%2520of%2520Specificity%2520of%2520Inhibition%2520of%2520the%2520Abl%2520Kinase%2520by%2520STI571%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D35%26spage%3D32214%26epage%3D32219%26doi%3D10.1074%2Fjbc.M111525200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradeen, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Comparison of Imatinib Mesylate, Dasatinib (BMS-354825), and Nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-Based Mutagenesis Screen: High Efficacy of Drug Combinations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2332</span>– <span class="NLM_lpage">2338</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-02-004580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2006-02-004580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=16772610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCgur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=2332-2338&issue=7&author=H.+A.+Bradeenauthor=C.+A.+Eideauthor=T.+O%E2%80%99Hareauthor=K.+J.+Johnsonauthor=S.+G.+Willisauthor=F.+Y.+Leeauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Comparison+of+Imatinib+Mesylate%2C+Dasatinib+%28BMS-354825%29%2C+and+Nilotinib+%28AMN107%29+in+an+N-ethyl-N-nitrosourea+%28ENU%29-Based+Mutagenesis+Screen%3A+High+Efficacy+of+Drug+Combinations&doi=10.1182%2Fblood-2006-02-004580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations</span></div><div class="casAuthors">Bradeen, Heather A.; Eide, Christopher A.; O'Hare, Thomas; Johnson, Kara J.; Willis, Stephanie G.; Lee, Francis Y.; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2332-2338</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors with activity against many imatinib mesylate-resistant BCR-ABL kinase domain (KD) mutants, except T315I.  We used N-ethyl-N-nitrosourea (ENU)-exposed Ba/F3-p210BCR-ABL cells to compare incidence and types of KD mutants emerging in the presence of imatinib mesylate, dasatinib, and nilotinib, alone and in dual combinations.  Although ENU is expected to induce mutations in multiple proteins, resistant clones were almost exclusively BCR-ABL KD mutant at relevant concns. of nilotinib and dasatinib, consistent with a central role of KD mutations for resistance to these drugs.  Twenty different mutations were identified with imatinib mesylate, 10 with nilotinib (including only 1 novel mutation, E292V) and 9 with dasatinib.  At intermediate drug levels the spectrum narrowed to F317V and T315I for dasatinib and Y253H, E255V, and T315I for nilotinib.  Thus, cross-resistance is limited to T315I, which is also the only mutant isolated at drug concns. equiv. to maximal achievable plasma trough levels.  With drug combinations maximal suppression of resistant clone outgrowth was achieved at lower concns. compared with single agents, suggesting that such combinations may be equipotent to higher-dose single agents.  However, sequencing uniformly revealed T315I, consistent with the need for a T315I inhibitor, to completely block resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4zVg2sVqBbVg90H21EOLACvtfcHk0li6qs-jg2hKrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCgur%252FJ&md5=e360062ce60846e4f9eb6155d9a82669</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-004580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-004580%26sid%3Dliteratum%253Aachs%26aulast%3DBradeen%26aufirst%3DH.%2BA.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%2BJ.%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DComparison%2520of%2520Imatinib%2520Mesylate%252C%2520Dasatinib%2520%2528BMS-354825%2529%252C%2520and%2520Nilotinib%2520%2528AMN107%2529%2520in%2520an%2520N-ethyl-N-nitrosourea%2520%2528ENU%2529-Based%2520Mutagenesis%2520Screen%253A%2520High%2520Efficacy%2520of%2520Drug%2520Combinations%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26issue%3D7%26spage%3D2332%26epage%3D2338%26doi%3D10.1182%2Fblood-2006-02-004580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iuliucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4701</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/jm100395q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&issue=12&author=W.-S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28Imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+Potent%2C+Orally+Active+Pan-Inhibitor+of+Breakpoint+Cluster+Region-Abelson+%28BCR-ABL%29+Kinase+Including+the+T315I+Gatekeeper+Mutant&doi=10.1021%2Fjm100395q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl]benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span></div><div class="casAuthors">Huang, Wei-Sheng; Metcalf, Chester A.; Sundaramoorthi, Raji; Wang, Yihan; Zou, Dong; Thomas, R. Mathew; Zhu, Xiaotian; Cai, Lisi; Wen, David; Liu, Shuangying; Romero, Jan; Qi, Jiwei; Chen, Ingrid; Banda, Geetha; Lentini, Scott P.; Das, Sasmita; Xu, Qihong; Keats, Jeff; Wang, Frank; Wardwell, Scott; Ning, Yaoyu; Snodgrass, Joseph T.; Broudy, Marc I.; Russian, Karin; Zhou, Tianjun; Commodore, Lois; Narasimhan, Narayana I.; Mohemmad, Qurish K.; Iuliucci, John; Rivera, Victor M.; Dalgarno, David C.; Sawyer, Tomi K.; Clackson, Tim; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4701-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents.  This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation.  A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain.  Extensive SAR studies led to the discovery of development candidate benzamide I (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines.  Daily oral administration of I significantly prolonged survival of mice injected i.v. with BCR-ABLT315I expressing Ba/F3 cells.  These data, coupled with a favorable ADME profile, support the potential of I to be an effective treatment for CML, including patients refractory to all currently approved therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoci2zVFUazgLVg90H21EOLACvtfcHk0li6qs-jg2hKrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D&md5=0dcd7b4ff31164b1d9883e897b7058ff</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528Imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520Potent%252C%2520Orally%2520Active%2520Pan-Inhibitor%2520of%2520Breakpoint%2520Cluster%2520Region-Abelson%2520%2528BCR-ABL%2529%2520Kinase%2520Including%2520the%2520T315I%2520Gatekeeper%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D12%26spage%3D4701%26epage%3D4719%26doi%3D10.1021%2Fjm100395q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.2174/092986711795656135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.2174%2F092986711795656135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21517764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2146-2157&issue=14&author=X.+Y.+Luauthor=Q.+Caiauthor=K.+Ding&title=Recent+Developments+in+the+Third+Generation+Inhibitors+of+Bcr-Abl+for+Overriding+T315I+Mutation&doi=10.2174%2F092986711795656135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span></div><div class="casAuthors">Lu, X. Y.; Cai, Q.; Ding, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2146-2157</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by disrupting important contact interactions between the inhibitors and the enzyme.  To overcome this particular resistance, several different strategies have been explored and many mols. have been investigated as capable of potently inhibiting Bcr-Abl T315I.  Herein, this review reports on some predominant examples of third generation inhibitors of Bcr-Abl active against the T315I mutation, and special attentions are paid to the "hybrid-design" strategy for creating type-II class ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoM774pVEqrVg90H21EOLACvtfcHk0liFfXazCXQkaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D&md5=23109d1eb81a48f93cdf9ffbb4728c7a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F092986711795656135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795656135%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DRecent%2520Developments%2520in%2520the%2520Third%2520Generation%2520Inhibitors%2520of%2520Bcr-Abl%2520for%2520Overriding%2520T315I%2520Mutation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D14%26spage%3D2146%26epage%3D2157%26doi%3D10.2174%2F092986711795656135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doornmalen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>), <span class="NLM_elocation-id">e92146</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0092146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1371%2Fjournal.pone.0092146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24651269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKjurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&issue=3&author=J.+C.+Uitdehaagauthor=J.+A.+de+Roosauthor=A.+M.+van+Doornmalenauthor=M.+B.+Prinsenauthor=J.+de+Manauthor=Y.+Tanizawaauthor=Y.+Kawaseauthor=K.+Yoshinoauthor=R.+C.+Buijsmanauthor=G.+J.+Zaman&title=Comparison+of+the+Cancer+Gene+Targeting+and+Biochemical+Selectivities+of+All+Targeted+Kinase+Inhibitors+Approved+for+Clinical+Use&doi=10.1371%2Fjournal.pone.0092146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; de Roos, Jeroen A. D. M.; van Doornmalen, Antoon M.; Prinsen, Martine B. W.; de Man, Jos; Tanizawa, Yoshinori; Kawase, Yusuke; Yoshino, Kohichiro; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e92146/1-e92146/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The anti-proliferative activities of all twenty-five targeted kinase inhibitor drugs that are in clin. use were measured in two large assay panels: (1) a panel of proliferation assays of forty-four human cancer cell lines from diverse tumor tissue origins; and (2) a panel of more than 300 kinase enzyme activity assays.  This study provides a head-on comparison of all kinase inhibitor drugs in use, and for six of these drugs, the first kinome profiling data in the public domain.  Correlation of drug activities with cancer gene mutations revealed novel drug sensitivity markers, suggesting that cancers dependent on mutant CTNNB1 will respond to trametinib and other MEK inhibitors, and cancers dependent on SMAD4 to small mol. EGFR inhibitor drugs.  Comparison of cellular targeting efficacies reveals the most targeted inhibitors for EGFR-, ABL1- and BRAF(V600E)-driven cell growth, and demonstrates that the best targeted agents combine high biochem. potency with good selectivity.  For ABL1 inhibitors, we computationally deduce optimized kinase profiles for use in a next generation of drugs.  Our study shows the power of combining biochem. and cellular profiling data in the evaluation of kinase inhibitor drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVetYWQk4-rVg90H21EOLACvtfcHk0liFfXazCXQkaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKjurnL&md5=3bbedb8c0a1c7f724f4cde734c38668d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0092146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0092146%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BDoornmalen%26aufirst%3DA.%2BM.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DTanizawa%26aufirst%3DY.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DYoshino%26aufirst%3DK.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26atitle%3DComparison%2520of%2520the%2520Cancer%2520Gene%2520Targeting%2520and%2520Biochemical%2520Selectivities%2520of%2520All%2520Targeted%2520Kinase%2520Inhibitors%2520Approved%2520for%2520Clinical%2520Use%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D3%26doi%3D10.1371%2Fjournal.pone.0092146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molica, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib: A Review of Efficacy and Safety</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.2174/1568009617666171002142659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.2174%2F1568009617666171002142659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28969556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=847-856&issue=9&author=F.+Massaroauthor=M.+Molicaauthor=M.+Breccia&title=Ponatinib%3A+A+Review+of+Efficacy+and+Safety&doi=10.2174%2F1568009617666171002142659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib: A Review of Efficacy and Safety</span></div><div class="casAuthors">Massaro, Fulvio; Molica, Matteo; Breccia, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">847-856</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I mutation.  In different trials this drug showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 mutations.  For this reason, ponatinib is currently indicated for the treatment of chronic myeloid leukemia (CML) in every phase of disease resistant and/or intolerant to dasatinib and nilotinib and for whom imatinib is not indicated anymore or for patients with T315I mutation.  The drug is also indicated for Ph+ acute lymphoblastic leukemia (ALL).  Ponatinib was temporarily suspended in 2013 for the occurrence of cardiovascular thrombotic events.  Since then, different investigators analyzed baseline characteristics of patient candidates for ponatinib, esp. cardiovascular profile, in order to describe general management recommendations in this setting.  In this review, clin. trials data about the use of ponatinib in CML and Ph+ ALL patients will be discussed.  It will be focused also about the safety and tolerability profile of the drug and future perspectives of employment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorPMsOjRTIyrVg90H21EOLACvtfcHk0li56rYM6kWI4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWjsLrM&md5=78a025a9f4d42947fe3e194192810245</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1568009617666171002142659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666171002142659%26sid%3Dliteratum%253Aachs%26aulast%3DMassaro%26aufirst%3DF.%26aulast%3DMolica%26aufirst%3DM.%26aulast%3DBreccia%26aufirst%3DM.%26atitle%3DPonatinib%253A%2520A%2520Review%2520of%2520Efficacy%2520and%2520Safety%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2018%26volume%3D18%26issue%3D9%26spage%3D847%26epage%3D856%26doi%3D10.2174%2F1568009617666171002142659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&issue=1&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0li56rYM6kWI4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26issue%3D1%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming EML4–ALK Fusion Gene in Non-Small-Cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span> (<span class="NLM_issue">7153</span>),  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&issue=7153&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+Transforming+EML4%E2%80%93ALK+Fusion+Gene+in+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lhzk3hWcrQgfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520EML4%25E2%2580%2593ALK%2520Fusion%2520Gene%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26issue%3D7153%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dubé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&issue=18&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28PF-02341066%29%2C+a+Potent+and+Selective+Dual+Inhibitor+of+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lhzk3hWcrQgfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Dual%2520Inhibitor%2520of%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D18%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tursi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span> <span> </span><span class="NLM_article-title">First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">2167</span>– <span class="NLM_lpage">2177</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1408440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25470694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2167-2177&issue=23&author=B.+J.+Solomonauthor=T.+Mokauthor=D.-W.+Kimauthor=Y.-L.+Wuauthor=K.+Nakagawaauthor=T.+Mekhailauthor=E.+Felipauthor=F.+Cappuzzoauthor=J.+Paoliniauthor=T.+Usariauthor=S.+Iyerauthor=A.+Reismanauthor=K.+D.+Wilnerauthor=J.+Tursiauthor=F.+Blackhall&title=First-Line+Crizotinib+versus+Chemotherapy+in+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1408440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span></div><div class="casAuthors">Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2167-2177/1-2167-2177/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with std. chemotherapy as first-line treatment for advanced ALK-pos. non-small-cell lung cancer (NSCLC) is unknown.  METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-pos. nonsquamous NSCLC who had received no previous systemic treatment for advanced disease.  Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive i.v. chemotherapy (pemetrexed, 500 mg per square meter of bodysurface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per mL per min) every 3 wk for up to six cycles.  Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy.  The primary end point was progression-free survival as assessed by independent radiol. review.  RESULTS Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 mo vs. 7.0 mo; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001).  Objective response rates were 74% and 45 %, resp. (P<0.001).  Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-yr survival was 84% with crizotinib and 79% with chemotherapy.  The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite.  As compared with chemotherapy, crizotinib was assocd. with greater redn. in lung cancer symptoms and greater improvement in quality of life.  CONCLUSIONS Crizotinib was superior to std. first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7N7XM7ywBLVg90H21EOLACvtfcHk0lg9sM01MkM9Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D&md5=afd3c75ef95aff5c0fa12b6b7e22b46a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408440%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPaolini%26aufirst%3DJ.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DReisman%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DTursi%26aufirst%3DJ.%26aulast%3DBlackhall%26aufirst%3DF.%26atitle%3DFirst-Line%2520Crizotinib%2520versus%2520Chemotherapy%2520in%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D23%26spage%3D2167%26epage%3D2177%26doi%3D10.1056%2FNEJMoa1408440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curran, M. P.</span></span> <span> </span><span class="NLM_article-title">Crizotinib</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.2165/11207680-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.2165%2F11207680-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=22191798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC38XislWntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=99-107&issue=1&author=M.+P.+Curran&title=Crizotinib&doi=10.2165%2F11207680-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib: in locally advanced or metastatic non-small cell lung cancer</span></div><div class="casAuthors">Curran, Monique P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Crizotinib is an inhibitor of receptor tyrosine kinases (including anaplastic lymphoma kinase [ALK]).  Oral crizotinib 250 mg twice daily was assocd. with clin. meaningful response rates in two non-comparative trials (phase I and phase II) in patients with locally advanced or metastatic ALK-pos. non-small cell lung cancer (NSCLC).  In the phase I trial (median duration of treatment of 32 wk) and phase II trial (median duration of treatment of 22 wk), the objective response rate in crizotinib recipients was 61% and 50%, resp., and the median duration of response was 48.1 and 41.9 wk, resp.  Responses were rapid, with the majority of patients achieving an objective response within the first 8 wk of treatment.  Crizotinib was generally well tolerated, with most adverse reactions being grade 1 or 2.  The most commonly reported treatment-related adverse reactions were vision disorder, gastrointestinal disorders and edema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLnnvG1FnetbVg90H21EOLACvtfcHk0lg9sM01MkM9Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XislWntb4%253D&md5=2943c2176e47f1af9ae1762f21e8f873</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2165%2F11207680-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11207680-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCurran%26aufirst%3DM.%2BP.%26atitle%3DCrizotinib%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26issue%3D1%26spage%3D99%26epage%3D107%26doi%3D10.2165%2F11207680-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&issue=18&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+Mutations+in+Lung+Cancer+That+Confer+Resistance+to+ALK+Inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0ljK_3gt3sh0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Mutations%2520in%2520Lung%2520Cancer%2520That%2520Confer%2520Resistance%2520to%2520ALK%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D18%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10927</span>– <span class="NLM_lpage">10954</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00446</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00446" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10927-10954&issue=24&author=X.+Kongauthor=P.+Panauthor=H.+Sunauthor=H.+Xiaauthor=X.+Wangauthor=Y.+Liauthor=T.+Hou&title=Drug+Discovery+Targeting+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.9b00446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Kong, Xiaotian; Pan, Peichen; Sun, Huiyong; Xia, Hongguang; Wang, Xuwen; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10927-10954</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, esp. anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas.  Currently, five small-mol. inhibitors of ALK, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, have been approved by the U.S.  Food and Drug Administration (FDA) against ALK-pos. NSCLCs.  Novel type-I1/2 and type-II ALK inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported.  Moreover, the "proteolysis targeting chimera" (PROTAC) technique has been successfully applied in developing ALK degraders, which opened a new avenue for targeted ALK therapies.  This review provides an overview of the physiol. and biol. functions of ALK, the discovery and development of drugs targeting ALK by focusing on their chemotypes, activity, selectivity, and resistance as well as potential therapeutic strategies to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LmONQduM_bVg90H21EOLACvtfcHk0ljK_3gt3sh0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E&md5=6c9aadf015cba2f11b2c2f747eea3eec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DDrug%2520Discovery%2520Targeting%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954%26doi%3D10.1021%2Facs.jmedchem.9b00446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK) Inhibitors in the Treatment of ALK-Driven Lung Cancers</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.phrs.2017.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28077299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=343-356&author=R.+Roskoski&title=Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+in+the+Treatment+of+ALK-Driven+Lung+Cancers&doi=10.1016%2Fj.phrs.2017.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">343-356</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase is expressed in two-thirds of the anaplastic large-cell lymphomas as an NPM-ALK fusion protein.  Physiol. ALK is a receptor protein-tyrosine kinase within the insulin receptor superfamily of proteins that participates in nervous system development.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The amino-terminal portions of the ALK fusion proteins result in dimerization and subsequent activation of the ALK protein kinase domain that plays a key role in the pathogenesis of various tumors.  Downstream signaling from the ALK fusion protein leads to the activation of the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathways.  Moreover, nearly two dozen ALK activating mutations are involved in the pathogenesis of childhood neuroblastomas.  The occurrence of oncogenic ALK-fusion proteins, particularly in non-small cell lung cancer, has fostered considerable interest in the development of ALK inhibitors.  Crizotinib was the first such inhibitor approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer in 2011.  The median time for the emergence of crizotinib drug resistance is 10.5 mo after the initiation of therapy.  Such resistance prompted the development of second-generation drugs including ceritinib and alectinib, which are approved for the treatment of non-small cell lung cancer.  Unlike the single gatekeeper mutation that occurs in drug-resistant epidermal growth factor receptor in lung cancer, nearly a dozen different mutations in the catalytic domain of ALK fusion proteins have been discovered that result in crizotinib resistance.  Crizotinib, ceritinib, and alectinib form a complex within the front cleft between the small and large lobes of an inactive ALK protein-kinase domain with a compact activation segment.  These drugs are classified as type I1/2 B inhibitors because they bind to an inactive enzyme and they do not extend past the gatekeeper into the back pocket of the drug binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq0rrYNRqutrVg90H21EOLACvtfcHk0ljK_3gt3sh0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D&md5=49200353921714b975e564df79631578</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520ALK-Driven%2520Lung%2520Cancers%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D117%26spage%3D343%26epage%3D356%26doi%3D10.1016%2Fj.phrs.2017.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kain, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwak-Tapp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span> <span> </span><span class="NLM_article-title">Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&issue=4&author=S.-H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-Generation+Sequencing+Reveals+a+Novel+NSCLC+ALK+F1174V+Mutation+and+Confirms+ALK+G1202R+Mutation+Confers+High-Level+Resistance+to+Alectinib+%28CH5424802%2FRO5424802%29+in+ALK-Rearranged+NSCLC+Patients+Who+Progressed+on+Crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-Generation%2520Sequencing%2520Reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520Mutation%2520and%2520Confirms%2520ALK%2520G1202R%2520Mutation%2520Confers%2520High-Level%2520Resistance%2520to%2520Alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-Rearranged%2520NSCLC%2520Patients%2520Who%2520Progressed%2520on%2520Crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies to Overcome Crizotinib Resistance in Non-Small Cell Lung Cancers Harboring the Fusion Oncogene EML4-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&issue=18&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+Strategies+to+Overcome+Crizotinib+Resistance+in+Non-Small+Cell+Lung+Cancers+Harboring+the+Fusion+Oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0liYz7CBtHo8cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Strategies%2520to%2520Overcome%2520Crizotinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancers%2520Harboring%2520the%2520Fusion%2520Oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D18%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodack, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezwada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span> <span> </span><span class="NLM_article-title">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccell.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26144315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=70-81&issue=1&author=H.+Y.+Zouauthor=L.+Fribouletauthor=D.+P.+Kodackauthor=L.+D.+Engstromauthor=Q.+Liauthor=M.+Westauthor=R.+W.+Tangauthor=H.+Wangauthor=K.+Tsaparikosauthor=J.+Wangauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=D.+M.+Dinhauthor=H.+Lamauthor=J.+L.+Lamauthor=S.+Yamazakiauthor=W.+Huauthor=B.+Patelauthor=D.+Bezwadaauthor=R.+L.+Friasauthor=E.+Lifshitsauthor=S.+Mahmoodauthor=J.+F.+Gainorauthor=T.+Affolterauthor=P.+B.+Lappinauthor=H.+Gukasyanauthor=N.+Leeauthor=S.+Dengauthor=R.+K.+Jainauthor=T.+W.+Johnsonauthor=A.+T.+Shawauthor=V.+R.+Fantinauthor=T.+Smeal&title=PF-06463922%2C+an+ALK%2FROS1+Inhibitor%2C+Overcomes+Resistance+to+First+and+Second+Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1016%2Fj.ccell.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zou, Helen Y.; Friboulet, Luc; Kodack, David P.; Engstrom, Lars D.; Li, Qiuhua; West, Melissa; Tang, Ruth W.; Wang, Hui; Tsaparikos, Konstantinos; Wang, Jinwei; Timofeevski, Sergei; Katayama, Ryohei; Dinh, Dac M.; Lam, Hieu; Lam, Justine L.; Yamazaki, Shinji; Hu, Wenyue; Patel, Bhushankumar; Bezwada, Divya; Frias, Rosa L.; Lifshits, Eugene; Mahmood, Sidra; Gainor, Justin F.; Affolter, Timothy; Lappin, Patrick B.; Gukasyan, Hovhannes; Lee, Nathan; Deng, Shibing; Jain, Rakesh K.; Johnson, Ted W.; Shaw, Alice T.; Fantin, Valeria R.; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-81</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We report the preclin. evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.  Compared with other clin. available ALK inhibitors, PF-06463922 displayed superior potency against all known clin. acquired ALK mutations, including the highly resistant G1202R mutant.  Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner.  Finally, PF-06463922 demonstrated high selectivity and safety margins in a variety of preclin. studies.  These results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clin. available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jseXrLwlSLVg90H21EOLACvtfcHk0lgH_f1PprrNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E&md5=5bd2b7be6086f607b33b2255ad350486</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKodack%26aufirst%3DD.%2BP.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DBezwada%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DGukasyan%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DPF-06463922%252C%2520an%2520ALK%252FROS1%2520Inhibitor%252C%2520Overcomes%2520Resistance%2520to%2520First%2520and%2520Second%2520Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D1%26spage%3D70%26epage%3D81%26doi%3D10.1016%2Fj.ccell.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorlatinib, Y.</span></span> <span> </span><span class="NLM_article-title">First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1041-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-018-1041-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30604291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=93-98&issue=1&author=Y.+Syedauthor=Y.+Lorlatinib&title=First+Global+Approval&doi=10.1007%2Fs40265-018-1041-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lorlatinib is an oral small mol. inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Based on results from a phase I/II trial, lorlatinib received approval in Japan in Sept. 2018 and in the USA in Nov. 2018 for the treatment of ALK-pos. NSCLC.  This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU4Wwiia48VbVg90H21EOLACvtfcHk0lgH_f1PprrNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D&md5=f041ba0200e2d607bb2a014884455990</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1041-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1041-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%26aulast%3DLorlatinib%26aufirst%3DY.%26atitle%3DFirst%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D1%26spage%3D93%26epage%3D98%26doi%3D10.1007%2Fs40265-018-1041-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lgH_f1PprrNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span> <span> </span><span class="NLM_article-title">Trk Receptors: Roles in Neuronal Signal Transduction</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.72.121801.161629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1146%2Fannurev.biochem.72.121801.161629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12676795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=609-642&issue=1&author=E.+J.+Huangauthor=L.+F.+Reichardt&title=Trk+Receptors%3A+Roles+in+Neuronal+Signal+Transduction&doi=10.1146%2Fannurev.biochem.72.121801.161629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptors: roles in neuronal signal transduction</span></div><div class="casAuthors">Huang, Eric J.; Reichardt, Louis F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">609-642</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Trk receptors are a family of 3 receptor tyrosine kinases, each of which can be activated by ≥1 of 4 neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).  Neurotrophin signaling through these receptors regulates cell survival, proliferation, the fate of neural precursors, axon and dendrite growth and patterning, and the expression and activity of functionally important proteins, such as ion channels and neurotransmitter receptors.  In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity.  The cytoplasmic domains of Trk receptors contain several sites of tyrosine phosphorylation that recruit intermediates in intracellular signaling cascades.  As a result, Trk receptor signaling activates several small G proteins, including Ras, Rap-1, and the Cdc-42-Rac-Rho family, as well as pathways regulated by MAP kinase, PI 3-kinase and phospholipase-C-γ (PLC-γ).  Trk receptor activation has different consequences in different cells, and the specificity of downstream Trk receptor-mediated signaling is controlled through expression of intermediates in these signaling pathways and membrane trafficking that regulates localization of different signaling constituents.  Perhaps the most fascinating aspect of Trk receptor-mediated signaling is its interplay with signaling promoted by the pan-neurotrophin receptor p75NTR.  P75NTR activates a distinct set of signaling pathways within cells that are in some instances synergistic and in other instances antagonistic to those activated by Trk receptors.  Several of these are proapoptotic but are suppressed by Trk receptor-initiated signaling.  P75NTR also influences the conformations of Trk receptors; this modifies ligand-binding specificity and affinity with important developmental consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH3Pdvfi72LVg90H21EOLACvtfcHk0liQrpu-UKZahQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D&md5=939bf60802da0a203c2e0d8585e28dd9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.72.121801.161629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.72.121801.161629%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DE.%2BJ.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26atitle%3DTrk%2520Receptors%253A%2520Roles%2520in%2520Neuronal%2520Signal%2520Transduction%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2003%26volume%3D72%26issue%3D1%26spage%3D609%26epage%3D642%26doi%3D10.1146%2Fannurev.biochem.72.121801.161629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25527197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=25-34&issue=1&author=A.+Vaishnaviauthor=A.+T.+Leauthor=R.+C.+Doebele&title=TRKing+Down+an+Old+Oncogene+in+a+New+Era+of+Targeted+Therapy&doi=10.1158%2F2159-8290.CD-14-0765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span></div><div class="casAuthors">Vaishnavi, Aria; Le, Anh T.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date.  These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago.  However, no drug has yet been approved by the FDA for cancers harboring this oncogene.  This review will discuss the biol. of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets.  Significance: Precision oncol. approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples.  Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types.  The scientific rationale for the targeting of the TRK oncogene family will be discussed here.  Cancer Discov; 5(1); 25-34. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUH4ooHY0TbVg90H21EOLACvtfcHk0liQrpu-UKZahQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D&md5=02103d46d85b6dc948dba58d32ffba9f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0765%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTRKing%2520Down%2520an%2520Old%2520Oncogene%2520in%2520a%2520New%2520Era%2520of%2520Targeted%2520Therapy%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D1%26spage%3D25%26epage%3D34%26doi%3D10.1158%2F2159-8290.CD-14-0765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkaniga, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaganti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-y.</span></span> <span> </span><span class="NLM_article-title">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1731</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1731-1760&issue=4&author=W.+Yanauthor=N.+R.+Lakkanigaauthor=F.+Carlomagnoauthor=M.+Santoroauthor=N.+Q.+McDonaldauthor=F.+Lvauthor=N.+Gunagantiauthor=B.+Frettauthor=H.-y.+Li&title=Insights+into+Current+Tropomyosin+Receptor+Kinase+%28TRK%29+Inhibitors%3A+Development+and+Clinical+Application&doi=10.1021%2Facs.jmedchem.8b01092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span></div><div class="casAuthors">Yan, Wei; Lakkaniga, Naga Rajiv; Carlomagno, Francesca; Santoro, Massimo; McDonald, Neil Q.; Lv, Fengping; Gunaganti, Naresh; Frett, Brendan; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1731-1760</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib.  Annually, it is estd. that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement.  In this Perspective, we discuss current development and clin. applications for TRK precision medicine by providing the following: (1) the biol. background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and anal. of their cocrystal structures, (3) an overview of TRK clin. trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwUthQyJEzFrVg90H21EOLACvtfcHk0ljL1dOOyuELyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO&md5=5ce2f8d295cf46f84b46f5890dad0160</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01092%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DLakkaniga%26aufirst%3DN.%2BR.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DGunaganti%26aufirst%3DN.%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.-y.%26atitle%3DInsights%2520into%2520Current%2520Tropomyosin%2520Receptor%2520Kinase%2520%2528TRK%2529%2520Inhibitors%253A%2520Development%2520and%2520Clinical%2520Application%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1731%26epage%3D1760%26doi%3D10.1021%2Facs.jmedchem.8b01092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larotrectinib, J.</span></span> <span> </span><span class="NLM_article-title">First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1044-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-018-1044-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30635837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=201-206&issue=2&author=L.+Scottauthor=J.+Larotrectinib&title=First+Global+Approval&doi=10.1007%2Fs40265-018-1044-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib: First Global Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-206</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (Vitrakvi) is an orally administered, small mol., highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncol. in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbor neurotrophic receptor tyrosine kinase (NTRK) gene fusions.  In Nov. 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.  A registration application for the use of larotrectinib in pediatric and adult patients with locally advanced or metastatic solid tumors with NTRK gene fusion proteins has been submitted in the EU.  This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and pediatric patients with solid tumors that have NTRK gene fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMpwdBG0H7ELVg90H21EOLACvtfcHk0ljL1dOOyuELyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D&md5=8c3d442665ece609cc09422052903696</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1044-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1044-x%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%26aulast%3DLarotrectinib%26aufirst%3DJ.%26atitle%3DFirst%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D2%26spage%3D201%26epage%3D206%26doi%3D10.1007%2Fs40265-018-1044-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">628</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&issue=4&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.-M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan%E2%80%93TRK%2C+ROS1%2C+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0ljL1dOOyuELyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan%25E2%2580%2593TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D4%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Entrectinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01177-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-019-01177-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31372957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1477-1483&issue=13&author=Z.+T.+Al-Salamaauthor=S.+J.+Keam&title=Entrectinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01177-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib: First Global Approval</span></div><div class="casAuthors">Al-Salama Zaina T; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1477-1483</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Entrectinib (Rozlytrek(®)) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment of various solid tumours harbouring NTRK1/2/3 or ROS1 gene fusions.  In June 2019, entrectinib received its first global approval in Japan, for the treatment of adult and paediatric patients with NTRK fusion-positive, advanced or recurrent solid tumours and is under regulatory review for the treatment of adult patients with ROS1-positive non-small cell lung cancer (NSCLC).  Entrectinib is also under regulatory review in the USA (PDUFA date 18 August 2019) and EU [Priority Medicines (PRIME) designation] for NTRK-positive solid tumours and ROS1-positive NSCLC.  This article summarizes the milestones in the development of entrectinib leading to this first global approval for solid tumours in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqIyGZmvQlpEkUaC_kzhvyfW6udTcc2eY1Yci1jJHbcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D&md5=750c86d20c43273cf07f505988ac8dbd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01177-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01177-y%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DEntrectinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D13%26spage%3D1477%26epage%3D1483%26doi%3D10.1007%2Fs40265-019-01177-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/s41571-018-0113-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41571-018-0113-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30333516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=731-747&issue=12&author=E.+Coccoauthor=M.+Scaltritiauthor=A.+Drilon&title=NTRK+Fusion-Positive+Cancers+and+TRK+Inhibitor+Therapy&doi=10.1038%2Fs41571-018-0113-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK fusion-positive cancers and TRK inhibitor therapy</span></div><div class="casAuthors">Cocco, Emiliano; Scaltriti, Maurizio; Drilon, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, resp.) are oncogenic drivers of various adult and paediatric tumor types.  These fusions can be detected in the clinic using a variety of methods, including tumor DNA and RNA sequencing and plasma cell-free DNA profiling.  The treatment of patients with NTRK fusion-pos. cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is assocd. with high response rates (>75%), regardless of tumor histol.  First-generation TRK inhibitors are well tolerated by most patients, with toxicity profiles characterized by occasional off-tumor, on-target adverse events (attributable to TRK inhibition in non-malignant tissues).  Despite durable disease control in many patients, advanced-stage NTRK fusion-pos. cancers eventually become refractory to TRK inhibition; resistance can be mediated by the acquisition of NTRK kinase domain mutations.  Fortunately, certain resistance mutations can be overcome by second-generation TRK inhibitors, including LOXO-195 and TPX-0005 that are being explored in clin. trials.  In this Review, we discuss the biol. of NTRK fusions, strategies to target these drivers in the treatment-naive and acquired-resistance disease settings, and the unique safety profile of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2tGShkjX-5LVg90H21EOLACvtfcHk0lgb2aqsTGw2Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO&md5=fbc1f5b0de3614008f1b1f1e2e6167ce</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fs41571-018-0113-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-018-0113-0%26sid%3Dliteratum%253Aachs%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DNTRK%2520Fusion-Positive%2520Cancers%2520and%2520TRK%2520Inhibitor%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D12%26spage%3D731%26epage%3D747%26doi%3D10.1038%2Fs41571-018-0113-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisafulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rospo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-15-0940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26546295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36-44&issue=1&author=M.+Russoauthor=S.+Misaleauthor=G.+Weiauthor=G.+Siravegnaauthor=G.+Crisafulliauthor=L.+Lazzariauthor=G.+Cortiauthor=G.+Rospoauthor=L.+Novaraauthor=B.+Mussolinauthor=A.+Bartoliniauthor=N.+Camauthor=R.+Patelauthor=S.+Yanauthor=R.+Shoemakerauthor=R.+Wildauthor=F.+Di+Nicolantonioauthor=A.+S.+Bianchiauthor=G.+Liauthor=S.+Sienaauthor=A.+Bardelli&title=Acquired+Resistance+to+the+TRK+Inhibitor+Entrectinib+in+Colorectal+Cancer&doi=10.1158%2F2159-8290.CD-15-0940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span></div><div class="casAuthors">Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Bianchi, Andrea Sartore; Li, Gang; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clin. testing in colorectal cancer and other tumor types.  A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance.  To characterize the mol. bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed.  Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C.  Biochem. and pharmacol. anal. in multiple preclin. models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib.  These findings can be immediately exploited to design next-generation TRKA inhibitors.  Significance: We provide proof of principle that analyses of xenopatients (avatar) and liq. biopsies allow the identification of drug resistance mechanisms in parallel with clin. treatment of an individual patient.  We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Unyh1xjaoLVg90H21EOLACvtfcHk0lgXXFxjg1f6Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D&md5=5baa54a784e355b6afa50336b2708052</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0940%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DCrisafulli%26aufirst%3DG.%26aulast%3DLazzari%26aufirst%3DL.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DRospo%26aufirst%3DG.%26aulast%3DNovara%26aufirst%3DL.%26aulast%3DMussolin%26aufirst%3DB.%26aulast%3DBartolini%26aufirst%3DA.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DAcquired%2520Resistance%2520to%2520the%2520TRK%2520Inhibitor%2520Entrectinib%2520in%2520Colorectal%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D1%26spage%3D36%26epage%3D44%26doi%3D10.1158%2F2159-8290.CD-15-0940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&issue=9&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.-I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+Next-Generation+TRK+Kinase+Inhibitor+Overcomes+Acquired+Resistance+to+Prior+TRK+Kinase+Inhibition+in+Patients+with+TRK+Fusion-Positive+Solid+Tumors&doi=10.1158%2F2159-8290.CD-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. ©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0lgXXFxjg1f6Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520Next-Generation%2520TRK%2520Kinase%2520Inhibitor%2520Overcomes%2520Acquired%2520Resistance%2520to%2520Prior%2520TRK%2520Kinase%2520Inhibition%2520in%2520Patients%2520with%2520TRK%2520Fusion-Positive%2520Solid%2520Tumors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D9%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.CD-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&issue=10&author=A.+Drilonauthor=S.+I.+Ouauthor=B.+C.+Choauthor=D.+W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.+J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+Is+a+Next-Generation+ROS1%2FTRK%2FALK+Inhibitor+That+Potently+Inhibits+ROS1%2FTRK%2FALK+Solvent-Front+Mutations&doi=10.1158%2F2159-8290.CD-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0lhCo5NJTwuCRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520Is%2520a%2520Next-Generation%2520ROS1%252FTRK%252FALK%2520Inhibitor%2520That%2520Potently%2520Inhibits%2520ROS1%252FTRK%252FALK%2520Solvent-Front%2520Mutations%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D10%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.CD-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khozin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helms, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Hakim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2436</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-14-3157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25754348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2436-2439&issue=11&author=S.+Khozinauthor=G.+M.+Blumenthalauthor=L.+Zhangauthor=S.+Tangauthor=M.+Browerauthor=E.+Foxauthor=W.+Helmsauthor=R.+Leongauthor=P.+Songauthor=Y.+Panauthor=Q.+Liuauthor=P.+Zhaoauthor=H.+Zhaoauthor=D.+Luauthor=Z.+Tangauthor=A.+Al+Hakimauthor=K.+Boydauthor=P.+Keeganauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+Approval%3A+Ceritinib+for+the+Treatment+of+Metastatic+Anaplastic+Lymphoma+Kinase-Positive+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-14-3157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Khozin, Sean; Blumenthal, Gideon M.; Zhang, Lijun; Tang, Shenghui; Brower, Margaret; Fox, Emily; Helms, Whitney; Leong, Ruby; Song, Pengfei; Pan, Yuzhuo; Liu, Qi; Zhao, Ping; Zhao, Hong; Lu, Donghao; Tang, Zhe; Al Hakim, Ali; Boyd, Karen; Keegan, Patricia; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2436-2439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Apr. 29, 2014, the FDA granted accelerated approval to ceritinib (ZYKADIA; Novartis Pharmaceuticals Corporation), a breakthrough therapy-designated drug, for the treatment of patients with anaplastic lymphoma kinase (ALK)-pos., metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The approval was based on a single-arm multicenter trial enrolling 163 patients with metastatic ALK-pos. NSCLC who had disease progression on (91%) or intolerance to crizotinib.  Patients received ceritinib at a starting dose of 750 mg orally once daily.  The objective response rate (ORR) by a blinded independent review committee was 44% (95% CI, 36-52), and the median duration of response (DOR) was 7.1 mo.  The ORR by investigator assessment was similar.  Safety was evaluated in 255 patients.  The most common adverse reactions and lab. abnormalities included diarrhea (86%), nausea (80%), increased alanine transaminase (80%), increased aspartate transaminase (75%), vomiting (60%), increased glucose (49%), and increased lipase (28%).  Although 74% of patients required at least one dose redn. or interruption due to adverse reactions, the discontinuation rate due to adverse reactions was low (10%).  With this safety profile, the benefit-risk anal. was considered favorable because of the clin. meaningful ORR and DOR.  Clin Cancer Res; 21(11); 2436-9. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoopHbie8F3MLVg90H21EOLACvtfcHk0lhCo5NJTwuCRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D&md5=0b83c696c11bdc5281cdae60a8b0bf50</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3157%26sid%3Dliteratum%253Aachs%26aulast%3DKhozin%26aufirst%3DS.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DBrower%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DHelms%26aufirst%3DW.%26aulast%3DLeong%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DAl%2BHakim%26aufirst%3DA.%26aulast%3DBoyd%26aufirst%3DK.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%253A%2520Ceritinib%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D11%26spage%3D2436%26epage%3D2439%26doi%3D10.1158%2F1078-0432.CCR-14-3157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-014-0251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24980964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1285-1291&issue=11&author=S.+Dhillonauthor=M.+Clark&title=Ceritinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita; Clark, Madeleine</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1285-1291</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ceritinib is an oral anaplastic lymphoma kinase (ALK) inhibitor developed by Novartis for the treatment of tumors characterised by genetic abnormalities in ALK.  ALK is a member of the insulin receptor family of tyrosine kinases that can become oncogenic when fused to other proteins.  Ceritinib has been approved in the US under 'Breakthrough Therapy' designation for the second-line treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Regulatory submissions have also been made in the EU and other countries.  Phase III development is ongoing worldwide to evaluate ceritinib both as a first- and second-line therapy for ALK-pos. NSCLC.  This article summarizes the milestones in the development of ceritinib leading to this first approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1rTUW_DPL7Vg90H21EOLACvtfcHk0lh-r2Z8DgrSkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK&md5=ec44e05bf8556567826c3eb7f5dbd5dc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0251-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DM.%26atitle%3DCeritinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D11%26spage%3D1285%26epage%3D1291%26doi%3D10.1007%2Fs40265-014-0251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&issue=14&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0lh-r2Z8DgrSkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D14%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerwen, S. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span> <span> </span><span class="NLM_article-title">Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1535-7163.MCT-18-0877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30381447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1els7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=470-481&issue=2&author=J.+C.+M.+Uitdehaagauthor=J.+J.+Kooijmanauthor=J.+de+Roosauthor=M.+B.+W.+Prinsenauthor=J.+Dylusauthor=N.+Willemsen-Seegersauthor=Y.+Kawaseauthor=M.+Sawaauthor=J.+de+Manauthor=S.+J.+C.+van+Gerwenauthor=R.+C.+Buijsmanauthor=G.+J.+R.+Zaman&title=Combined+Cellular+and+Biochemical+Profiling+to+Identify+Predictive+Drug+Response+Biomarkers+for+Kinase+Inhibitors+Approved+for+Clinical+Use+between+2013+and+2017&doi=10.1158%2F1535-7163.MCT-18-0877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; Kooijman, Jeffrey J.; De Roos, Jeroen A. D. M.; Prinsen, Martine B. W.; Dylus, Jelle; Willemsen-Seegers, Nicole; Kawase, Yusuke; Sawa, Masaaki; De Man, Jos; Van Gerwen, Suzanne J. C.; Buijsman, Rogier C.; Zamad, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">470-481</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Kinase inhibitors form the largest class of precision medicine.  From 2013 to 2017, 17 kinase inhibitors have been approved, with 8 different mechanisms.  We present a comprehensive profiling study of all 17 inhibitors on a biochem. assay panel of 280 kinases and proliferation assays of 108 cancer cell lines.  Drug responses of the cell lines were related to the presence of frequently recurring point mutations, insertions, deletions, and amplifications in 15 well-known oncogenes and tumor-suppressor genes.  In addn., drug responses were correlated with basal gene expression levels with a focus on 383 clin. actionable genes.  Cell lines harboring actionable mutations defined in the FDA labels, such as mutant BRAF(V600E) for cobimetinib, or ALK gene translocation for ALK inhibitors, are generally 10 times more sensitive compared with wild-type cell lines.  This sensitivity window is more narrow for markers that failed to meet endpoints in clin. trials, for instance CDKN2A loss for CDK4/6 inhibitors (2.7-fold) and KRAS mutation for cobimetinib (2.3-fold).  Our data underscore the rationale of a no. of recently opened clin. trials, such as ibrutinib in ERBB2- or ERBB4-expressing cancers.  We propose and validate new response biomarkers, such as mutation in FBXW7 or SMAD4 for EGFR and HER2 inhibitors, ETV4 and ETV5 expression for MEK inhibitors, and JAK3 expression for ALK inhibitors.  Potentially, these new markers could be combined to improve response rates.  This comprehensive overview of biochem. and cellular selectivities of approved kinase inhibitor drugs provides a rich resource for drug repurposing, basket trial design, and basic cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd-nMoDtTIj7Vg90H21EOLACvtfcHk0lhJFmB6nFOxAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1els7g%253D&md5=309b9e50321428f3f66eab7da09293f6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0877%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%2BM.%26aulast%3DKooijman%26aufirst%3DJ.%2BJ.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%2BW.%26aulast%3DDylus%26aufirst%3DJ.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DSawa%26aufirst%3DM.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3Dvan%2BGerwen%26aufirst%3DS.%2BJ.%2BC.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26atitle%3DCombined%2520Cellular%2520and%2520Biochemical%2520Profiling%2520to%2520Identify%2520Predictive%2520Drug%2520Response%2520Biomarkers%2520for%2520Kinase%2520Inhibitors%2520Approved%2520for%2520Clinical%2520Use%2520between%25202013%2520and%25202017%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26issue%3D2%26spage%3D470%26epage%3D481%26doi%3D10.1158%2F1535-7163.MCT-18-0877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squillace, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadworny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miret, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5527</span>– <span class="NLM_lpage">5538</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-16-0569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=27780853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5527-5538&issue=22&author=S.+Zhangauthor=R.+Anjumauthor=R.+Squillaceauthor=S.+Nadwornyauthor=T.+Zhouauthor=J.+Keatsauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=D.+Millerauthor=Y.+Songauthor=L.+Eichingerauthor=L.+Moranauthor=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=Y.+Wangauthor=Q.+Mohemmadauthor=H.+G.+Jangauthor=E.+Yeauthor=N.+Narasimhanauthor=F.+Wangauthor=J.+Miretauthor=X.+Zhuauthor=T.+Clacksonauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=V.+M.+Rivera&title=The+Potent+ALK+Inhibitor+Brigatinib+%28AP26113%29+Overcomes+Mechanisms+of+Resistance+to+First-+and+Second-Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1158%2F1078-0432.CCR-16-0569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zhang, Sen; Anjum, Rana; Squillace, Rachel; Nadworny, Sara; Zhou, Tianjun; Keats, Jeff; Ning, Yaoyu; Wardwell, Scott D.; Miller, David; Song, Youngchul; Eichinger, Lindsey; Moran, Lauren; Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Wang, Yihan; Mohemmad, Qurish; Jang, Hyun Gyung; Ye, Emily; Narasimhan, Narayana; Wang, Frank; Miret, Juan; Zhu, Xiaotian; Clackson, Tim; Dalgarno, David; Shakespeare, William C.; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5527-5538</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain.  Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified.  Here, we report the structure and first comprehensive preclin. evaluation of the next-generation ALK TKI brigatinib.  Exptl. Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib.  The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines.  The brigatinib-ALK co-structure was detd.  Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases.  Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib.  Superior efficacy of brigatinib was also obsd. in mice with ALK+ tumors implanted s.c. or intracranially.  Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clin. achievable concns.  Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R.  The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.  Conclusions: Brigatinib is a highly potent and selective ALK inhibitor.  These findings provide the mol. basis for the promising activity being obsd. in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clin. trials.  Clin Cancer Res; 22(22); 5527-38. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwQUn_qLy7bVg90H21EOLACvtfcHk0lhJFmB6nFOxAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O&md5=1ece23bf36e807562023d0b814c990c7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0569%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DSquillace%26aufirst%3DR.%26aulast%3DNadworny%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEichinger%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMohemmad%26aufirst%3DQ.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DYe%26aufirst%3DE.%26aulast%3DNarasimhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMiret%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DThe%2520Potent%2520ALK%2520Inhibitor%2520Brigatinib%2520%2528AP26113%2529%2520Overcomes%2520Mechanisms%2520of%2520Resistance%2520to%2520First-%2520and%2520Second-Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D22%26spage%3D5527%26epage%3D5538%26doi%3D10.1158%2F1078-0432.CCR-16-0569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK: Precision Medicine Takes on Drug Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-16-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28122866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=137-155&issue=2&author=J.+J.+Linauthor=G.+J.+Rielyauthor=A.+T.+Shaw&title=Targeting+ALK%3A+Precision+Medicine+Takes+on+Drug+Resistance&doi=10.1158%2F2159-8290.CD-16-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK: Precision Medicine Takes on Drug Resistance</span></div><div class="casAuthors">Lin, Jessica J.; Riely, Gregory J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-155</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a validated mol. target in several ALK-rearranged malignancies, including non-small cell lung cancer.  However, the clin. benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance.  Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic.  In this review, we summarize the current successes and challenges of targeting ALK.  Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance.  This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms.  Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome.  Cancer Discov; 7(2); 137-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmMz7s4fYu7Vg90H21EOLACvtfcHk0li3vmoW9da6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D&md5=6f7d5358d13c75b215b0d1e6ce8ac8ff</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1123%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTargeting%2520ALK%253A%2520Precision%2520Medicine%2520Takes%2520on%2520Drug%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D2%26spage%3D137%26epage%3D155%26doi%3D10.1158%2F2159-8290.CD-16-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brigatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0776-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-017-0776-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28597393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1131-1135&issue=10&author=A.+Markham&title=Brigatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0776-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Brigatinib (ALUNBRIG) is a small mol. antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company).  In Apr. 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-pos. metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants.  This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCYwTukZCLVg90H21EOLACvtfcHk0li3vmoW9da6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL&md5=c03f9d61e8e8fd4187d47ee207452f31</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0776-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0776-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrigatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26issue%3D10%26spage%3D1131%26epage%3D1135%26doi%3D10.1007%2Fs40265-017-0776-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&issue=3&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0ljZUr92l8VPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26issue%3D3%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">ERBB Receptors and Cancer: the Complexity of Targeted Inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&issue=5&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+Receptors+and+Cancer%3A+the+Complexity+of+Targeted+Inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0ljZUr92l8VPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520Receptors%2520and%2520Cancer%253A%2520the%2520Complexity%2520of%2520Targeted%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26issue%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. E.</span></span> <span> </span><span class="NLM_article-title">Mutations of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer-Search and Ddestroy</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2005.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ejca.2005.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=16364841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&issue=1&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+Epidermal+Growth+Factor+Receptor+in+Non-Small+Cell+Lung+Cancer-Search+and+Ddestroy&doi=10.1016%2Fj.ejca.2005.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy</span></div><div class="casAuthors">Chan, S. K.; Gullick, W. J.; Hill, M. E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase, by the small mol. drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer.  However, it is now apparent that only a subset of patients responds to such treatment.  Two publications in early 2004 reported the presence of activating mutations in the EGFR tyrosine kinase gene conferring exquisite sensitivity to these drugs.  Several publications have since reported prospective data consistent with this finding.  This brief review summarizes the mutation data from 15 such studies in terms of mutation frequency by clinicopathol. features and correlation with response to tyrosine kinase inhibition.  A new paradigm for the routine detection of such mutations is needed to facilitate patient selection for treatment and further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2iKbYyg0gqbVg90H21EOLACvtfcHk0ljZUr92l8VPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL&md5=01e38085f3beed6636d5e3979d4b9c5a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer-Search%2520and%2520Ddestroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26issue%3D1%26spage%3D17%26epage%3D23%26doi%3D10.1016%2Fj.ejca.2005.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span> <span> </span><span class="NLM_article-title">EGFR Antagonists in Cancer Treatment</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0707704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=18337605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&issue=11&author=F.+Ciardielloauthor=G.+Tortora&title=EGFR+Antagonists+in+Cancer+Treatment&doi=10.1056%2FNEJMra0707704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antagonists in cancer treatment</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1160-1174</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on epidermal growth factor receptor (EGFR) in human carcinogenesis, development of EGFR antagonists for anticancer therapy, and clin. efficacy of EGFR antagonists in human cancers.  Predicting the response to anti-EGFR drugs and future directions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNHvRENSffLVg90H21EOLACvtfcHk0lhxW2IpEBAWPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D&md5=2834999545fd643c6f727d80d357134d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520Antagonists%2520in%2520Cancer%2520Treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26issue%3D11%26spage%3D1160%26epage%3D1174%26doi%3D10.1056%2FNEJMra0707704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lhxW2IpEBAWPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&issue=6&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+Mutation+in+EGFR+Kinase+Causes+Drug+Resistance+by+Increasing+the+Affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhxW2IpEBAWPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520Mutation%2520in%2520EGFR%2520Kinase%2520Causes%2520Drug%2520Resistance%2520by%2520Increasing%2520the%2520Affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D6%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S Resistance Mutations in NSCLC: Current Developments in Medicinal Chemistry</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1002/med.21488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fmed.21488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29377179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1550-1581&issue=5&author=X.+Luauthor=L.+Yuauthor=Z.+Zhangauthor=X.+Renauthor=J.+B.+Smaillauthor=K.+Ding&title=Targeting+EGFRL858R%2FT790M+and+EGFRL858R%2FT790M%2FC797S+Resistance+Mutations+in+NSCLC%3A+Current+Developments+in+Medicinal+Chemistry&doi=10.1002%2Fmed.21488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry</span></div><div class="casAuthors">Lu, Xiaoyun; Yu, Lei; Zhang, Zhang; Ren, Xiaomei; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1550-1581</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Both the first-generation reversible epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib and the second-generation covalent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib have significantly improved the survival of non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations.  However, a secondary EGFRT790M mutation leads to the clin. acquired resistance to the first- and second-generation EGFR-TKIs drugs.  A no. of the third-generation wild-type sparing EGFR inhibitors, for example, WZ4002, CO1686, AZD9291, HM61713, EGF816, ASP8173, and PF0674775, have been developed, among which AZD9291 has been approved by US FDA for the treatment of NSCLC patients with EGFRT790M.  More recently, a tertiary EGFRC797S mutation was reported as the dominant resistance mechanism to the third-generation irreversible inhibitors.  It is highly desirable to develop the fourth-generation EGFR inhibitors.  This review summarizes the mechanisms of acquired resistance and the latest medicinal chem. advances on the third- and fourth-generation EGFR inhibitors, with special attention being paid to the allosteric and reversible inhibitors combating the tertiary EGFRC797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNK_1c8SI0qbVg90H21EOLACvtfcHk0ljmtgF9wE1PbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P&md5=71288118ca1d9eaab6d07b056bb5ab56</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fmed.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21488%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DTargeting%2520EGFRL858R%252FT790M%2520and%2520EGFRL858R%252FT790M%252FC797S%2520Resistance%2520Mutations%2520in%2520NSCLC%253A%2520Current%2520Developments%2520in%2520Medicinal%2520Chemistry%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581%26doi%3D10.1002%2Fmed.21488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): a Randomised, Open-Label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&issue=11&author=Y.+L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+Versus+Gefitinib+as+First-Line+Treatment+for+Patients+with+EGFR-Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28ARCHER+1050%29%3A+a+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0ljmtgF9wE1PbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520EGFR-Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ARCHER%25201050%2529%253A%2520a%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5530</span>– <span class="NLM_lpage">5537</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-2571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-10-2571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21775534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5530-5537&issue=17&author=G.+R.+Oxnardauthor=M.+E.+Arcilaauthor=J.+Chmieleckiauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=New+Strategies+in+Overcoming+Acquired+Resistance+to+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+in+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-10-2571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Arcila, Maria E.; Chmielecki, Juliann; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5530-5537</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The management of non-small cell lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in epidermal growth factor receptor (EGFR) are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKI).  In these patients, acquired resistance to EGFR-TKI develops after a median of 10 to 14 mo, at which time the current std. practice is to switch to conventional cytotoxic chemotherapy.  Several possible mechanisms for acquired resistance have been identified, the most common being the development of an EGFR T790M gatekeeper mutation in more than 50% of cases.  In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies.  Clin Cancer Res; 17(17); 5530-7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqYmPYYBThNLVg90H21EOLACvtfcHk0ljH1s2QaAmRmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN&md5=209a41173563ee3776e020c0dacdd465</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2571%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNew%2520Strategies%2520in%2520Overcoming%2520Acquired%2520Resistance%2520to%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26issue%3D17%26spage%3D5530%26epage%3D5537%26doi%3D10.1158%2F1078-0432.CCR-10-2571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Strategies for Overcoming Resistance to EGFR Family Tyrosine Kinase Inhibitors</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2011.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ctrv.2011.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21367530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFGisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=456-464&issue=6&author=G.+Giacconeauthor=Y.+Wang&title=Strategies+for+Overcoming+Resistance+to+EGFR+Family+Tyrosine+Kinase+Inhibitors&doi=10.1016%2Fj.ctrv.2011.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors</span></div><div class="casAuthors">Giaccone, Giuseppe; Wang, Yisong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">456-464</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib have been incorporated into treatment paradigms for patients with advanced non-small cell lung cancer.  These agents are particularly effective in a subset of patients whose tumors harbor activating epidermal growth factor receptor mutations.  However, most patients do not respond to these tyrosine kinase inhibitors, and those who do will eventually acquire resistance that typically results from a secondary epidermal growth factor receptor mutation (e.g., T790M), mesenchymal-epithelial transition factor amplification, or activation of other signaling pathways.  For patients whose tumors have wild-type epidermal growth factor receptor, there are several known mechanisms of initial resistance (e.g., Kirsten rat sarcoma viral oncogene homolog mutations) but these do not account for all cases, suggesting that unknown mechanisms also contribute.  To potentially overcome the issue of resistance, next-generation tyrosine kinase inhibitors are being developed, which irreversibly block multiple epidermal growth factor receptor family members (e.g., afatinib [BIBW 2992] and PF-00299804) and/or vascular endothelial growth factor receptor pathways (e.g., BMS-690514 and XL647).  In addn., drugs that block parallel signaling pathways or signaling mols. downstream of the epidermal growth factor receptor, such as the insulin-like growth factor-1 receptor and the mammalian target of rapamycin, are undergoing clin. evaluation.  As drug resistance appears to be pleomorphic, combinations of drugs or drugs with multiple targets may be more effective in circumventing resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomHSJ2bX3NArVg90H21EOLACvtfcHk0ljH1s2QaAmRmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFGisb4%253D&md5=f2f0779828bf000585c03bebf6ce9c76</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2011.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2011.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DStrategies%2520for%2520Overcoming%2520Resistance%2520to%2520EGFR%2520Family%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2011%26volume%3D37%26issue%3D6%26spage%3D456%26epage%3D464%26doi%3D10.1016%2Fj.ctrv.2011.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragane, N.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Acquired Resistance to Afatinib Clarified with Liquid Biopsy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e0209384</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0209384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1371%2Fjournal.pone.0209384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30550608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlGjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&issue=12&author=T.+Nakamuraauthor=C.+Nakashimaauthor=K.+Komiyaauthor=K.+Kiteraauthor=M.+Hiraiauthor=S.+Kimuraauthor=N.+Aragane&title=Mechanisms+of+Acquired+Resistance+to+Afatinib+Clarified+with+Liquid+Biopsy&doi=10.1371%2Fjournal.pone.0209384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to afatinib clarified with liquid biopsy</span></div><div class="casAuthors">Nakamura, Tomomi; Nakashima, Chiho; Komiya, Kazutoshi; Kitera, Kazuki; Hirai, Mitsuharu; Kimura, Shinya; Aragane, Naoko</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0209384</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Although mechanisms of acquired resistance to 1st and 3rd generation EGFR-TKI continue to be elucidated, there have been few clin. investigations into the mechanisms of acquired resistance to the 2nd generation EGFR-TKI afatinib.  We analyzed data from 20 patients with advanced lung adenocarcinoma who acquired resistance to afatinib, including resistance during EGFR-TKI re-challenge.  We examd. EGFR T790M and C797S mutations, BRAF V600E mutation, and MET amplification with the MBP-QP method and with droplet digital PCR using ctDNA and re-biopsy samples obtained before and after afatinib treatment.  Just before afatinib treatment, 15 of the 20 patients were T790M neg. and five were pos.  Among the T790M neg. patients, 40.0% (6/15) became pos. at the time of PD under afatinib.  In patients pos. for T790M, changes in T790M allele frequency were correlated with afatinib treatment efficacy.  C797S was not detected in any patients just before afatinib treatment, but it appeared after treatment in three patients, although with very low allele frequency.  Two of these three patients, although pos. for both C797S and T790M, achieved PR to osimertinib.  However, PFS of these patients was somewhat shorter than that of patients pos. for T790M only.  BRAF V600E was detected in one patient at PD under afatinib.  MET amplification was not detected in this study.  T790M is assocd. with acquired resistance to afatinib, as with 1st generation EGFR-TKI, but with somewhat lower frequency.  The influence of C797S on resistance to afatinib is less than that of T790M, but C797S might cause shorter PFS under osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWFck7DSCdLVg90H21EOLACvtfcHk0ljH1s2QaAmRmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlGjtbc%253D&md5=9121d85daf0996334730f58bcf0a329c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0209384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0209384%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DC.%26aulast%3DKomiya%26aufirst%3DK.%26aulast%3DKitera%26aufirst%3DK.%26aulast%3DHirai%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DAragane%26aufirst%3DN.%26atitle%3DMechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Afatinib%2520Clarified%2520with%2520Liquid%2520Biopsy%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0209384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors Against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span> (<span class="NLM_issue">7276</span>),  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+Against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgRoe1CGnBGfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520Against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Red Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgRoe1CGnBGfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&issue=20&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+That+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0liK9PYo3xlBQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520That%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Proteome-Wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1388</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.chembiol.2017.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28965727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1388-1400&issue=11&author=S.+Niessenauthor=M.+M.+Dixauthor=S.+Barbasauthor=Z.+E.+Potterauthor=S.+Luauthor=O.+Brodskyauthor=S.+Plankenauthor=D.+Behennaauthor=C.+Almadenauthor=K.+S.+Gajiwalaauthor=K.+Ryanauthor=R.+Ferreauthor=M.+R.+Lazearauthor=M.+M.+Haywardauthor=J.+C.+Kathauthor=B.+F.+Cravatt&title=Proteome-Wide+Map+of+Targets+of+T790M-EGFR-Directed+Covalent+Inhibitors&doi=10.1016%2Fj.chembiol.2017.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">proteome-wide map of targets of t790m-egfr-directed covalent inhibitors</span></div><div class="casAuthors">Niessen, Sherry; Dix, Melissa M.; Barbas, Sabrina; Potter, Zachary E.; Lu, Shuyan; Brodsky, Oleg; Planken, Simon; Behenna, Douglas; Almaden, Chau; Gajiwala, Ketan S.; Ryan, Kevin; Ferre, RoseAnn; Lazear, Michael R.; Hayward, Matthew M.; Kath, John C.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1388-1400.e7</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancers that have kinase-activating epidermal growth factor receptor (EGFR) mutations are highly responsive to first- and second-generation EGFR inhibitors.  However, these patients often relapse due to a secondary, drug-resistant mutation in EGFR whereby the gatekeeper threonine is converted to methionine (T790M).  Several third-generation EGFR inhibitors have been developed that irreversibly inactivate T790M-EGFR while sparing wild-type EGFR, thus reducing epithelium-based toxicities.  Using chem. proteomics, we show here that individual T790M-EGFR inhibitors exhibit strikingly distinct off-target profiles in human cells.  The FDA-approved drug osimertinib (AZD9291), in particular, was found to covalently modify cathepsins in cell and animal models, which correlated with lysosomal accumulation of the drug.  Our findings thus show how chem. proteomics can be used to differentiate covalent kinase inhibitors based on global selectivity profiles in living systems and identify specific off-targets of these inhibitors that may affect drug activity and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP837IUk45tLVg90H21EOLACvtfcHk0lgx-ppQ-l0TcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrnL&md5=dc2db6d29932ffdb991027ba272bd149</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DBarbas%26aufirst%3DS.%26aulast%3DPotter%26aufirst%3DZ.%2BE.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DLazear%26aufirst%3DM.%2BR.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DProteome-Wide%2520Map%2520of%2520Targets%2520of%2520T790M-EGFR-Directed%2520Covalent%2520Inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D1388%26epage%3D1400%26doi%3D10.1016%2Fj.chembiol.2017.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niiro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. A.</span></span> <span> </span><span class="NLM_article-title">Regulation of B-Cell Fate by Antigen-Receptor Signals</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1038/nri955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnri955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12461567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFKnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=945-956&issue=12&author=H.+Niiroauthor=E.+A.+Clark&title=Regulation+of+B-Cell+Fate+by+Antigen-Receptor+Signals&doi=10.1038%2Fnri955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Decision making in the Immune System: Regulation of B-cell fate by antigen-receptor signals</span></div><div class="casAuthors">Niiro, Hiroaki; Clark, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent evidence indicates that B cells are instructed continuously by B-cell receptor (BCR) signals to make crucial cell-fate decisions at several checkpoints during their development.  Targeted disruption of BCR signaling components leads to distinct blocks in B-cell maturation, which indicates that key kinases and adaptors fine-tune BCR signaling to direct appropriate cell fates.  Recent progress in unravelling the mol. mechanisms of the BCR signaling pathways has helped to clarify how BCR signals regulate the proliferation, survival and apoptosis of developing B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Rvo57viTPbVg90H21EOLACvtfcHk0lgx-ppQ-l0TcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFKnu7k%253D&md5=067cedc0cf02eaa7984509776bb34e9e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnri955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri955%26sid%3Dliteratum%253Aachs%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DE.%2BA.%26atitle%3DRegulation%2520of%2520B-Cell%2520Fate%2520by%2520Antigen-Receptor%2520Signals%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2002%26volume%3D2%26issue%3D12%26spage%3D945%26epage%3D956%26doi%3D10.1038%2Fnri955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of B-Cell Lymphoma Pathogenesis</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1038/nrc1589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc1589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15803153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=251-262&issue=4&author=R.+K%C3%BCppers&title=Mechanisms+of+B-Cell+Lymphoma+Pathogenesis&doi=10.1038%2Fnrc1589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of B-cell lymphoma pathogenesis</span></div><div class="casAuthors">Kueppers, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosomal translocations involving the Ig loci are a hallmark of many types of B-cell lymphoma.  Other factors, however, also have important roles in the pathogenesis of B-cell malignancies.  Most B-cell lymphomas depend on the expression of a B-cell receptor (BCR) for survival, and in several B-cell malignancies antigen activation of lymphoma cells through BCR signaling seems to be an important factor for lymphoma pathogenesis.  Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJru-Lq2OdbVg90H21EOLACvtfcHk0lj0VX2Y2KNHow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D&md5=c8451de36e49f59432a4cee00419f97d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fnrc1589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1589%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCppers%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520B-Cell%2520Lymphoma%2520Pathogenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26issue%3D4%26spage%3D251%26epage%3D262%26doi%3D10.1038%2Fnrc1589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal
Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s Tyrosine Kinase in B Cells and Malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&issue=1&author=S.+Pal%0ASinghauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B+Cells+and+Malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2eaKXfDCANc6dbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B%2520Cells%2520and%2520Malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s Tyrosine Kinase in B Cell Malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&issue=4&author=R.+W.+Hendriksauthor=S.+Yuvarajauthor=L.+P.+Kil&title=Targeting+Bruton%E2%80%99s+Tyrosine+Kinase+in+B+Cell+Malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0lj0VX2Y2KNHow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%2BP.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B%2520Cell%2520Malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D4%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The Development of Bruton’s Tyrosine Kinase (BTK) Inhibitors From 2012 to 2017: A Mini-Review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+Development+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+From+2012+to+2017%3A+A+Mini-Review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0ljXGyMMFIQ9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520Development%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520From%25202012%2520to%25202017%253A%2520A%2520Mini-Review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&issue=1&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0ljXGyMMFIQ9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D1%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&issue=6&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-Cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0ljXGyMMFIQ9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-Cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D6%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&issue=1&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0liiDqmUB9zEaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D1%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapatka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppert, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steggerda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span> <span> </span><span class="NLM_article-title">Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1400029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24869598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2286-2294&issue=24&author=J.+A.+Woyachauthor=R.+R.+Furmanauthor=T.-M.+Liuauthor=H.+G.+Ozerauthor=M.+Zapatkaauthor=A.+S.+Ruppertauthor=L.+Xueauthor=D.+H.-H.+Liauthor=S.+M.+Steggerdaauthor=M.+Verseleauthor=S.+S.+Daveauthor=J.+Zhangauthor=A.+S.+Yilmazauthor=S.+M.+Jaglowskiauthor=K.+A.+Blumauthor=A.+Lozanskiauthor=G.+Lozanskiauthor=D.+F.+Jamesauthor=J.+C.+Barrientosauthor=P.+Lichterauthor=S.+Stilgenbauerauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=A.+J.+Johnsonauthor=J.+C.+Byrd&title=Resistance+Mechanisms+for+the+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+Ibrutinib&doi=10.1056%2FNEJMoa1400029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib</span></div><div class="casAuthors">Woyach, Jennifer A.; Furman, Richard R.; Liu, Ta-Ming; Ozer, Hatice Gulcin; Zapatka, Marc; Ruppert, Amy S.; Xue, Ling; Li, Daniel Hsieh-Hsin; Steggerda, Susanne M.; Versele, Matthias; Dave, Sandeep S.; Zhang, Jenny; Yilmaz, Ayse Selen; Jaglowski, Samantha M.; Blum, Kristie A.; Lozanski, Arletta; Lozanski, Gerard; James, Danelle F.; Barrientos, Jacqueline C.; Lichter, Peter; Stilgenbauer, Stephan; Buggy, Joseph J.; Chang, Betty Y.; Johnson, Amy J.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2286-2294, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).  Resistance to irreversible kinase inhibitors and resistance assocd. with BTK inhibition have not been characterized.  Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important.  We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance.  Methods: We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy.  We then performed functional anal. of identified mutations.  In addn., we performed Ion Torrent sequencing for identified resistance mutations on samples from nine patients with prolonged lymphocytosis.  Results: We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLCγ2 in two patients.  Functional anal. showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib.  The R665W and L845F mutations in PLCγ2 are both potentially gain-of-function mutations that lead to autonomous B-cell-receptor activity.  These mutations were not found in any of the patients with prolonged lymphocytosis who were taking ibrutinib.  Conclusions: Resistance to the irreversible BTK inhibitor ibrutinib often involves mutation of a cysteine residue where ibrutinib binding occurs.  This finding, combined with two addnl. mutations in PLCγ2 that are immediately downstream of BTK, underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrutinib in CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpktSKmZODIjLVg90H21EOLACvtfcHk0liiDqmUB9zEaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ&md5=9eaf9f3ed7518c264b413ef4fe826985</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400029%26sid%3Dliteratum%253Aachs%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DT.-M.%26aulast%3DOzer%26aufirst%3DH.%2BG.%26aulast%3DZapatka%26aufirst%3DM.%26aulast%3DRuppert%26aufirst%3DA.%2BS.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%2BH.-H.%26aulast%3DSteggerda%26aufirst%3DS.%2BM.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DDave%26aufirst%3DS.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYilmaz%26aufirst%3DA.%2BS.%26aulast%3DJaglowski%26aufirst%3DS.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DLozanski%26aufirst%3DA.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DLichter%26aufirst%3DP.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DResistance%2520Mechanisms%2520for%2520the%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D24%26spage%3D2286%26epage%3D2294%26doi%3D10.1056%2FNEJMoa1400029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Liberto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blecua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen-Kiang, S.</span></span> <span> </span><span class="NLM_article-title">Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25082755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1022-1035&issue=9&author=D.+Chironauthor=M.+Di+Libertoauthor=P.+Martinauthor=X.+Huangauthor=J.+Sharmanauthor=P.+Blecuaauthor=S.+Mathewauthor=P.+Vijayauthor=K.+Engauthor=S.+Aliauthor=A.+Johnsonauthor=B.+Changauthor=S.+Elyauthor=O.+Elementoauthor=C.+E.+Masonauthor=J.+P.+Leonardauthor=S.+Chen-Kiang&title=Cell-Cycle+Reprogramming+for+PI3K+Inhibition+Overrides+a+Relapse-Specific+C481S+BTK+Mutation+Revealed+by+Longitudinal+Functional+Genomics+in+Mantle+Cell+Lymphoma&doi=10.1158%2F2159-8290.CD-14-0098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma</span></div><div class="casAuthors">Chiron, David; Di Liberto, Maurizio; Martin, Peter; Huang, Xiangao; Sharman, Jeff; Blecua, Pedro; Mathew, Susan; Vijay, Priyanka; Eng, Ken; Ali, Siraj; Johnson, Amy; Chang, Betty; Ely, Scott; Elemento, Olivier; Mason, Christopher E.; Leonard, John P.; Chen-Kiang, Selina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1022-1035</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Longitudinal anal. of MCL tumors identified the relapse-specific BTKC481S mutation and provided evidence that targeting CDK4 overcomes ibrutinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76gjvFtJiRrVg90H21EOLACvtfcHk0liyNCFNW1i62g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur7E&md5=5257fed997f3484db60a49c7e30ed0f1</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0098%26sid%3Dliteratum%253Aachs%26aulast%3DChiron%26aufirst%3DD.%26aulast%3DDi%2BLiberto%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DSharman%26aufirst%3DJ.%26aulast%3DBlecua%26aufirst%3DP.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DVijay%26aufirst%3DP.%26aulast%3DEng%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DEly%26aufirst%3DS.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DMason%26aufirst%3DC.%2BE.%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DCell-Cycle%2520Reprogramming%2520for%2520PI3K%2520Inhibition%2520Overrides%2520a%2520Relapse-Specific%2520C481S%2520BTK%2520Mutation%2520Revealed%2520by%2520Longitudinal%2520Functional%2520Genomics%2520in%2520Mantle%2520Cell%2520Lymphoma%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1022%26epage%3D1035%26doi%3D10.1158%2F2159-8290.CD-14-0098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bond, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK in CLL: Beyond Ibrutinib</span>. <i>Curr. Hematol. Malig. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1007/s11899-019-00512-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs11899-019-00512-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31028669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fpslygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=197-205&issue=3&author=D.+A.+Bondauthor=J.+A.+Woyach&title=Targeting+BTK+in+CLL%3A+Beyond+Ibrutinib&doi=10.1007%2Fs11899-019-00512-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK in CLL: Beyond Ibrutinib</span></div><div class="casAuthors">Bond David A; Woyach Jennifer A</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance.  In this review, we summarize the emerging data for alternative BTKi.  RECENT FINDINGS:  Second-generation BTKi include acalabrutinib, zanubrutinib, and tirabrutinib which offer greater BTK selectivity.  While these agents may limit off-target toxicity, they do not overcome common mechanisms of ibrutinib resistance.  Reversible BTKi including vecabrutinib and LOXO-305 inhibit BTK in the presence of C481S mutation, and non-selective reversible BTKi, including ARQ-531, may retain activity despite mutations within PLCG2.  Early-phase studies are underway to establish the clinical efficacy and toxicity of these agents.  A randomized trial of ibrutinib versus acalabrutinib is ongoing, and acalabrutinib may be an option for ibrutinib-intolerant patients.  Results from ongoing trials of alternate BTKi will help to define their role in CLL therapy as single agents or in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ28N5K1jZXbmZyxfu64m4ffW6udTcc2ea3asYsieu02rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fpslygsw%253D%253D&md5=4b0f317b8fd4818220d906d889450158</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs11899-019-00512-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-019-00512-0%26sid%3Dliteratum%253Aachs%26aulast%3DBond%26aufirst%3DD.%2BA.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520BTK%2520in%2520CLL%253A%2520Beyond%2520Ibrutinib%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D197%26epage%3D205%26doi%3D10.1007%2Fs11899-019-00512-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhowski, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettl, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddocks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andritsos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapalombella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eathiraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadessa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1300</span>– <span class="NLM_lpage">1315</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-1409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-17-1409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30093506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1300-1315&issue=10&author=S.+D.+Reiffauthor=R.+Mantelauthor=L.+L.+Smithauthor=J.+T.+Greeneauthor=E.+M.+Muhowskiauthor=C.+A.+Fabianauthor=V.+M.+Goettlauthor=M.+Tranauthor=B.+K.+Harringtonauthor=K.+A.+Rogersauthor=F.+T.+Awanauthor=K.+Maddocksauthor=L.+Andritsosauthor=A.+M.+Lehmanauthor=D.+Sampathauthor=R.+Lapalombellaauthor=S.+Eathirajauthor=G.+Abbadessaauthor=B.+Schwartzauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+A.+Woyach&title=The+BTK+Inhibitor+ARQ+531+Targets+Ibrutinib-Resistant+CLL+and+Richter+Transformation&doi=10.1158%2F2159-8290.CD-17-1409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation</span></div><div class="casAuthors">Reiff, Sean D.; Mantel, Rose; Smith, Lisa L.; Greene, J. T.; Muhowski, Elizabeth M.; Fabian, Catherine A.; Goettl, Virginia M.; Tran, Minh; Harrington, Bonnie K.; Rogers, Kerry A.; Awan, Farrukh T.; Maddocks, Kami; Andritsos, Leslie; Lehman, Amy M.; Sampath, Deepa; Lapalombella, Rosa; Eathiraj, Sudharshan; Abbadessa, Giovanni; Schwartz, Brian; Johnson, Amy J.; Byrd, John C.; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1300-1315</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematol. malignancies, including chronic lymphocytic leukemia (CLL).  Here, we describe preclin. investigations of ARQ 531, a potent, reversible inhibitor of BTK with addnl. activity against Src family kinases and kinases related to ERK signaling.  We hypothesized that targeting addnl. kinases would improve global inhibition of signaling pathways, producing more robust responses.  In vitro treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B-cell receptor (BCR) signaling, viability, migration, CD40 and CD86 expression, and NF-κB gene transcription.  In vivo, ARQ 531 was found to increase survival over ibrutinib in a murine Eμ-TCL1 engraftment model of CLL and a murine Eμ-MYC/TCL1 engraftment model resembling Richter transformation.  Addnl., ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCΓ 2 mutants, which facilitate clin. resistance to ibrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPG67bk_6NSrVg90H21EOLACvtfcHk0lh0ynHesaENGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLo%253D&md5=3b968f070e3c9a0995abe6b8ddd58c47</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-1409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-1409%26sid%3Dliteratum%253Aachs%26aulast%3DReiff%26aufirst%3DS.%2BD.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DGreene%26aufirst%3DJ.%2BT.%26aulast%3DMuhowski%26aufirst%3DE.%2BM.%26aulast%3DFabian%26aufirst%3DC.%2BA.%26aulast%3DGoettl%26aufirst%3DV.%2BM.%26aulast%3DTran%26aufirst%3DM.%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DRogers%26aufirst%3DK.%2BA.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DMaddocks%26aufirst%3DK.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLapalombella%26aufirst%3DR.%26aulast%3DEathiraj%26aufirst%3DS.%26aulast%3DAbbadessa%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520BTK%2520Inhibitor%2520ARQ%2520531%2520Targets%2520Ibrutinib-Resistant%2520CLL%2520and%2520Richter%2520Transformation%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D10%26spage%3D1300%26epage%3D1315%26doi%3D10.1158%2F2159-8290.CD-17-1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&issue=6&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+Potent%2C+Selective%2C+and+Noncovalent+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+in+Early+Clinical+Development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lh0ynHesaENGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Noncovalent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D6%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhowski, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">Noncovalent Inhibition of C481S Bruton Tyrosine Kinase by GDC-0853: A New Treatment Strategy for Ibrutinib-Resistant CLL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-809020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2017-10-809020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30018078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=1039-1049&issue=10&author=S.+D.+Reiffauthor=E.+M.+Muhowskiauthor=D.+Guinnauthor=A.+Lehmanauthor=C.+A.+Fabianauthor=C.+Cheneyauthor=R.+Mantelauthor=L.+Smithauthor=A.+J.+Johnsonauthor=W.+B.+Youngauthor=A.+R.+Johnsonauthor=L.+Liuauthor=J.+C.+Byrdauthor=J.+A.+Woyach&title=Noncovalent+Inhibition+of+C481S+Bruton+Tyrosine+Kinase+by+GDC-0853%3A+A+New+Treatment+Strategy+for+Ibrutinib-Resistant+CLL&doi=10.1182%2Fblood-2017-10-809020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent inhibition of C481S Bruton tyrosinekinase by GDC-0853: A new treatment strategy foribrutinib-resistant CLL</span></div><div class="casAuthors">Reiff, Sean D.; Muhowski, Elizabeth M.; Guinn, Daphne; Lehman, Amy; Fabian, Catherine A.; Cheney, Carolyn; Mantel, Rose; Smith, Lisa; Johnson, Amy J.; Young, Wendy B.; Johnson, Adam R.; Liu, Lichuan; Byrd, John C.; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The clin. success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as aneffective strategy for treating hematol. malignancies, including chronic lymphocyticleukemia (CLL).  Despite ibrutinib's ability to produce durable remissions in patients, acquiredresistance can develop, mostly commonly by mutation of C481 of BTK in theibrutinib binding site.  Here, we characterize a novel BTK inhibitor, GDC-0853, to evaluateits preclin. efficacy in ibrutinib-naive and ibrutinib-resistant CLL.  GDC-0853 is uniqueamong reported BTK inhibitors in that it does not rely upon covalent reaction with C481 tostabilize its occupancy within BTK's ATP binding site.  As with ibrutinib,GDC-0853 potently reduces B-cell receptor signaling, viability, NF-κB-dependent transcription,activation, and migration in treatment na.ovrddot.ive CLL cells.  We found that GDC-0853also inhibits the most commonly reported ibrutinib-resistant BTK mutant (C481S) both in abiochem. enzyme activity assay and in a stably transfected 293T cell line and maintainscytotoxicity against patient CLL cells harboring C481S BTK mutations.  Addnl., GDC-0853 does not inhibit endothelial growth factor receptor or ITK, 2 alternative targets ofibrutinib that are likely responsible for some adverse events and may reduce the efficacy of ibrutinib-antibodycombinations, resp.  Our results using GDC-0853 indicate that noncovalent, selective BTK inhibition may beeffective in CLL either as monotherapy or in combination with therapeutic antibodies, esp. among the emergingpopulation of patients with acquired resistance to ibrutinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLuDzLD7FMb7Vg90H21EOLACvtfcHk0liEfFPgZdM_aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL&md5=f867a4ef8469fb2db96eb45c481a7b76</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-809020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-809020%26sid%3Dliteratum%253Aachs%26aulast%3DReiff%26aufirst%3DS.%2BD.%26aulast%3DMuhowski%26aufirst%3DE.%2BM.%26aulast%3DGuinn%26aufirst%3DD.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DFabian%26aufirst%3DC.%2BA.%26aulast%3DCheney%26aufirst%3DC.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DNoncovalent%2520Inhibition%2520of%2520C481S%2520Bruton%2520Tyrosine%2520Kinase%2520by%2520GDC-0853%253A%2520A%2520New%2520Treatment%2520Strategy%2520for%2520Ibrutinib-Resistant%2520CLL%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3D10%26spage%3D1039%26epage%3D1049%26doi%3D10.1182%2Fblood-2017-10-809020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00480</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00480" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2897-2907&issue=10&author=A.+R.+Johnsonauthor=P.+B.+Kohliauthor=A.+Katewaauthor=E.+Gogolauthor=L.+D.+Belmontauthor=R.+Choyauthor=E.+Penuelauthor=L.+Burtonauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+F.+Ortwineauthor=K.+Bowmanauthor=Y.+Frankeauthor=C.+Tamauthor=A.+Estevezauthor=K.+Mortaraauthor=J.+Wuauthor=H.+Liauthor=M.+Linauthor=P.+Bergeronauthor=J.+J.+Crawfordauthor=W.+B.+Young&title=Battling+Btk+Mutants+With+Noncovalent+Inhibitors+That+Overcome+Cys481+and+Thr474+Mutations&doi=10.1021%2Facschembio.6b00480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span></div><div class="casAuthors">Johnson, Adam R.; Kohli, Pawan Bir; Katewa, Arna; Gogol, Emily; Belmont, Lisa D.; Choy, Regina; Penuel, Elicia; Burton, Luciana; Eigenbrot, Charles; Yu, Christine; Ortwine, Daniel F.; Bowman, Krista; Franke, Yvonne; Tam, Christine; Estevez, Alberto; Mortara, Kyle; Wu, Jiansheng; Li, Hong; Lin, May; Bergeron, Philippe; Crawford, James J.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2897-2907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown impressive clin. efficacy in a range of B-cell malignancies, however acquired resistance has emerged and second generation therapies are now being sought.  Ibrutinib is a covalent, irreversible inhibitor that modifies Cys481 in the ATP binding site of Btk and renders the enzyme inactive, thereby blocking B-cell receptor signal transduction.  Not surprisingly, Cys481 is the most commonly mutated Btk residue in cases of acquired resistance to ibrutinib.  Mutations at other sites, including Thr474, a gatekeeper residue, have also been detected.  Herein the authors describe noncovalent Btk inhibitors that differ from covalent inhibitors like ibrutinib in that they do not interact with Cys481, they potently inhibit the ibrutinib-resistant Btk C481S mutant in vitro and in cells, and they are exquisitely selective for Btk.  Noncovalent inhibitors such as GNE-431 also show excellent potency against the C481R, T474I, and T474M mutants.  X-ray crystallog. anal. of Btk provides insight into the unique mode of binding of these inhibitors that explains their high selectivity for Btk and their retained activity against mutant forms of Btk.  This class of noncovalent Btk inhibitors may provide a treatment option to patients, esp. those who have acquired resistance to ibrutinib by mutation of Cys481 or Thr474.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkuzaMmxhJ67Vg90H21EOLACvtfcHk0liEfFPgZdM_aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E&md5=1e0458160f967ed01c259751cc2118e1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00480%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DBattling%2520Btk%2520Mutants%2520With%2520Noncovalent%2520Inhibitors%2520That%2520Overcome%2520Cys481%2520and%2520Thr474%2520Mutations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3D2897%26epage%3D2907%26doi%3D10.1021%2Facschembio.6b00480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lh8WNVqC4y9rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalsy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-15-0399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25934077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=713-722&issue=7&author=Z.+Piotrowskaauthor=M.+J.+Niederstauthor=C.+A.+Karlovichauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=M.+Mino-Kenudsonauthor=L.+Fultonauthor=A.+N.+Hataauthor=E.+L.+Lockermanauthor=A.+Kalsyauthor=S.+Digumarthyauthor=A.+Muzikanskyauthor=M.+Raponiauthor=A.+R.+Garciaauthor=H.+E.+Mulveyauthor=M.+K.+Parksauthor=R.+H.+DiCeccaauthor=D.+Dias-Santagataauthor=A.+J.+Iafrateauthor=A.+T.+Shawauthor=A.+R.+Allenauthor=J.+A.+Engelmanauthor=L.+V.+Sequist&title=Heterogeneity+Underlies+the+Emergence+of+EGFR+T790+Wild-Type+Clones+Following+Treatment+of+T790M-Positive+Cancers+with+a+Third-Generation+EGFR+Inhibitor&doi=10.1158%2F2159-8290.CD-15-0399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span></div><div class="casAuthors">Piotrowska, Zofia; Niederst, Matthew J.; Karlovich, Chris A.; Wakelee, Heather A.; Neal, Joel W.; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N.; Lockerman, Elizabeth L.; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Raponi, Mitch; Garcia, Angel R.; Mulvey, Hillary E.; Parks, Melissa K.; DiCecca, Richard H.; Dias-Santagata, Dora; Iafrate, A. John; Shaw, Alice T.; Allen, Andrew R.; Engelman, Jeffrey A.; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance.  We biopsied patients at rociletinib progression to explore resistance mechanisms.  Among 12 patients with T790M-pos. cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies.  Two T790-wild-type cancers underwent small cell lung cancer transformation; three T790M-pos. cancers acquired EGFR amplification.  We documented T790-wild-type and T790M-pos. clones coexisting within a single pre-rociletinib biopsy.  The pretreatment fraction of T790M-pos. cells affected response to rociletinib.  Longitudinal circulating tumor DNA (ctDNA) anal. revealed an increase in plasma EGFR-activating mutation, and T790M heralded rociletinib resistance in some patients, whereas in others the activating mutation increased but T790M remained suppressed.  Together, these findings demonstrate the role of tumor heterogeneity when therapies targeting a singular resistance mechanism are used.  To further improve outcomes, combination regimens that also target T790-wild-type clones are required.  Significance: This report documents that half of T790M-pos. EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance.  We show that tumor heterogeneity has important clin. implications and that plasma ctDNA analyses can sometimes predict emerging resistance mechanisms.  Cancer Discov; 5(7); 713-22. ©2015 AACR.  See related commentary by Ichihara and Lovly, p. 694.  This article is highlighted in the In This Issue feature, p.  681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4z_KYM4-R7Vg90H21EOLACvtfcHk0lh8WNVqC4y9rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF&md5=6512fff2abf24f5bef615a70b0f89c56</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0399%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DParks%26aufirst%3DM.%2BK.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DHeterogeneity%2520Underlies%2520the%2520Emergence%2520of%2520EGFR%2520T790%2520Wild-Type%2520Clones%2520Following%2520Treatment%2520of%2520T790M-Positive%2520Cancers%2520with%2520a%2520Third-Generation%2520EGFR%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D7%26spage%3D713%26epage%3D722%26doi%3D10.1158%2F2159-8290.CD-15-0399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&issue=17&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+Allelic+Context+of+the+C797S+Mutation+Acquired+upon+Treatment+with+Third-Generation+EGFR+Inhibitors+Impacts+Sensitivity+to+Subsequent+Treatment+Strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0lgk5KKExf6uig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Allelic%2520Context%2520of%2520the%2520C797S%2520Mutation%2520Acquired%2520upon%2520Treatment%2520with%2520Third-Generation%2520EGFR%2520Inhibitors%2520Impacts%2520Sensitivity%2520to%2520Subsequent%2520Treatment%2520Strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors Against C797S Resistance in Non-Small-Cell Lung Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&issue=10&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+Progress+of+Small-Molecule+Epidermal+Growth+Factor+Receptor+%28EGFR%29+Inhibitors+Against+C797S+Resistance+in+Non-Small-Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lgk5KKExf6uig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520Progress%2520of%2520Small-Molecule%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Inhibitors%2520Against%2520C797S%2520Resistance%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+Boseauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+Dobelauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtmullerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+Selective+and+Rigidify%3A+The+Discovery+Path+toward+a+Next+Generation+of+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lhGlUcvVKu_cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DBose%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DDobel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520Selective%2520and%2520Rigidify%253A%2520The%2520Discovery%2520Path%2520toward%2520a%2520Next%2520Generation%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4293</span>– <span class="NLM_lpage">4305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4293-4305&issue=8&author=D.+E.+Heppnerauthor=M.+Guntherauthor=F.+Wittlingerauthor=S.+A.+Lauferauthor=M.+J.+Eck&title=Structural+Basis+for+EGFR+Mutant+Inhibition+by+Trisubstituted+Imidazole+Inhibitors&doi=10.1021%2Facs.jmedchem.0c00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors</span></div><div class="casAuthors">Heppner, David E.; Gunther, Marcel; Wittlinger, Florian; Laufer, Stefan A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4293-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy.  Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism.  To dissect the mol. basis for their activity, we detd. the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallog.  These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the "αC-helix out" inactive state.  Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant.  Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHNY-o4bNl6bVg90H21EOLACvtfcHk0lhGlUcvVKu_cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D&md5=0ee498e9de51374ad9a049d7ffd9fa24</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DWittlinger%26aufirst%3DF.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructural%2520Basis%2520for%2520EGFR%2520Mutant%2520Inhibition%2520by%2520Trisubstituted%2520Imidazole%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305%26doi%3D10.1021%2Facs.jmedchem.0c00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant EGFR(L858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&issue=15&author=J.+Shenauthor=T.+Zhangauthor=S.+J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.+H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-Based+Design+of+5-Methylpyrimidopyridone+Derivatives+as+New+Wild-Type+Sparing+Inhibitors+of+the+Epidermal+Growth+Factor+Receptor+Triple+Mutant+EGFR%28L858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0ljxG5bxUPXBuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-Based%2520Design%2520of%25205-Methylpyrimidopyridone%2520Derivatives%2520as%2520New%2520Wild-Type%2520Sparing%2520Inhibitors%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Triple%2520Mutant%2520EGFR%2528L858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">New Promise and Opportunities for Allosteric Kinase Inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1002/anie.201914525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fanie.201914525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=32313322" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=X.+Luauthor=J.+B.+Smaillauthor=K.+Ding&title=New+Promise+and+Opportunities+for+Allosteric+Kinase+Inhibitors&doi=10.1002%2Fanie.201914525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fanie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201914525%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DNew%2520Promise%2520and%2520Opportunities%2520for%2520Allosteric%2520Kinase%2520Inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26doi%3D10.1002%2Fanie.201914525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Emergence of Allosteric Drug-Resistance Mutations: New Challenges for Allosteric Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.drudis.2019.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31634592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=177-184&issue=1&author=S.+Luauthor=Y.+Qiuauthor=D.+Niauthor=X.+Heauthor=J.+Puauthor=J.+Zhang&title=Emergence+of+Allosteric+Drug-Resistance+Mutations%3A+New+Challenges+for+Allosteric+Drug+Discovery&doi=10.1016%2Fj.drudis.2019.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery</span></div><div class="casAuthors">Lu, Shaoyong; Qiu, Yuran; Ni, Duan; He, Xinheng; Pu, Jun; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allosteric drugs have several significant advantages over traditional orthosteric drugs, encompassing higher selectivity and lower toxicity.  Although allosteric drugs have potential advantages as therapeutic agents to treat human diseases, allosteric drug-resistance mutations still occur, rendering these drugs ineffective.  Here, we review the emergence of allosteric drug-resistance mutations with an emphasis on examples covering clin. important therapeutic targets, including Breakpoint cluster region-Abelson tyrosine kinase (Bcr-Abl), Akt kinase [also called Protein Kinase B (PKB)], isocitrate dehydrogenase (IDH), MAPK/ERK kinase (MEK), and SRC homol. 2 domain-contg. phosphatase 2 (SHP2).  We also discuss challenges assocd. with tackling allosteric drug resistance and the possible strategies to overcome this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4a4rK610lLLVg90H21EOLACvtfcHk0ljxG5bxUPXBuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I&md5=052d6b87051bd173ab692aa963bdd3ea</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DEmergence%2520of%2520Allosteric%2520Drug-Resistance%2520Mutations%253A%2520New%2520Challenges%2520for%2520Allosteric%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26issue%3D1%26spage%3D177%26epage%3D184%26doi%3D10.1016%2Fj.drudis.2019.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrián, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajpai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bcr–Abl by Combining Allosteric with ATP-Binding-Site Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span> (<span class="NLM_issue">7280</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nature08675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature08675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=20072125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=501-506&issue=7280&author=J.+Zhangauthor=F.+J.+Adri%C3%A1nauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+G.+Liauthor=R.+E.+Iacobauthor=T.+Simauthor=J.+Powersauthor=C.+Dierksauthor=F.+Sunauthor=G.-R.+Guoauthor=Q.+Dingauthor=B.+Okramauthor=Y.+Choiauthor=A.+Wojciechowskiauthor=X.+Dengauthor=G.+Liuauthor=G.+Fendrichauthor=A.+Straussauthor=N.+Vajpaiauthor=S.+Grzesiekauthor=T.+Tuntlandauthor=Y.+Liuauthor=B.+Bursulayaauthor=M.+Azamauthor=P.+W.+Manleyauthor=J.+R.+Engenauthor=G.+Q.+Daleyauthor=M.+Warmuthauthor=N.+S.+Gray&title=Targeting+Bcr%E2%80%93Abl+by+Combining+Allosteric+with+ATP-Binding-Site+Inhibitors&doi=10.1038%2Fnature08675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Adrian, Francisco J.; Jahnke, Wolfgang; Cowan-Jacob, Sandra W.; Li, Allen G.; Iacob, Roxana E.; Sim, Taebo; Powers, John; Dierks, Christine; Sun, Fangxian; Guo, Gui-Rong; Ding, Qiang; Okram, Barun; Choi, Yongmun; Wojciechowski, Amy; Deng, Xianming; Liu, Guoxun; Fendrich, Gabriele; Strauss, Andre; Vajpai, Navratna; Grzesiek, Stephan; Tuntland, Tove; Liu, Yi; Bursulaya, Badry; Azam, Mohammad; Manley, Paul W.; Engen, John R.; Daley, George Q.; Warmuth, Markus; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7280</span>),
    <span class="NLM_cas:pages">501-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In an effort to find new pharmacol. modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor.  Here, using soln. NMR, X-ray crystallog., mutagenesis and hydrogen exchange mass spectrometry, we show that GNF-2 binds to the myristate-binding site of Abl, leading to changes in the structural dynamics of the ATP-binding site.  GNF-5, an analog of GNF-2 with improved pharmacokinetic properties, when used in combination with the ATP-competitive inhibitors imatinib or nilotinib, suppressed the emergence of resistance mutations in vitro, displayed additive inhibitory activity in biochem. and cellular assays against T315I mutant human Bcr-Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bone-marrow transplantation model.  These results show that therapeutically relevant inhibition of Bcr-Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtkKFuTQx1LVg90H21EOLACvtfcHk0ljo32F3DPvOPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D&md5=46c122384fa004d27865c77f4a9165b7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnature08675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08675%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAdri%25C3%25A1n%26aufirst%3DF.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DDierks%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DG.-R.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Bcr%25E2%2580%2593Abl%2520by%2520Combining%2520Allosteric%2520with%2520ATP-Binding-Site%2520Inhibitors%26jtitle%3DNature%26date%3D2010%26volume%3D463%26issue%3D7280%26spage%3D501%26epage%3D506%26doi%3D10.1038%2Fnature08675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonamici, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groell, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellé, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wylie, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8120</span>– <span class="NLM_lpage">8135</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKru7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8120-8135&issue=18&author=J.+Schoepferauthor=W.+Jahnkeauthor=G.+Berelliniauthor=S.+Buonamiciauthor=S.+Cotestaauthor=S.+W.+Cowan-Jacobauthor=S.+Doddauthor=P.+Drueckesauthor=D.+Fabbroauthor=T.+Gabrielauthor=J.-M.+Groellauthor=R.+M.+Grotzfeldauthor=A.+Q.+Hassanauthor=C.+Henryauthor=V.+Iyerauthor=D.+Jonesauthor=F.+Lombardoauthor=A.+Looauthor=P.+W.+Manleyauthor=X.+Pell%C3%A9author=G.+Rummelauthor=B.+Salemauthor=M.+Warmuthauthor=A.+A.+Wylieauthor=T.+Zollerauthor=A.+L.+Marzinzikauthor=P.+Furet&title=Discovery+of+Asciminib+%28ABL001%29%2C+an+Allosteric+Inhibitor+of+the+Tyrosine+Kinase+Activity+of+BCR-ABL1&doi=10.1021%2Facs.jmedchem.8b01040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1</span></div><div class="casAuthors">Schoepfer, Joseph; Jahnke, Wolfgang; Berellini, Giuliano; Buonamici, Silvia; Cotesta, Simona; Cowan-Jacob, Sandra W.; Dodd, Stephanie; Drueckes, Peter; Fabbro, Doriano; Gabriel, Tobias; Groell, Jean-Marc; Grotzfeld, Robert M.; Hassan, A. Quamrul; Henry, Chrystele; Iyer, Varsha; Jones, Darryl; Lombardo, Franco; Loo, Alice; Manley, Paul W.; Pelle, Xavier; Rummel, Gabriele; Salem, Bahaa; Warmuth, Markus; Wylie, Andrew A.; Zoller, Thomas; Marzinzik, Andreas L.; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8120-8135</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of asciminib I, an allosteric inhibitor of the BCR-ABL1 kinase for use in treating chronic myelogenous leukemia (CML), is delineated.  I binds to the myristate pocket of BCR-ABL1 and maintains activity against cancer cells possessing ATP-site mutations in BCR-ABL1 that render them resistant to tyrosine kinase inhibitors; cancer cells resistant to myristate-site mutations are likely to be susceptible to ATP-competitive inhibitors so that combinations of I and tyrosine kinase inhibitors should suppress the emergence of resistance.  Fragment-based screening using NMR and X-ray yielded ligands for the myristate pocket, while an NMR-based conformational assay guided the transformation of these inactive ligands into ABL1 inhibitors.  Further structure-based optimization for potency, physicochem., pharmacokinetic, and drug-like properties, culminated in I which is currently undergoing clin. studies in CML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIQbEIXXgRgbVg90H21EOLACvtfcHk0ljo32F3DPvOPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKru7bN&md5=023a566cdf4faba6dfc05501b8b6a6ed</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01040%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DBerellini%26aufirst%3DG.%26aulast%3DBuonamici%26aufirst%3DS.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGroell%26aufirst%3DJ.-M.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DPell%25C3%25A9%26aufirst%3DX.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWylie%26aufirst%3DA.%2BA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Asciminib%2520%2528ABL001%2529%252C%2520an%2520Allosteric%2520Inhibitor%2520of%2520the%2520Tyrosine%2520Kinase%2520Activity%2520of%2520BCR-ABL1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D18%26spage%3D8120%26epage%3D8135%26doi%3D10.1021%2Facs.jmedchem.8b01040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wylie, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonamici, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanasse, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">The Allosteric Inhibitor ABL001 Enables Dual Targeting of BCR–ABL1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span> (<span class="NLM_issue">7647</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1038/nature21702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature21702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28329763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=733-737&issue=7647&author=A.+A.+Wylieauthor=J.+Schoepferauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+Looauthor=P.+Furetauthor=A.+L.+Marzinzikauthor=X.+Pelleauthor=J.+Donovanauthor=W.+Zhuauthor=S.+Buonamiciauthor=A.+Q.+Hassanauthor=F.+Lombardoauthor=V.+Iyerauthor=M.+Palmerauthor=G.+Berelliniauthor=S.+Doddauthor=S.+Thohanauthor=H.+Bitterauthor=S.+Branfordauthor=D.+M.+Rossauthor=T.+P.+Hughesauthor=L.+Petruzzelliauthor=K.+G.+Vanasseauthor=M.+Warmuthauthor=F.+Hofmannauthor=N.+J.+Keenauthor=W.+R.+Sellers&title=The+Allosteric+Inhibitor+ABL001+Enables+Dual+Targeting+of+BCR%E2%80%93ABL1&doi=10.1038%2Fnature21702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1</span></div><div class="casAuthors">Wylie, Andrew A.; Schoepfer, Joseph; Jahnke, Wolfgang; Cowan-Jacob, Sandra W.; Loo, Alice; Furet, Pascal; Marzinzik, Andreas L.; Pelle, Xavier; Donovan, Jerry; Zhu, Wenjing; Buonamici, Silvia; Hassan, A. Quamrul; Lombardo, Franco; Iyer, Varsha; Palmer, Michael; Berellini, Giuliano; Dodd, Stephanie; Thohan, Sanjeev; Bitter, Hans; Branford, Susan; Ross, David M.; Hughes, Timothy P.; Petruzzelli, Lilli; Vanasse, K. Gary; Warmuth, Markus; Hofmann, Francesco; Keen, Nicholas J.; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7647</span>),
    <span class="NLM_cas:pages">733-737</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is driven by the activity of the BCR-ABL1 fusion oncoprotein.  ABL1 kinase inhibitors have improved the clin. outcomes for patients with CML, with over 80% of patients treated with imatinib surviving for more than 10 years.  Second-generation ABL1 kinase inhibitors induce more potent mol. responses in both previously untreated and imatinib-resistant patients with CML.  Studies in patients with chronic-phase CML have shown that around 50% of patients who achieve and maintain undetectable BCR-ABL1 transcript levels for at least 2 years remain disease-free after the withdrawal of treatment.  Here we characterize ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clin. development testing in patients with CML and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia.  In contrast to catalytic-site ABL1 kinase inhibitors, ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation.  ABL001 and second-generation catalytic inhibitors have similar cellular potencies but distinct patterns of resistance mutations, with genetic barcoding studies revealing pre-existing clonal populations with no shared resistance between ABL001 and the catalytic inhibitor nilotinib.  Consistent with this profile, acquired resistance was obsd. with single-agent therapy in mice; however, the combination of ABL001 and nilotinib led to complete disease control and eradicated CML xenograft tumors without recurrence after the cessation of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreJ5YSS_wiS7Vg90H21EOLACvtfcHk0lime_BWbtlLUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWntbc%253D&md5=20d00f222ab8d9387cb340a9531b8ba5</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnature21702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21702%26sid%3Dliteratum%253Aachs%26aulast%3DWylie%26aufirst%3DA.%2BA.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DPelle%26aufirst%3DX.%26aulast%3DDonovan%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBuonamici%26aufirst%3DS.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DBerellini%26aufirst%3DG.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DThohan%26aufirst%3DS.%26aulast%3DBitter%26aufirst%3DH.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DPetruzzelli%26aufirst%3DL.%26aulast%3DVanasse%26aufirst%3DK.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DThe%2520Allosteric%2520Inhibitor%2520ABL001%2520Enables%2520Dual%2520Targeting%2520of%2520BCR%25E2%2580%2593ABL1%26jtitle%3DNature%26date%3D2017%26volume%3D543%26issue%3D7647%26spage%3D733%26epage%3D737%26doi%3D10.1038%2Fnature21702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antelope, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabriskie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomicter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szankasi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayuela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2844</span>– <span class="NLM_lpage">2847</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fleu.2017.264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28819281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWntL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=2844-2847&issue=12&author=W.+Qiangauthor=O.+Antelopeauthor=M.+S.+Zabriskieauthor=A.+D.+Pomicterauthor=N.+A.+Velloreauthor=P.+Szankasiauthor=D.+Reaauthor=J.+M.+Cayuelaauthor=T.+W.+Kelleyauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hare&title=Mechanisms+of+Resistance+to+the+BCR-ABL1+Allosteric+Inhibitor+Asciminib&doi=10.1038%2Fleu.2017.264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib</span></div><div class="casAuthors">Qiang, W.; Antelope, O.; Zabriskie, M. S.; Pomicter, A. D.; Vellore, N. A.; Szankasi, P.; Rea, D.; Cayuela, J. M.; Kelley, T. W.; Deininger, M. W.; O'Hare, T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2844-2847</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The development of asciminib (ABL001),1 a highly potent and specific ABL1/ABL2/BCR-ABL1 tyrosine kinase inhibitor (TKI) with an allosteric mechanism of action that culminated from research in academic and pharmaceutical industry labs. spanning more than a decade.  Currently in clin. trials for relapsed/refractory Philadelphia chromosome-pos. (Ph+) leukemia patients (ClinicalTrials.gov: NCT02081378), asciminib represents a major advance from the structurally related, prototype compds. GNF-2 and GNF-5.2,3,4 We investigated mechanisms of asciminib resistance and identified two major categories: (1) upregulation of the ABCG2 efflux pump, resulting in undetectable intracellular asciminib levels and (2) emergence of BCR-ABL1 mutations at the myristoyl-binding site and at a distant residue.  We generated five asciminib-resistant, BCR-ABL1-pos. cell lines by adapting to increasing concns. of asciminib (range: 20-10 000 nm): K562asciminib-R, LAMA84asciminib-R, KYO1asciminib-R, Ba/F3 BCR-ABL1asciminib-R and KCL-22asciminib-R cells (Supplementary Methods).  In K562asciminib-R cells, methanethiosulfonate-based cell proliferation assays demonstrated a ∼60-fold increase in asciminib IC50 compared to parental K562 cells, despite remaining sensitive to the ATP-competitive TKIs imatinib, nilotinib, dasatinib and ponatinib (Figure 1a; Supplementary Table S1).  Immunoblot anal. revealed similar results, showing marked restoration of BCR-ABL1 tyrosine kinase activity and downstream STAT5 tyrosine phosphorylation in the presence of asciminib but not ponatinib (Supplementary Figure S1a).  However, next-generation sequencing (NGS) and Sanger sequencing of the BCR-ABL1 kinase domain identified no mutations (Supplementary Table S2).5 To check for the possibility of reduced intracellular drug concns., asciminib levels were measured following treatment using a customized liq. chromatog.-mass spectrometry/mass spectrometry (LC-MS/MS) method.6 Asciminib was undetectable in K562asciminib-R cells, but present at substantial levels in parental K562 cells (Supplementary Figure S1b), with an inhibitor-based screen for potential involvement of efflux pumps (Supplementary Figure S1c) and anal. by qPCR and immunoblot (Figure 1b) all implicating ABCG2.  Cell proliferation expts. revealed that the ABCG2 inhibitor Ko143 (100 nm) restored asciminib effectiveness against K562asciminib-R cells but had no effect on the asciminib IC50 for K562 cells (Figure 1c).  Similar results were obtained for LAMA84asciminib-R (Supplementary Figure S2; Supplementary Table S1) and KYO1asciminib-R cells (Supplementary Figure S3; Supplementary Table S1).  Our findings support ABCG2-mediated efflux of asciminib as the major mechanism of resistance in these cell lines, warrant its profiling among patients with asciminib resistance in the clinic, and suggest that combining asciminib with an ABCG2 inhibitor could override resistance, though development of clin. ABCG2 inhibitors is at the investigational stage.7, 8 In contrast, mutation-based resistance mechanisms were obsd. in Ba/F3 BCR-ABL1asciminib-R and KCL-22asciminib-R cells.  In Ba/F3 BCR-ABL1asciminib-R cells, a>1000-fold increase in asciminib IC50 over Ba/F3 BCR-ABL1 cells was obsd., despite undiminished sensitivity to ATP-competitive TKIs (Figure 2a; Supplementary Table S1).  While immunoblot anal. demonstrated restored BCR-ABL1 signaling in Ba/F3 BCR-ABL1asciminib-R cells treated with asciminib (Supplementary Figure S4a), LC-MS/MS anal. showed similar amts. of asciminib in Ba/F3 BCR-ABL1 and Ba/F3 BCR-ABL1asciminib-R cells and there was no evidence of efflux pump involvement (Supplementary Figure S4b-e).  NGS and Sanger sequencing of the BCR-ABL1 kinase domain identified a novel BCR-ABL1C464W mutation (Supplementary Table S2), mol. modeling of which suggested that the bulky tryptophan residue impedes access of asciminib to the myristoyl-binding pocket, consistent with high-level resistance (Figure 2b).  While other BCR-ABL1 mutations within or near the myristoyl-binding pocket (for example, A337V; P465S; V468F) have been shown to confer asciminib resistance,1 this is the first report of BCR-ABL1C464W as an asciminib-resistant mutant.  KCL-22asciminib-R cells exhibited two mutations at similar allelic frequencies:9 BCR-ABL1M244V near the ATP-binding site and BCR-ABL1A337V in the myristoyl-binding pocket (Supplementary Table S2), and single-cell sorting followed by clonal sequencing revealed a BCR-ABL1M244V/A337V compd. mutation.10, 11 KCL-22asciminib-R cells were completely insensitive to asciminib (IC50: 10 000 nm as compared to 2.2 nm for parental KCL-22 cells), but remained sensitive to ATP-binding site TKIs (Figure 2c; Supplementary Figure S5a; Supplementary Table S1).  LC/MS-MS showed comparable intracellular asciminib levels in KCL-22asciminib-R and KCL-22 cells, and there was no evidence of either altered effectiveness of asciminib against KCL-22asciminib-R cells by inclusion of an efflux pump inhibitor or upregulation of an efflux pump by qPCR or ABCG2 immunoblot (Supplementary Figure S5b-e).  Sequencing of increasingly asciminib-resistant cells collected in the process of generating the final KCL-22asciminib-R cell line revealed a progression from BCR-ABL1A337V to BCR-ABL1M244V/A337V (Figure 2d).  The reported asciminib IC50 value of 702 nM for KCL-22A337V cells1 is consistent with the inability of this mutation alone to confer the high-level resistance obsd. in KCL-22asciminib-R cells.  The BCR-ABL1M244V/A337V compd. mutant confers high-level asciminib resistance but inclusion of clin. achievable concns. of imatinib lead to outgrowth of BCR-ABL1S229P/T315I at the expense of BCR-ABL1M244V/A337V (Supplementary Figure S6), highlighting a potential complication of addressing asciminib resistance by switching to or including an ATP-binding site TKI.  Taken together, our findings suggest that mechanisms of acquired resistance to the allosteric BCR-ABL1 inhibitor asciminib involve restoration of BCR-ABL1 signaling, due to either asciminib efflux or select BCR-ABL1 mutations.  It may be possible to override ABCG2-mediated drug efflux by dose escalation of asciminib.  The achievable clin. dose is estd. to be at least 1μm.12 Another possibility to circumvent this resistance mechanism is to design an allosteric inhibitor that is not a substrate for efflux pump(s).  While development of a next-generation allosteric inhibitor13 is possible, the potential for cross-resistant myristoyl-binding pocket mutations may be high, as those obsd. for asciminib to date completely block inhibitor access to the binding pocket.  Alternatively, myristoyl-binding site mutation-based resistance to asciminib could be countered with an ATP-binding site TKI, though such a mutation occurring in tandem with an addnl. kinase domain mutation could result in resistance to both types of inhibitor.  The strategy of simultaneously treating with asciminib and an ATP-binding site TKI (imatinib, nilotinib or dasatinib) to minimize opportunity for resistance is under clin. investigation.  Ponatinib, which has activity against the T315I mutant and reported potency as an ABCG2 inhibitor,14, 15 may also warrant consideration in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRMgO1FwXE47Vg90H21EOLACvtfcHk0lime_BWbtlLUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWntL3F&md5=e769bc2091eebd5f0e838fa6cf18d749</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.264%26sid%3Dliteratum%253Aachs%26aulast%3DQiang%26aufirst%3DW.%26aulast%3DAntelope%26aufirst%3DO.%26aulast%3DZabriskie%26aufirst%3DM.%2BS.%26aulast%3DPomicter%26aufirst%3DA.%2BD.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3DSzankasi%26aufirst%3DP.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DCayuela%26aufirst%3DJ.%2BM.%26aulast%3DKelley%26aufirst%3DT.%2BW.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520the%2520BCR-ABL1%2520Allosteric%2520Inhibitor%2520Asciminib%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26issue%3D12%26spage%3D2844%26epage%3D2847%26doi%3D10.1038%2Fleu.2017.264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabriskie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage Stevens, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antelope, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Than, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomicter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szankasi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayuela, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccell.2019.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31543464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=431-443&issue=4&author=C.+A.+Eideauthor=M.+S.+Zabriskieauthor=S.+L.+Savage+Stevensauthor=O.+Antelopeauthor=N.+A.+Velloreauthor=H.+Thanauthor=A.+R.+Schultzauthor=P.+Clairauthor=A.+D.+Bowlerauthor=A.+D.+Pomicterauthor=D.+Yanauthor=A.+V.+Seninaauthor=W.+Qiangauthor=T.+W.+Kelleyauthor=P.+Szankasiauthor=M.+C.+Heinrichauthor=J.+W.+Tynerauthor=D.+Reaauthor=J.-M.+Cayuelaauthor=D.-W.+Kimauthor=C.+E.+Tognonauthor=T.+O%E2%80%99Hareauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Combining+the+Allosteric+Inhibitor+Asciminib+with+Ponatinib+Suppresses+Emergence+of+and+Restores+Efficacy+against+Highly+Resistant+BCR-ABL1+Mutants&doi=10.1016%2Fj.ccell.2019.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants</span></div><div class="casAuthors">Eide, Christopher A.; Zabriskie, Matthew S.; Savage Stevens, Samantha L.; Antelope, Orlando; Vellore, Nadeem A.; Than, Hein; Schultz, Anna Reister; Clair, Phillip; Bowler, Amber D.; Pomicter, Anthony D.; Yan, Dongqing; Senina, Anna V.; Qiang, Wang; Kelley, Todd W.; Szankasi, Philippe; Heinrich, Michael C.; Tyner, Jeffrey W.; Rea, Delphine; Cayuela, Jean-Michel; Kim, Dong-Wook; Tognon, Cristina E.; O'Hare, Thomas; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-443.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-pos. (Ph+) leukemia is effectively managed with several approved drugs, including ponatinib for BCR-ABL1T315I-mutant disease.  However, therapy options are limited for patients with leukemic clones bearing multiple BCR-ABL1 mutations.  Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compd. mutants.  We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clin. isolates and cell lines.  Inclusion of asciminib restores ponatinib's effectiveness against currently untreatable compd. mutants at clin. achievable concns.  Our findings support combining asciminib with ponatinib as a treatment strategy for this molecularly defined group of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwcxeCHYx87Vg90H21EOLACvtfcHk0lime_BWbtlLUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M&md5=77fb1a5430c13932b2af244e8749e7ee</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DZabriskie%26aufirst%3DM.%2BS.%26aulast%3DSavage%2BStevens%26aufirst%3DS.%2BL.%26aulast%3DAntelope%26aufirst%3DO.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3DThan%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DA.%2BR.%26aulast%3DClair%26aufirst%3DP.%26aulast%3DBowler%26aufirst%3DA.%2BD.%26aulast%3DPomicter%26aufirst%3DA.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DSenina%26aufirst%3DA.%2BV.%26aulast%3DQiang%26aufirst%3DW.%26aulast%3DKelley%26aufirst%3DT.%2BW.%26aulast%3DSzankasi%26aufirst%3DP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DCayuela%26aufirst%3DJ.-M.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DCombining%2520the%2520Allosteric%2520Inhibitor%2520Asciminib%2520with%2520Ponatinib%2520Suppresses%2520Emergence%2520of%2520and%2520Restores%2520Efficacy%2520against%2520Highly%2520Resistant%2520BCR-ABL1%2520Mutants%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26issue%3D4%26spage%3D431%26epage%3D443%26doi%3D10.1016%2Fj.ccell.2019.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective Allosteric Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span> (<span class="NLM_issue">7605</span>),  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&issue=7605&author=Y.+Jiaauthor=C.-H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.-Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+Resistance+with+Mutant-Selective+Allosteric+Inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lhlgVIqmorJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520Resistance%2520with%2520Mutant-Selective%2520Allosteric%2520Inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26issue%3D7605%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&issue=7&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+J.+H.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Single+and+Dual+Targeting+of+Mutant+EGFR+with+an+Allosteric+Inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0lhlgVIqmorJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520Dual%2520Targeting%2520of%2520Mutant%2520EGFR%2520with%2520an%2520Allosteric%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_label">102. </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1549-1553&issue=11&author=D.+J.+H.+De+Clercqauthor=D.+E.+Heppnerauthor=C.+Toauthor=J.+Jangauthor=E.+Parkauthor=C.-H.+Yunauthor=M.+Mushajiangauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=D.+A.+Scottauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Discovery+and+Optimization+of+Dibenzodiazepinones+as+Allosteric+Mutant-Selective+EGFR+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102102.</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span></div><div class="casAuthors">De Clercq, Dries J. H.; Heppner, David E.; To, Ciric; Jang, Jaebong; Park, Eunyoung; Yun, Cai-Hong; Mushajiang, Mierzhati; Shin, Bo Hee; Gero, Thomas W.; Scott, David A.; Janne, Pasi A.; Eck, Michael J.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1549-1553</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors represent a promising new therapeutic strategy for targeting kinases harboring oncogenic driver mutations in cancers.  Here, we report the discovery, optimization, and structural characterization of allosteric mutant-selective EGFR inhibitors comprising a 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one scaffold.  Our structure-based medicinal chem. effort yielded an inhibitor (3) of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with an IC50 of ∼10 nM and high selectivity, as assessed by kinome profiling.  Further efforts to develop allosteric dibenzodiazepinone inhibitors may serve as the basis for new therapeutic options for targeting drug-resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyvHIT2KWY7Vg90H21EOLACvtfcHk0lhQN19yX3zPIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM&md5=9d8771e7444fa58f06dff284f6f393da</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00381%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Dibenzodiazepinones%2520as%2520Allosteric%2520Mutant-Selective%2520EGFR%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1549%26epage%3D1553%26doi%3D10.1021%2Facsmedchemlett.9b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00848</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00848" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=240-249&issue=3&author=X.+Sunauthor=Y.+Rao&title=PROTACs+as+Potential+Therapeutic+Agents+for+Cancer+Drug+Resistance&doi=10.1021%2Facs.biochem.9b00848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance</span></div><div class="casAuthors">Sun, Xiuyun; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Cancer drug resistance has become the major problem facing current clin. treatment via different kinds of therapies.  Proteolysis targeting chimeras (PROTACs) as a novel and powerful strategy have attracted a great deal of attention both from academia and from industry for their sensitivity to drug-resistant targets relying on their unique characteristics compared to those of traditional inhibitors.  PROTACs exert their function by degrading the target protein instead of inhibiting targets.  Thus, different kinds of resistance could be conquered by PROTACs such as target mutation or overexpression.  Various resistant targets have been overcome by PROTACs, including AR, ER, BTK, BET, and BCR-ABL.  Though PROTACs have achieved some significant advances in combating drug resistance, more cases are needed to prove the efficiency of PROTACs in addressing the hurdle of resistance in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_hi9ENDVPLVg90H21EOLACvtfcHk0lhQN19yX3zPIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP&md5=bb7d34974dcb22f73ce9ce60665c391f</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00848%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%2520as%2520Potential%2520Therapeutic%2520Agents%2520for%2520Cancer%2520Drug%2520Resistance%26jtitle%3DBiochemistry%26date%3D2020%26volume%3D59%26issue%3D3%26spage%3D240%26epage%3D249%26doi%3D10.1021%2Facs.biochem.9b00848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">When Kinases Meet PROTACs</span>. <i>Chin. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1002/cjoc.201800293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fcjoc.201800293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Whs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=971-977&issue=10&author=L.+Tanauthor=N.+S.+Gray&title=When+Kinases+Meet+PROTACs&doi=10.1002%2Fcjoc.201800293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">When Kinases Meet PROTACs</span></div><div class="casAuthors">Tan, Li; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-977</span>CODEN:
                <span class="NLM_cas:coden">CJOCEV</span>;
        ISSN:<span class="NLM_cas:issn">1001-604X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Small mol. drugs targeting kinases have revolutionized treatment options for millions of patients worldwide, esp. in oncol.  These targeted treatments have less side effects because they inhibit a specific dysfunctional kinase usually with relatively narrow selectivity.  However, kinase inhibitors do have well-established liabilities, most prominently the emergence of drug resistance.  Moreover, the majority of kinases are multidomain and multifunctional proteins that in addn. to their enzymic activity have scaffolding and other roles, and inhibitors seldom address these alternative functions.  Recently, small mol. mediated targeted protein degrdn. emerged as a new pharmacol. strategy.  The majority of small mol. degraders are bispecific mols. called proteolysis targeting chimeras (PROTACs), and their mechanism of action is based on simultaneous recruitment of the target of interest and an E3 ligase, resulting in target polyubiquitination and eventual destruction by the proteasome.  Over the last couple of years, PROTAC strategy has been developed and validated for a range of targets, including kinases.  Here, we introduce the targeted protein degrdn. strategy, provide an overview of representative kinase PROTACs, and describe design rationales, efficacy and specificity.  We also discuss their potential advantages, as well as comment on some of the limitations of this emerging pharmacol. modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSq2mWe6GuL7Vg90H21EOLACvtfcHk0liMX-WSC0uycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Whs7nO&md5=62bdc9ad20001b4f9a2167bc695757fe</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fcjoc.201800293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcjoc.201800293%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DWhen%2520Kinases%2520Meet%2520PROTACs%26jtitle%3DChin.%2520J.%2520Chem.%26date%3D2018%26volume%3D36%26issue%3D10%26spage%3D971%26epage%3D977%26doi%3D10.1002%2Fcjoc.201800293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTAC-Induced BTK Degradation as a Novel Ttherapy for Mutated BTK C481S Induced Ibrutinib-Resistant B-cell Malignancies</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1038/s41422-018-0055-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41422-018-0055-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29875397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ektbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=779-781&issue=7&author=Y.+Sunauthor=X.+Zhaoauthor=N.+Dingauthor=H.+Gaoauthor=Y.+Wuauthor=Y.+Yangauthor=M.+Zhaoauthor=J.+Hwangauthor=Y.+Songauthor=W.+Liuauthor=Y.+Rao&title=PROTAC-Induced+BTK+Degradation+as+a+Novel+Ttherapy+for+Mutated+BTK+C481S+Induced+Ibrutinib-Resistant+B-cell+Malignancies&doi=10.1038%2Fs41422-018-0055-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies</span></div><div class="casAuthors">Sun, Yonghui; Zhao, Xingwang; Ding, Ning; Gao, Hongying; Wu, Yue; Yang, Yiqing; Zhao, Meng; Hwang, Jinseok; Song, Yuqin; Liu, Wanli; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-781</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In this study, for the first time, we report the development of BTK-targeting degraders using the PROTAC strategy.  These PROTACs could ef fi ciently degrade ibrutinib-sensitive BTK-WT (wild type).  More importantly, our newly designed PROTACs also significantly induced the degrdn. of ibrutinib resistant BTK-C481S (50% degrdn. efficiency at 30 nM).  Furthermore, our PROTAC mols. ef fi ciently inhibited cell proliferation and colony formation, while exhibited no obvious inhibition (>1000 nM) of ITK, EGFR, and TEC, which are major off-targets of ibrutinib.  These data demonstrate the strong potential for developing PROTAC-based therapeutic mols.  The results indicate that the PROTAC strategy (protein degrdn. instead of inhibition) could be adopted as a general and powerful therapeutic treatment for drug-resistant cancers in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_FLdaUP_HLVg90H21EOLACvtfcHk0liMX-WSC0uycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ektbzO&md5=1cca51ac76ecb3b491da0117b21271fb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fs41422-018-0055-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-018-0055-1%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTAC-Induced%2520BTK%2520Degradation%2520as%2520a%2520Novel%2520Ttherapy%2520for%2520Mutated%2520BTK%2520C481S%2520Induced%2520Ibrutinib-Resistant%2520B-cell%2520Malignancies%26jtitle%3DCell%2520Res.%26date%3D2018%26volume%3D28%26issue%3D7%26spage%3D779%26epage%3D781%26doi%3D10.1038%2Fs41422-018-0055-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Degradation of Bruton’s Tyrosine Kinase Mutants by PROTACs for Potential Treatment of Ibrutinib-Resistant non-Hodgkin Lymphomas</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2105</span>– <span class="NLM_lpage">2110</span>, <span class="refDoi"> DOI: 10.1038/s41375-019-0440-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41375-019-0440-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30858551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=2105-2110&issue=8&author=Y.+Sunauthor=N.+Dingauthor=Y.+Songauthor=Z.+Yangauthor=W.+Liuauthor=J.+Zhuauthor=Y.+Rao&title=Degradation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Mutants+by+PROTACs+for+Potential+Treatment+of+Ibrutinib-Resistant+non-Hodgkin+Lymphomas&doi=10.1038%2Fs41375-019-0440-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas</span></div><div class="casAuthors">Sun Yonghui; Yang Zimo; Rao Yu; Ding Ning; Song Yuqin; Zhu Jun; Liu Wanli</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2105-2110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF-dfST00W0BcfW6udTcc2eYEMF2111kRTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D&md5=9d58ea99a2e3c695ee226e78431fce91</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41375-019-0440-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-019-0440-x%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDegradation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Mutants%2520by%2520PROTACs%2520for%2520Potential%2520Treatment%2520of%2520Ibrutinib-Resistant%2520non-Hodgkin%2520Lymphomas%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26issue%3D8%26spage%3D2105%26epage%3D2110%26doi%3D10.1038%2Fs41375-019-0440-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">3564</span>– <span class="NLM_lpage">3575</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3564-3575&issue=26&author=A.+D.+Buhimschiauthor=H.+A.+Armstrongauthor=M.+Toureauthor=S.+Jaime-Figueroaauthor=T.+L.+Chenauthor=A.+M.+Lehmanauthor=J.+A.+Woyachauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=C.+M.+Crews&title=Targeting+the+C481S+Ibrutinib-Resistance+Mutation+in+Bruton%E2%80%99s+Tyrosine+Kinase+Using+PROTAC-Mediated+Degradation&doi=10.1021%2Facs.biochem.8b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation</span></div><div class="casAuthors">Buhimschi, Alexandru D.; Armstrong, Haley A.; Toure, Momar; Jaime-Figueroa, Saul; Chen, Timothy L.; Lehman, Amy M.; Woyach, Jennifer A.; Johnson, Amy J.; Byrd, John C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3564-3575</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies.  Yet, more than 80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S).  Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist and these patients have poor outcomes.  To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degrdn. of both wild-type and C481S mutant BTK.  We selected a lead PROTAC, MT-802, from several candidates based on its potency to induce BTK knockdown.  MT-802 recruits BTK to the cereblon (CRBN) E3 ubiquitin ligase complex to trigger BTK ubiquitination and degrdn. via the proteasome.  MT-802 binds fewer off-target kinases than ibrutinib and retains equiv. potency (>99% degrdn. at nanomolar concns.) against wild-type and C481S BTK.  In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot.  Collectively, these data provide basis for further preclin. study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-ls5ps9FaLVg90H21EOLACvtfcHk0lhHMJZbTNX2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO&md5=bd27f09d041413c7bacb6d61fcb9a327</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00391%26sid%3Dliteratum%253Aachs%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DArmstrong%26aufirst%3DH.%2BA.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%2BL.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeting%2520the%2520C481S%2520Ibrutinib-Resistance%2520Mutation%2520in%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Using%2520PROTAC-Mediated%2520Degradation%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26issue%3D26%26spage%3D3564%26epage%3D3575%26doi%3D10.1021%2Facs.biochem.8b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-07-862953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2018-07-862953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30545835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlGjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2019&pages=952-961&issue=9&author=D.+Dobrovolskyauthor=E.+S.+Wangauthor=S.+Morrowauthor=C.+Leahyauthor=T.+Faustauthor=R.+P.+Nowakauthor=K.+A.+Donovanauthor=G.+Yangauthor=Z.+Liauthor=E.+S.+Fischerauthor=S.+P.+Treonauthor=D.+M.+Weinstockauthor=N.+S.+Gray&title=Bruton+Tyrosine+Kinase+Degradation+as+a+Therapeutic+Strategy+for+Cancer&doi=10.1182%2Fblood-2018-07-862953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase degradation as a therapeutic strategy for cancer</span></div><div class="casAuthors">Dobrovolsky, Dennis; Wang, Eric S.; Morrow, Sara; Leahy, Catharine; Faust, Tyler; Nowak, Radoslaw P.; Donovan, Katherine A.; Yang, Guang; Li, Zhengnian; Fischer, Eric S.; Treon, Steven P.; Weinstock, David M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">952-961</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies.  However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.  We hypothesized that small-mol.-induced BTK degrdn. may overcome some of the limitations of traditional enzymic inhibitors.  Here, we demonstrate that BTK degrdn. results in potent suppression of signaling and proliferation in cancer cells and that BTK degraders efficiently degrade C481S-BTK.  Moreover, we discovered DD-03-171, an optimized lead compd. that exhibits enhanced antiproliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading BTK, IKFZ1, and IKFZ3 as well as efficacy against patient-derived xenografts in vivo.  Thus, "triple degrdn." may be an effective therapeutic approach for treating MCL and overcoming ibrutinib resistance, thereby addressing a major unmet need in the treatment of MCL and other B-cell lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN4GLppunGArVg90H21EOLACvtfcHk0lhHMJZbTNX2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlGjtrY%253D&md5=ce7e48897378c2821d728daf6d9935d5</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-07-862953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-07-862953%26sid%3Dliteratum%253Aachs%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DMorrow%26aufirst%3DS.%26aulast%3DLeahy%26aufirst%3DC.%26aulast%3DFaust%26aufirst%3DT.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Degradation%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Cancer%26jtitle%3DBlood%26date%3D2019%26volume%3D133%26issue%3D9%26spage%3D952%26epage%3D961%26doi%3D10.1182%2Fblood-2018-07-862953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk Inhibition Suppresses B Cell- and Myeloid Cell-Mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&issue=1&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+Inhibition+Suppresses+B+Cell-+and+Myeloid+Cell-Mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0liB5WJZ2pr2hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520and%2520Myeloid%2520Cell-Mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26issue%3D1%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9281</span>– <span class="NLM_lpage">9298</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01264</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVantrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9281-9298&issue=20&author=Q.+Zhaoauthor=C.+Renauthor=L.+Liuauthor=J.+Chenauthor=Y.+Shaoauthor=N.+Sunauthor=R.+Sunauthor=Y.+Kongauthor=X.+Dingauthor=X.+Zhangauthor=Y.+Xuauthor=B.+Yangauthor=Q.+Yinauthor=X.+Yangauthor=B.+Jiang&title=Discovery+of+SIAIS178+as+an+Effective+BCR-ABL+Degrader+by+Recruiting+Von+Hippel-Lindau+%28VHL%29+E3+Ubiquitin+Ligase&doi=10.1021%2Facs.jmedchem.9b01264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase</span></div><div class="casAuthors">Zhao, Quanju; Ren, Chaowei; Liu, Linyi; Chen, Jinju; Shao, Yubao; Sun, Ning; Sun, Renhong; Kong, Ying; Ding, Xinyu; Zhang, Xianfang; Xu, Youwei; Yang, Bei; Yin, Qianqian; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9281-9298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oncogenic fusion protein BCR-ABL is the driving force of leukemogenesis in chronic myeloid leukemia (CML).  Despite great progress for CML treatment through application of tyrosine kinase inhibitors (TKIs) against BCR-ABL, long-term drug administration and clin. resistance continue to be an issue.  Herein, we described the design, synthesis, and evaluation of novel proteolysis-targeting chimeric (PROTAC) small mols. targeting BCR-ABL which connect dasatinib and VHL E3 ubiquitin ligase ligand by extensive optimization of linkers.  Our efforts have yielded SIAIS178 (19), which induces proper interaction between BCR-ABL and VHL ligase leading to effective degrdn. of BCR-ABL protein, achieves significant growth inhibition of BCR-ABL+ leukemic cells in vitro, and induces substantial tumor regression against K562 xenograft tumors in vivo.  In addn., SIAIS178 also degrades several clin. relevant resistance-conferring mutations.  Our data indicate that SIAIS178 as efficacious BCR-ABL degrader warrants extensive further investigation for the treatment of BCR-ABL+ leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLBFfujSx6ZbVg90H21EOLACvtfcHk0liB5WJZ2pr2hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVantrnN&md5=50ace274dbc6ef3931f86504a1be93a7</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01264%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520SIAIS178%2520as%2520an%2520Effective%2520BCR-ABL%2520Degrader%2520by%2520Recruiting%2520Von%2520Hippel-Lindau%2520%2528VHL%2529%2520E3%2520Ubiquitin%2520Ligase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D20%26spage%3D9281%26epage%3D9298%26doi%3D10.1021%2Facs.jmedchem.9b01264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs: Great Opportunities for Academia and Industry</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">64</span>, <span class="refDoi"> DOI: 10.1038/s41392-019-0101-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41392-019-0101-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31885879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=64&author=X.+Sunauthor=H.+Gaoauthor=Y.+Yangauthor=M.+Heauthor=Y.+Wuauthor=Y.+Songauthor=Y.+Tongauthor=Y.+Rao&title=PROTACs%3A+Great+Opportunities+for+Academia+and+Industry&doi=10.1038%2Fs41392-019-0101-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: great opportunities for academia and industry</span></div><div class="casAuthors">Sun Xiuyun; Gao Hongying; Yang Yiqing; He Ming; Wu Yue; Song Yugang; Tong Yan; Rao Yu; Sun Xiuyun; Gao Hongying; Yang Yiqing; Rao Yu</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although many kinds of therapies are applied in the clinic, drug-resistance is a major and unavoidable problem.  Another disturbing statistic is the limited number of drug targets, which are presently only 20-25% of all protein targets that are currently being studied.  Moreover, the focus of current explorations of targets are their enzymatic functions, which ignores the functions from their scaffold moiety.  As a promising and appealing technology, PROteolysis TArgeting Chimeras (PROTACs) have attracted great attention both from academia and industry for finding available approaches to solve the above problems.  PROTACs regulate protein function by degrading target proteins instead of inhibiting them, providing more sensitivity to drug-resistant targets and a greater chance to affect the nonenzymatic functions.  PROTACs have been proven to show better selectivity compared to classic inhibitors.  PROTACs can be described as a chemical knockdown approach with rapidity and reversibility, which presents new and different biology compared to other gene editing tools by avoiding misinterpretations that arise from potential genetic compensation and/or spontaneous mutations.  PRTOACs have been widely explored throughout the world and have outperformed not only in cancer diseases, but also in immune disorders, viral infections and neurodegenerative diseases.  Although PROTACs present a very promising and powerful approach for crossing the hurdles of present drug discovery and tool development in biology, more efforts are needed to gain to get deeper insight into the efficacy and safety of PROTACs in the clinic.  More target binders and more E3 ligases applicable for developing PROTACs are waiting for exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQretvERU2xT-_Q9URG6Dx8fW6udTcc2eYBiEan0U0mvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D&md5=7d9545a21e3a78cededf2977a31e8f7d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fs41392-019-0101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-019-0101-6%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%253A%2520Great%2520Opportunities%2520for%2520Academia%2520and%2520Industry%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2019%26volume%3D4%26spage%3D64%26doi%3D10.1038%2Fs41392-019-0101-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation: Expanding the Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&issue=12&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+Protein+Degradation%3A+Expanding+the+Toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0lh-6ckenv3X4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%253A%2520Expanding%2520the%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26issue%3D12%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leischner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illert, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bubnoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span> <span> </span><span class="NLM_article-title">The Secondary FLT3-ITD F691L Mutation Induces Resistance to AC220 in FLT3-ITD<sup>+</sup> AML But Retains in Vitro Sensitivity to PKC412 and Sunitinib</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1416</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fleu.2013.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=23392356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1416-1418&issue=6&author=C.+Albersauthor=H.+Leischnerauthor=M.+Verbeekauthor=C.+Yuauthor=A.+L.+Illertauthor=C.+Peschelauthor=N.+von+Bubnoffauthor=J.+Duyster&title=The+Secondary+FLT3-ITD+F691L+Mutation+Induces+Resistance+to+AC220+in+FLT3-ITD%2B+AML+But+Retains+in+Vitro+Sensitivity+to+PKC412+and+Sunitinib&doi=10.1038%2Fleu.2013.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib</span></div><div class="casAuthors">Albers, C.; Leischner, H.; Verbeek, M.; Yu, C.; Illert, A. L.; Peschel, C.; von Bubnoff, N.; Duyster, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1416-1418</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This paper discusses a secondary FLT3 internal tandem duplication (FLT3-ITD) mutation in a 48-yr-old female patient with FLT3-ITD+ acute myeloid leukemia (AML) mediating resistance to the FLT3 inhibitor AC220 but retains in vitro sensitivity to PKC412 and sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR7iOLeeWO5bVg90H21EOLACvtfcHk0lh-6ckenv3X4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFektb4%253D&md5=83b22218f5bac1e80c24f3fd60f35114</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.14%26sid%3Dliteratum%253Aachs%26aulast%3DAlbers%26aufirst%3DC.%26aulast%3DLeischner%26aufirst%3DH.%26aulast%3DVerbeek%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DThe%2520Secondary%2520FLT3-ITD%2520F691L%2520Mutation%2520Induces%2520Resistance%2520to%2520AC220%2520in%2520FLT3-ITD%252B%2520AML%2520But%2520Retains%2520in%2520Vitro%2520Sensitivity%2520to%2520PKC412%2520and%2520Sunitinib%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26issue%3D6%26spage%3D1416%26epage%3D1418%26doi%3D10.1038%2Fleu.2013.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koryotowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leversha, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMatteo, R. P.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4190</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&issue=11&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+Resistance+to+Imatinib+in+Gastrointestinal+Stromal+Tumor+Occurs+Through+Secondary+Gene+Mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0lh-xWZgJXx9Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520Resistance%2520to%2520Imatinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Occurs%2520Through%2520Secondary%2520Gene%2520Mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yi Zhang, Deqin Rong, Bingbing Li, <span class="NLM_string-name hlFld-ContribAuthor">Yuanxiang Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7900-7925. <a href="https://doi.org/10.1021/acs.jmedchem.0c02055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BEpigenetic%252BRegulators%252Bwith%252BCovalent%252BSmall-Molecule%252BInhibitors%26aulast%3DZhang%26aufirst%3DYi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26112020%26date%3D18022021%26volume%3D64%26issue%3D12%26spage%3D7900%26epage%3D7925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wuqing Deng, Xiaojuan Chen, Kaili Jiang, Xiaojuan Song, Minhao Huang, Zheng-Chao Tu, Zhang Zhang, Xiaojing Lin, Raquel Ortega, Adam V. Patterson, Jeff B. Smaill, Ke Ding, Suming Chen, Yongheng Chen, <span class="NLM_string-name hlFld-ContribAuthor">Xiaoyun Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 647-652. <a href="https://doi.org/10.1021/acsmedchemlett.1c00052" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00052%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInvestigation%252Bof%252BCovalent%252BWarheads%252Bin%252Bthe%252BDesign%252Bof%252B2-Aminopyrimidine-based%252BFGFR4%252BInhibitors%26aulast%3DDeng%26aufirst%3DWuqing%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D23012021%26date%3D19032021%26date%3D22032021%26volume%3D12%26issue%3D4%26spage%3D647%26epage%3D652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryan A. Brawn, Andrew Cook, Kiyoyuki Omoto, Jiyuan Ke, Craig Karr, Federico Colombo, Milena Virrankoski, Sudeep Prajapati, Dominic Reynolds, David M. Bolduc, Tuong-Vi Nguyen, Patricia Gee, Deanna Borrelli, Benjamin Caleb, Shihua Yao, Sean Irwin, Nicholas A. Larsen, Anand Selvaraj, Xuesong Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Stephanos Ioannidis</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 93-98. <a href="https://doi.org/10.1021/acsmedchemlett.0c00517" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00517%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BAminopyrazole%252BDerivatives%252Bas%252BPotent%252BInhibitors%252Bof%252BWild-Type%252Band%252BGatekeeper%252BMutant%252BFGFR2%252Band%252B3%26aulast%3DBrawn%26aufirst%3DRyan%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D25092020%26date%3D25112020%26date%3D02122020%26volume%3D12%26issue%3D1%26spage%3D93%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu‐juan  Feng</span>, <span class="hlFld-ContribAuthor ">Yu‐Lin  Ren</span>, <span class="hlFld-ContribAuthor ">Li‐Ming  Zhao</span>, <span class="hlFld-ContribAuthor ">Guo‐Qiang  Xue</span>, <span class="hlFld-ContribAuthor ">Wen‐Hao  Yu</span>, <span class="hlFld-ContribAuthor ">Jia‐Qi  Yang</span>, <span class="hlFld-ContribAuthor ">Jun‐Wei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel
              α‐Acyloxycarboxamide‐Based
              Derivatives as
              c‐Met
              Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2021,</strong> <em>39 </em>
                                    (8)
                                     , 2241-2250. <a href="https://doi.org/10.1002/cjoc.202100106" title="DOI URL">https://doi.org/10.1002/cjoc.202100106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.202100106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.202100106%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B%2525CE%2525B1%2525E2%252580%252590Acyloxycarboxamide%2525E2%252580%252590Based%252BDerivatives%252Bas%252Bc%2525E2%252580%252590Met%252BInhibitors%26aulast%3DFeng%26aufirst%3DYu%25E2%2580%2590juan%26date%3D2021%26date%3D2021%26volume%3D39%26issue%3D8%26spage%3D2241%26epage%3D2250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Du</span>, <span class="hlFld-ContribAuthor ">Biwei  Yang</span>, <span class="hlFld-ContribAuthor ">Quanlin  An</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Xin  Cao</span>, <span class="hlFld-ContribAuthor ">Jinglin  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Innovation</span><span> <strong>2021,</strong> <em>2 </em>
                                    (2)
                                     , 100103. <a href="https://doi.org/10.1016/j.xinn.2021.100103" title="DOI URL">https://doi.org/10.1016/j.xinn.2021.100103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xinn.2021.100103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xinn.2021.100103%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Innovation%26atitle%3DAcquired%252Bresistance%252Bto%252Bthird-generation%252BEGFR-TKIs%252Band%252Bemerging%252Bnext-generation%252BEGFR%252Binhibitors%26aulast%3DDu%26aufirst%3DXiaojing%26date%3D2021%26volume%3D2%26issue%3D2%26spage%3D100103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Cheng</span>, <span class="hlFld-ContribAuthor ">Xuexin  Feng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Li</span>, <span class="hlFld-ContribAuthor ">Feilong  Zhou</span>, <span class="hlFld-ContribAuthor ">Jin-Ming  Yang</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 552-565. <a href="https://doi.org/10.1039/D0MD00361A" title="DOI URL">https://doi.org/10.1039/D0MD00361A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00361A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00361A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPharmacological%252Binhibition%252Bof%252BNF-%2525CE%2525BAB-inducing%252Bkinase%252B%252528NIK%252529%252Bwith%252Bsmall%252Bmolecules%252Bfor%252Bthe%252Btreatment%252Bof%252Bhuman%252Bdiseases%26aulast%3DCheng%26aufirst%3DJing%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D552%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shenxin  Zeng</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Zheng</span>, <span class="hlFld-ContribAuthor ">Liyan cheng</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112981. <a href="https://doi.org/10.1016/j.ejmech.2020.112981" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112981%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProteolysis%252Btargeting%252Bchimera%252B%252528PROTAC%252529%252Bin%252Bdrug%252Bdiscovery%252Bparadigm%25253A%252BRecent%252Bprogress%252Band%252Bfuture%252Bchallenges%26aulast%3DZeng%26aufirst%3DShenxin%26date%3D2021%26volume%3D210%26spage%3D112981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SMKIs approved by the FDA from 2001 to May 2020. Examples that target kinase point mutations driving acquired resistance are colored in orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ponatinib was developed to avoid steric hindrance with gatekeeper Ile315 of Bcr-Abl T315I and overcome acquired resistance to imatinib. The T315I mutation leading to steric hindrance with imatinib is highlighted in blue spheres (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYY">2HYY</a>). The alkyne of ponatinib minimizes steric clash with Ile315 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3">3IK3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Lorlatinib is designed to avoid steric hindrance with gatekeeper Met1196 and solvent-front Arg1202 of ALK to overcome acquired resistance to crizotinib. The L1196M and G1202R mutations leading to steric hindrance with crizotinib are highlighted in blue spheres (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ANS">4ANS</a>). Lorlatinib demonstrates no steric clash with Met1196 and Gly1202 (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLJ">4CLJ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. LOXO-195 and TPX-0005 are designed to avoid steric hindrance with Arg595 and Cys677 of TRKA and overcome acquired resistance to larotrectinib. The G595R and G667C mutations leading to steric hindrance with larotrectinib are highlighted in blue spheres (docking based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE">4YNE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Ceritinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKC">4MKC</a>) is designed to make hydrophobic interactions with the ALK gatekeeper mutation Met1196 to overcome acquired resistance to crizotinib. Brigatinib is designed to make interactions with Met1196 and avoid steric hindrance with Arg1202 of ALK (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MX8">6MX8</a>). The ALK L1196M and G1202R mutations leading to steric hindrance with crizotinib are highlighted in blue spheres (generated from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ANS">4ANS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Afatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P">4G5P</a>), WZ4002 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>), and osimertinib (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) are designed to form a covalent bond with cysteine 797 to overcome acquired resistance to gefitinib caused by the gatekeeper T790M mutation. The T790M mutation leading to gefitinib resistance is highlighted in blue spheres (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Vecabrutinib, ARQ 531 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E4F">6E4F</a>), and GDC-0583 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI">5VFI</a>) are designed as reversible inhibitors of BTK to overcome acquired resistance to ibrutinib caused by the BTK C481S mutation. The BTK C481S resistance mutation is highlighted in blue ball and stick structures (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. BI-4020 is designed as a reversible fourth-generation EGFR inhibitor to overcome osimertinib/nazartinib acquired resistance caused by the EGFR C797S mutation based on the lead <b>19</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a>). The binding mode of nazartinib and BI-4020 with EGFR T790M is demonstrated with crystal structures of close nazartinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FEE">5FEE</a>) and BI-4020 analogs (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D">6S9D</a>), respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>23</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ">6JRJ</a>) is designed as a reversible EGFR T790M/C797S inhibitor, based on the reported irreversible EGFR T790M inhibitor <b>22</b>, to overcome acquired resistance to osimertinib caused by the C797S mutation. The ability of the C797S mutation to disturb covalent binding of osimertinib is highlighted in blue ball and stick structures (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Allosteric Abl kinase inhibitors <b>24</b>–<b>26</b> bind to the myristoyl pocket of Abl kinase and are considered as an effective strategy to overcome acquired resistance to imatinib caused by mutations in the ATP-binding domain of Bcr-Abl. An X-ray crystal structure of ABL001 (orange) and imatinib (pink) bound with Abl kinase is shown (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MO4">5MO4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Allosteric EGFR inhibitors <b>27</b> and <b>28</b> bind to the MT3 pocket of EGFR and represent promising strategies to overcome acquired resistance to osimertinib. An X-ray crystal structure of JBJ-04-125-02 (orange) and ATP (pink) bound with EGFR T790M is shown (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUK">6DUK</a>). The ability of the C797S mutation to disturb covalent binding of osimertinib is highlighted in blue ball and stick structures (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/medium/jm0c00507_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Representative BTK PROTACs <b>29</b>–<b>31</b> targeting the BTK C481S mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00507&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 114 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudarsanam, S.</span></span> <span> </span><span class="NLM_article-title">The Protein Kinase Complement of the Human Genome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5600</span>),  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1126/science.1075762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&issue=5600&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+Protein+Kinase+Complement+of+the+Human+Genome&doi=10.1126%2Fscience.1075762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0lg7CyE5UksSWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520Protein%2520Kinase%2520Complement%2520of%2520the%2520Human%2520Genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5600%26spage%3D1912%26epage%3D1934%26doi%3D10.1126%2Fscience.1075762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span> <span> </span><span class="NLM_article-title">Catalytic Mechanisms and Regulation of Protein Kinases</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>548</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-397918-6.00001-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2FB978-0-12-397918-6.00001-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25399640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Onu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2014&pages=1-21&author=Z.+Wangauthor=P.+A.+Cole&title=Catalytic+Mechanisms+and+Regulation+of+Protein+Kinases&doi=10.1016%2FB978-0-12-397918-6.00001-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic mechanisms and regulation of protein kinases</span></div><div class="casAuthors">Wang, Zhihong; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">Protein Kinase Inhibitors in Research and Medicine</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Protein kinases transfer a phosphoryl group from ATP onto target proteins and play a crit. role in signal transduction and other cellular processes.  Here, we review the kinase kinetic and chem. mechanisms and their application in understanding kinase structure and function.  Aberrant kinase activity has been implicated in many human diseases, in particular cancer.  We highlight applications of technologies and concepts derived from kinase mechanistic studies that have helped illuminate how kinases are regulated and contribute to pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHXE76kfXQ4LVg90H21EOLACvtfcHk0lhewEZoJZxfXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Onu7nJ&md5=1f9dfeabf33b69658eb0eadaad6606c3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-397918-6.00001-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-397918-6.00001-X%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DCatalytic%2520Mechanisms%2520and%2520Regulation%2520of%2520Protein%2520Kinases%26jtitle%3DMethods%2520Enzymol.%26date%3D2014%26volume%3D548%26spage%3D1%26epage%3D21%26doi%3D10.1016%2FB978-0-12-397918-6.00001-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Kinase Inhibitors: an Analysis of FDA-Approved Drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&issue=1&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small+Molecule+Kinase+Inhibitors%3A+an+Analysis+of+FDA-Approved+Drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0lhewEZoJZxfXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall%2520Molecule%2520Kinase%2520Inhibitors%253A%2520an%2520Analysis%2520of%2520FDA-Approved%2520Drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D1%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-Approved Small-Molecule Kinase Inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&issue=7&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-Approved+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lhewEZoJZxfXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-Approved%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26issue%3D7%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caivano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>351</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&issue=1&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+Mechanism+of+Action+of+Some+Commonly+Used+Protein+Kinase+Inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0ljhiGRAV3kW3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520Mechanism%2520of%2520Action%2520of%2520Some%2520Commonly%2520Used%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26issue%3D1%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Understanding and Targeting Resistance Mechanisms in NSCLC</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc.2017.84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29068003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtl2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=637-658&issue=11&author=J.+Rotowauthor=T.+G.+Bivona&title=Understanding+and+Targeting+Resistance+Mechanisms+in+NSCLC&doi=10.1038%2Fnrc.2017.84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding and targeting resistance mechanisms in NSCLC</span></div><div class="casAuthors">Rotow, Julia; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">637-658</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  In this Review, we discuss alterations in the targeted oncogene ('on-target' resistance) and in other downstream and parallel pathways ('off-target' resistance) leading to resistance to targeted therapies in NSCLC, and we provide an overview of the current understanding of the bidirectional interactions with the tumor microenvironment that promote therapeutic resistance.  We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins.  Finally, we discuss how understanding these themes can inform therapeutic strategies, including combination therapy approaches, and overcome the challenge of tumor heterogeneity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDDpt7GHS9PbVg90H21EOLACvtfcHk0ljhiGRAV3kW3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtl2rtw%253D%253D&md5=f8ee7b5e94a150d4f14d3d243954ce34</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.84%26sid%3Dliteratum%253Aachs%26aulast%3DRotow%26aufirst%3DJ.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DUnderstanding%2520and%2520Targeting%2520Resistance%2520Mechanisms%2520in%2520NSCLC%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D11%26spage%3D637%26epage%3D658%26doi%3D10.1038%2Fnrc.2017.84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1002/anie.201710398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fanie.201710398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2307-2313&issue=9&author=J.+Lategahnauthor=M.+Keulauthor=D.+Rauh&title=Lessons+To+Be+Learned%3A+The+Molecular+Basis+of+Kinase-Targeted+Therapies+and+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1002%2Fanie.201710398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2313</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The treatment of non-small cell lung cancer (NSCLC) is currently experiencing a revolution.  Over the last decade, the knowledge gained about the biochem. features of biomarkers and their predictive abilities has led to the development of targeted small-mol. inhibitors that present an alternative to harsh chemotherapy.  The use of these new therapies has improved the quality of life and increased the survival of patients.  The occurrence of inevitable drug resistance requires the const. development of precision medicine.  The detailed understanding of the target biol. and the search for innovative chem. approaches has encouraged investigations in this field.  Herein, the authors review selected aspects of the mol. targets and present an overview of current topics and challenges in the rational development of small mols. to target NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowadpmmNyvGbVg90H21EOLACvtfcHk0ljhiGRAV3kW3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D&md5=78d3ce523d076c820cb7fcbf9a321e63</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710398%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DLessons%2520To%2520Be%2520Learned%253A%2520The%2520Molecular%2520Basis%2520of%2520Kinase-Targeted%2520Therapies%2520and%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26issue%3D9%26spage%3D2307%26epage%3D2313%26doi%3D10.1002%2Fanie.201710398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span> <span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0lihG3h70FRbdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagitani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&issue=6&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.-Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+Inhibitor+Ceritinib+Overcomes+Crizotinib+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0lihG3h70FRbdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520Inhibitor%2520Ceritinib%2520Overcomes%2520Crizotinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D6%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span> <span> </span><span class="NLM_article-title">PF-06463922 is a Potent and Selective Next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib Resistant ROS1 Mutations</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3498</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420785112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1073%2Fpnas.1420785112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25733882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3493-3498&issue=11&author=H.+Y.+Zouauthor=Q.+Liauthor=L.+D.+Engstromauthor=M.+Westauthor=V.+Applemanauthor=K.+A.+Wongauthor=M.+McTigueauthor=Y.-L.+Dengauthor=W.+Liuauthor=A.+Broounauthor=S.+Timofeevskiauthor=S.+R.+P.+McDonnellauthor=P.+Jiangauthor=M.+D.+Falkauthor=P.+B.+Lappinauthor=T.+Affolterauthor=T.+Nicholsauthor=W.+Huauthor=J.+Lamauthor=T.+W.+Johnsonauthor=T.+Smealauthor=A.+Charestauthor=V.+R.+Fantin&title=PF-06463922+is+a+Potent+and+Selective+Next-Generation+ROS1%2FALK+Inhibitor+Capable+of+Blocking+Crizotinib+Resistant+ROS1+Mutations&doi=10.1073%2Fpnas.1420785112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Engstrom, Lars D.; West, Melissa; Appleman, Vicky; Wong, Katy A.; McTigue, Michele; Deng, Ya-Li; Liu, Wei; Brooun, Alexei; Timofeevski, Sergei; McDonnell, Scott R. P.; Jiang, Ping; Falk, Matthew D.; Lappin, Patrick B.; Affolter, Timothy; Nichols, Tim; Hu, Wenyue; Lam, Justine; Johnson, Ted W.; Smeal, Tod; Charest, Al; Fantin, Valeria R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3493-3498</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Oncogenic c-ros oncogene 1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy.  The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clin. activity in ROS1 fusion-pos. non-small cell lung cancer.  However, emerging clin. evidence has shown that patients can develop resistance by acquiring secondary point mutations in ROS1 kinase.  In this study the authors characterized the ROS1 activity of PF-06463922, a novel, orally available, CNS-penetrant, ATP-competitive small-mol. inhibitor of ALK/ROS1.  In vitro, PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1G2032R mutation and the ROS1G2026M gatekeeper mutation.  Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase.  A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable interactions contributing to the high-affinity binding.  In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1G2032R mutation.  Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.  Taken together, the authors' results indicate that PF-06463922 has potential for treating ROS1 fusion-pos. cancers, including those requiring agents with CNS-penetrating properties, as well as for overcoming crizotinib resistance driven by ROS1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5t2o5BKPhK7Vg90H21EOLACvtfcHk0lg4LICdCrAVow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D&md5=8f549572dfac12c74b88705d57979c09</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420785112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420785112%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%2BP.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DCharest%26aufirst%3DA.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26atitle%3DPF-06463922%2520is%2520a%2520Potent%2520and%2520Selective%2520Next-Generation%2520ROS1%252FALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520Crizotinib%2520Resistant%2520ROS1%2520Mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26issue%3D11%26spage%3D3493%26epage%3D3498%26doi%3D10.1073%2Fpnas.1420785112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lg4LICdCrAVow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Etten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltimore, D.</span></span> <span> </span><span class="NLM_article-title">Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr/abl Gene of the Philadelphia Chromosome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>247</i></span> (<span class="NLM_issue">4944</span>),  <span class="NLM_fpage">824</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1126/science.2406902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.2406902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=2406902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFaqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=824-830&issue=4944&author=G.+Daleyauthor=R.+Van+Ettenauthor=D.+Baltimore&title=Induction+of+Chronic+Myelogenous+Leukemia+in+Mice+by+the+P210bcr%2Fabl+Gene+of+the+Philadelphia+Chromosome&doi=10.1126%2Fscience.2406902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Phildelphia chromosome</span></div><div class="casAuthors">Daley, George Q.; Van Etten, Richard A.; Baltimore, David</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">4944</span>),
    <span class="NLM_cas:pages">824-30</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">In tumor cells from virtually all patients with chronic myelogenous leukemia, the Philadelphia chromosome, a fusion of chromosomes 9 and 22, directs the synthesis of the P210bcr/abl protein.  The protein-tyrosine kinase activity and hybrid structure of P210bcr/abl are similar to the oncogene product of the Abelson murine leukemia virus, P160gag/v-abl, which induces acute lymphomas.  To det. whether P210bcr/abl can induce chronic myelogenous leukemia, murine bone marrow was infected with a retrovirus encoding P210bcr/abl and transplanted into irradiated syngeneic recipients.  Transplant recipients developed several hematol. malignancies; prominent among them was a myeloproliferative syndrome closely resembling the chronic phase of human chronic myelogenous leukemia.  Tumor tissue from diseased mice harbored the provirus encoding P210bcr/abl.  These results demonstrate that P210bcr/abl expression can induce chronic myelogenous leukemia.  Retrovirus-mediated expression of the protein provides a murine model system for further anal. of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsvVgj_mQk5rVg90H21EOLACvtfcHk0lgppyUdlr4tNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFaqs7c%253D&md5=6f36223545c27d509c8ff075de8eb4ca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.2406902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2406902%26sid%3Dliteratum%253Aachs%26aulast%3DDaley%26aufirst%3DG.%26aulast%3DVan%2BEtten%26aufirst%3DR.%26aulast%3DBaltimore%26aufirst%3DD.%26atitle%3DInduction%2520of%2520Chronic%2520Myelogenous%2520Leukemia%2520in%2520Mice%2520by%2520the%2520P210bcr%252Fabl%2520Gene%2520of%2520the%2520Philadelphia%2520Chromosome%26jtitle%3DScience%26date%3D1990%26volume%3D247%26issue%3D4944%26spage%3D824%26epage%3D830%26doi%3D10.1126%2Fscience.2406902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWhirter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span> <span> </span><span class="NLM_article-title">The Human Leukemia Oncogene bcr-abl Abrogates the Anchorage Requirement But Not the Growth Factor Requirement for Proliferation</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1128/MCB.15.3.1286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1128%2FMCB.15.3.1286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=7862122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADyaK2MXjsl2rtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=1286-1293&issue=3&author=M.+W.+Renshawauthor=J.+R.+McWhirterauthor=J.+Y.+Wang&title=The+Human+Leukemia+Oncogene+bcr-abl+Abrogates+the+Anchorage+Requirement+But+Not+the+Growth+Factor+Requirement+for+Proliferation&doi=10.1128%2FMCB.15.3.1286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation</span></div><div class="casAuthors">Renshaw, Mark W.; McWhirter, John R.; Wang, Jean Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1286-93</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Proliferation of normal cells in a multicellular organism requires not only growth factors but also the proper attachment to the extracellular matrix.  A hallmark of neoplastic transformation is the loss of anchorage dependence which usually accompanies the loss of growth factor requirement.  The Bcr-Abl tyrosine kinase of human leukemias is shown here to abrogate only the anchorage, not the growth factor, requirement.  Bcr-Abl-transformed cells grow in soft agar but do not proliferate in serum-free media.  Bcr-Abl does not activate the tetradecanoyl phorbol acetate response element (TRE).  However, Bcr-Abl can alleviate the anchorage requirement for the induction of the TRE enhancer; i.e., it allows serum to activate the TRE in detached cells.  This activity is dependent on the assocn. of an active Bcr-Abl tyrosine kinase with the actin filaments.  Despite its assocn. with the adapter protein Grb2, Bcr-Abl's effect on the TRE enhancer is not blocked by dominant neg. Ras or Raf.  The finding that Bcr-Abl tyrosine kinase abrogates only anchorage dependence may have important implications on the pathogenesis of chronic myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0gyI1Wh9CvrVg90H21EOLACvtfcHk0lgppyUdlr4tNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsl2rtr4%253D&md5=eb67facca4fedf9e1204994636d208ae</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.3.1286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.3.1286%26sid%3Dliteratum%253Aachs%26aulast%3DRenshaw%26aufirst%3DM.%2BW.%26aulast%3DMcWhirter%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26atitle%3DThe%2520Human%2520Leukemia%2520Oncogene%2520bcr-abl%2520Abrogates%2520the%2520Anchorage%2520Requirement%2520But%2520Not%2520the%2520Growth%2520Factor%2520Requirement%2520for%2520Proliferation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26issue%3D3%26spage%3D1286%26epage%3D1293%26doi%3D10.1128%2FMCB.15.3.1286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">5486</span>),  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&issue=5486&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+Mechanism+for+STI-571+Inhibition+of+Abelson+Tyrosine+Kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lhdxM2VDNQItQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520Mechanism%2520for%2520STI-571%2520Inhibition%2520of%2520Abelson%2520Tyrosine%2520Kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26issue%3D5486%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4236</span>– <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+Structures+of+the+Kinase+Domain+of+c-Abl+in+Complex+with+the+Small+Molecule+Inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lhdxM2VDNQItQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520Kinase%2520Domain%2520of%2520c-Abl%2520in%2520Complex%2520with%2520the%2520Small%2520Molecule%2520Inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W. N.</span></span> <span> </span><span class="NLM_article-title">Bcr-Abl Kinase Domain Mutations, Drug Resistance, and the Road to a Ccure For Chronic Myeloid Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2242</span>– <span class="NLM_lpage">2249</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-03-066936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2007-03-066936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17496200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCnsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&issue=7&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+N.+Deininger&title=Bcr-Abl+Kinase+Domain+Mutations%2C+Drug+Resistance%2C+and+the+Road+to+a+Ccure+For+Chronic+Myeloid+Leukemia&doi=10.1182%2Fblood-2007-03-066936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span></div><div class="casAuthors">O'Hare, Thomas; Eide, Christopher A.; Deininger, Michael W. N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2242-2249</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML).  Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance.  We also provide a perspective on how the secondline Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, esp. in relation to specific KD mutations.  We discuss the growing importance of the multi-inhibitor-resistant 315T>I mutant and the therapeutic potential that a 315T>I inhibitor would have.  Last, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodEKBGc_yDbLVg90H21EOLACvtfcHk0lhdxM2VDNQItQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCnsb%252FE&md5=8a46ac53b7de9fe81e9508015f5b347b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-03-066936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-03-066936%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26atitle%3DBcr-Abl%2520Kinase%2520Domain%2520Mutations%252C%2520Drug%2520Resistance%252C%2520and%2520the%2520Road%2520to%2520a%2520Ccure%2520For%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26issue%3D7%26spage%3D2242%26epage%3D2249%26doi%3D10.1182%2Fblood-2007-03-066936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorre, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&issue=2&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+Kinase+Domain+Mutations+Confer+Polyclonal+Resistance+to+the+Tyrosine+Kinase+Inhibitor+Imatinib+%28STI571%29+in+Chronic+Phase+and+Blast+Crisis+Chronic+Myeloid+Leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0liBMkdgYZhrrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520Kinase%2520Domain%2520Mutations%2520Confer%2520Polyclonal%2520Resistance%2520to%2520the%2520Tyrosine%2520Kinase%2520Inhibitor%2520Imatinib%2520%2528STI571%2529%2520in%2520Chronic%2520Phase%2520and%2520Blast%2520Crisis%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26issue%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorre, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwood, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span> (<span class="NLM_issue">5531</span>),  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1126/science.1062538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1126%2Fscience.1062538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=11423618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVKrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=876-880&issue=5531&author=M.+E.+Gorreauthor=M.+Mohammedauthor=K.+Ellwoodauthor=N.+Hsuauthor=R.+Paquetteauthor=P.+N.+Raoauthor=C.+L.+Sawyers&title=Clinical+Resistance+to+STI-571+Cancer+Therapy+Caused+by+BCR-ABL+Gene+Mutation+or+Amplification&doi=10.1126%2Fscience.1062538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification</span></div><div class="casAuthors">Gorre, Mercedes E.; Mohammed, Mansoor; Ellwood, Katharine; Hsu, Nicholas; Paquette, Ron; Rao, P. Nagesh; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5531</span>),
    <span class="NLM_cas:pages">876-880</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Clin. studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse.  Through biochem. and mol. anal. of clin. material, we find that drug resistance is assocd. with the reactivation of BCR-ABL signal transduction in all cases examd.  In six of nine patients, resistance was assocd. with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a crit. hydrogen bond with the drug.  This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution expt.  In three patients, resistance was assocd. with progressive BCR-ABL gene amplification.  These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest STI-571 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGNMgCA30skrVg90H21EOLACvtfcHk0liBMkdgYZhrrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVKrsbs%253D&md5=6aad1d55ff37d879c992968ddf5eaf20</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscience.1062538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1062538%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DMohammed%26aufirst%3DM.%26aulast%3DEllwood%26aufirst%3DK.%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DClinical%2520Resistance%2520to%2520STI-571%2520Cancer%2520Therapy%2520Caused%2520by%2520BCR-ABL%2520Gene%2520Mutation%2520or%2520Amplification%26jtitle%3DScience%26date%3D2001%26volume%3D293%26issue%3D5531%26spage%3D876%26epage%3D880%26doi%3D10.1126%2Fscience.1062538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Second Generation Inhibitors of BCR-ABL for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nrc2126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=345-356&issue=5&author=E.+Weisbergauthor=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=A.+Hochhausauthor=J.+D.+Griffin&title=Second+Generation+Inhibitors+of+BCR-ABL+for+the+Treatment+of+Imatinib-Resistant+Chronic+Myeloid+Leukaemia&doi=10.1038%2Fnrc2126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a small-mol. ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein.  However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance.  Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib-resistant CML.  Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlco2ZKndcbVg90H21EOLACvtfcHk0lgaNCNVbbuPKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D&md5=36735dff94df075862a60b26d3f358e5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2126%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DSecond%2520Generation%2520Inhibitors%2520of%2520BCR-ABL%2520for%2520the%2520Treatment%2520of%2520Imatinib-Resistant%2520Chronic%2520Myeloid%2520Leukaemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D5%26spage%3D345%26epage%3D356%26doi%3D10.1038%2Fnrc2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">32214</span>– <span class="NLM_lpage">32219</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111525200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1074%2Fjbc.M111525200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12077114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32214-32219&issue=35&author=A.+S.+Corbinauthor=E.+Buchdungerauthor=F.+Pascalauthor=B.+J.+Druker&title=Analysis+of+the+Structural+Basis+of+Specificity+of+Inhibition+of+the+Abl+Kinase+by+STI571&doi=10.1074%2Fjbc.M111525200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571</span></div><div class="casAuthors">Corbin, Amie S.; Buchdunger, Elisabeth; Pascal, Furet; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">32214-32219</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">STI571, a selective inhibitor of Bcr-Abl, has been a successful therapeutic agent in clin. trials for chronic myelogenous leukemia.  Chronic phase chronic myelogenous leukemia patients treated with STI571 have durable responses; however, most responding blast phase patients relapse despite continued therapy.  Co-crystn. studies of Abl kinase and an STI571-related compd. identify specific amino acid residues as crit. to STI571 binding, one of which, T315, has been characterized as an acquired Thr to Ile mutation in relapsed patients.  Other studies, however, suggest that mutations other than these predicted contact points are capable of conferring STI571 resistance in relapsed patients.  Using a variety of models of STI571 binding to the Abl kinase, we have performed an extensive mutational anal. of sites that might alter the sensitivity of the Abl kinase to STI571.  Although mutation of many of the predicted contact points between Abl and STI571 result in a kinase-inactive protein, addnl. mutations that render the Abl kinase less sensitive to STI571 demonstrate a broad range of possibilities for clin. resistance that are now becoming evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1BukCe_64-LVg90H21EOLACvtfcHk0lgaNCNVbbuPKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslyjs7c%253D&md5=abc06de1a8f2889b4674423d76d23d30</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111525200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111525200%26sid%3Dliteratum%253Aachs%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DPascal%26aufirst%3DF.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAnalysis%2520of%2520the%2520Structural%2520Basis%2520of%2520Specificity%2520of%2520Inhibition%2520of%2520the%2520Abl%2520Kinase%2520by%2520STI571%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D35%26spage%3D32214%26epage%3D32219%26doi%3D10.1074%2Fjbc.M111525200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradeen, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Comparison of Imatinib Mesylate, Dasatinib (BMS-354825), and Nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-Based Mutagenesis Screen: High Efficacy of Drug Combinations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2332</span>– <span class="NLM_lpage">2338</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-02-004580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2006-02-004580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=16772610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCgur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=2332-2338&issue=7&author=H.+A.+Bradeenauthor=C.+A.+Eideauthor=T.+O%E2%80%99Hareauthor=K.+J.+Johnsonauthor=S.+G.+Willisauthor=F.+Y.+Leeauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Comparison+of+Imatinib+Mesylate%2C+Dasatinib+%28BMS-354825%29%2C+and+Nilotinib+%28AMN107%29+in+an+N-ethyl-N-nitrosourea+%28ENU%29-Based+Mutagenesis+Screen%3A+High+Efficacy+of+Drug+Combinations&doi=10.1182%2Fblood-2006-02-004580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations</span></div><div class="casAuthors">Bradeen, Heather A.; Eide, Christopher A.; O'Hare, Thomas; Johnson, Kara J.; Willis, Stephanie G.; Lee, Francis Y.; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2332-2338</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors with activity against many imatinib mesylate-resistant BCR-ABL kinase domain (KD) mutants, except T315I.  We used N-ethyl-N-nitrosourea (ENU)-exposed Ba/F3-p210BCR-ABL cells to compare incidence and types of KD mutants emerging in the presence of imatinib mesylate, dasatinib, and nilotinib, alone and in dual combinations.  Although ENU is expected to induce mutations in multiple proteins, resistant clones were almost exclusively BCR-ABL KD mutant at relevant concns. of nilotinib and dasatinib, consistent with a central role of KD mutations for resistance to these drugs.  Twenty different mutations were identified with imatinib mesylate, 10 with nilotinib (including only 1 novel mutation, E292V) and 9 with dasatinib.  At intermediate drug levels the spectrum narrowed to F317V and T315I for dasatinib and Y253H, E255V, and T315I for nilotinib.  Thus, cross-resistance is limited to T315I, which is also the only mutant isolated at drug concns. equiv. to maximal achievable plasma trough levels.  With drug combinations maximal suppression of resistant clone outgrowth was achieved at lower concns. compared with single agents, suggesting that such combinations may be equipotent to higher-dose single agents.  However, sequencing uniformly revealed T315I, consistent with the need for a T315I inhibitor, to completely block resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4zVg2sVqBbVg90H21EOLACvtfcHk0ljcjoD3Thz5rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCgur%252FJ&md5=e360062ce60846e4f9eb6155d9a82669</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-004580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-004580%26sid%3Dliteratum%253Aachs%26aulast%3DBradeen%26aufirst%3DH.%2BA.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%2BJ.%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DComparison%2520of%2520Imatinib%2520Mesylate%252C%2520Dasatinib%2520%2528BMS-354825%2529%252C%2520and%2520Nilotinib%2520%2528AMN107%2529%2520in%2520an%2520N-ethyl-N-nitrosourea%2520%2528ENU%2529-Based%2520Mutagenesis%2520Screen%253A%2520High%2520Efficacy%2520of%2520Drug%2520Combinations%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26issue%3D7%26spage%3D2332%26epage%3D2338%26doi%3D10.1182%2Fblood-2006-02-004580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iuliucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4701</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/jm100395q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&issue=12&author=W.-S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28Imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+Potent%2C+Orally+Active+Pan-Inhibitor+of+Breakpoint+Cluster+Region-Abelson+%28BCR-ABL%29+Kinase+Including+the+T315I+Gatekeeper+Mutant&doi=10.1021%2Fjm100395q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl]benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span></div><div class="casAuthors">Huang, Wei-Sheng; Metcalf, Chester A.; Sundaramoorthi, Raji; Wang, Yihan; Zou, Dong; Thomas, R. Mathew; Zhu, Xiaotian; Cai, Lisi; Wen, David; Liu, Shuangying; Romero, Jan; Qi, Jiwei; Chen, Ingrid; Banda, Geetha; Lentini, Scott P.; Das, Sasmita; Xu, Qihong; Keats, Jeff; Wang, Frank; Wardwell, Scott; Ning, Yaoyu; Snodgrass, Joseph T.; Broudy, Marc I.; Russian, Karin; Zhou, Tianjun; Commodore, Lois; Narasimhan, Narayana I.; Mohemmad, Qurish K.; Iuliucci, John; Rivera, Victor M.; Dalgarno, David C.; Sawyer, Tomi K.; Clackson, Tim; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4701-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents.  This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation.  A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain.  Extensive SAR studies led to the discovery of development candidate benzamide I (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines.  Daily oral administration of I significantly prolonged survival of mice injected i.v. with BCR-ABLT315I expressing Ba/F3 cells.  These data, coupled with a favorable ADME profile, support the potential of I to be an effective treatment for CML, including patients refractory to all currently approved therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoci2zVFUazgLVg90H21EOLACvtfcHk0ljcjoD3Thz5rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D&md5=0dcd7b4ff31164b1d9883e897b7058ff</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528Imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520Potent%252C%2520Orally%2520Active%2520Pan-Inhibitor%2520of%2520Breakpoint%2520Cluster%2520Region-Abelson%2520%2528BCR-ABL%2529%2520Kinase%2520Including%2520the%2520T315I%2520Gatekeeper%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D12%26spage%3D4701%26epage%3D4719%26doi%3D10.1021%2Fjm100395q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.2174/092986711795656135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.2174%2F092986711795656135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21517764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2146-2157&issue=14&author=X.+Y.+Luauthor=Q.+Caiauthor=K.+Ding&title=Recent+Developments+in+the+Third+Generation+Inhibitors+of+Bcr-Abl+for+Overriding+T315I+Mutation&doi=10.2174%2F092986711795656135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span></div><div class="casAuthors">Lu, X. Y.; Cai, Q.; Ding, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2146-2157</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by disrupting important contact interactions between the inhibitors and the enzyme.  To overcome this particular resistance, several different strategies have been explored and many mols. have been investigated as capable of potently inhibiting Bcr-Abl T315I.  Herein, this review reports on some predominant examples of third generation inhibitors of Bcr-Abl active against the T315I mutation, and special attentions are paid to the "hybrid-design" strategy for creating type-II class ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoM774pVEqrVg90H21EOLACvtfcHk0lhS_bpobfPtBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D&md5=23109d1eb81a48f93cdf9ffbb4728c7a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F092986711795656135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795656135%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DRecent%2520Developments%2520in%2520the%2520Third%2520Generation%2520Inhibitors%2520of%2520Bcr-Abl%2520for%2520Overriding%2520T315I%2520Mutation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D14%26spage%3D2146%26epage%3D2157%26doi%3D10.2174%2F092986711795656135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doornmalen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>), <span class="NLM_elocation-id">e92146</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0092146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1371%2Fjournal.pone.0092146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24651269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKjurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&issue=3&author=J.+C.+Uitdehaagauthor=J.+A.+de+Roosauthor=A.+M.+van+Doornmalenauthor=M.+B.+Prinsenauthor=J.+de+Manauthor=Y.+Tanizawaauthor=Y.+Kawaseauthor=K.+Yoshinoauthor=R.+C.+Buijsmanauthor=G.+J.+Zaman&title=Comparison+of+the+Cancer+Gene+Targeting+and+Biochemical+Selectivities+of+All+Targeted+Kinase+Inhibitors+Approved+for+Clinical+Use&doi=10.1371%2Fjournal.pone.0092146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; de Roos, Jeroen A. D. M.; van Doornmalen, Antoon M.; Prinsen, Martine B. W.; de Man, Jos; Tanizawa, Yoshinori; Kawase, Yusuke; Yoshino, Kohichiro; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e92146/1-e92146/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The anti-proliferative activities of all twenty-five targeted kinase inhibitor drugs that are in clin. use were measured in two large assay panels: (1) a panel of proliferation assays of forty-four human cancer cell lines from diverse tumor tissue origins; and (2) a panel of more than 300 kinase enzyme activity assays.  This study provides a head-on comparison of all kinase inhibitor drugs in use, and for six of these drugs, the first kinome profiling data in the public domain.  Correlation of drug activities with cancer gene mutations revealed novel drug sensitivity markers, suggesting that cancers dependent on mutant CTNNB1 will respond to trametinib and other MEK inhibitors, and cancers dependent on SMAD4 to small mol. EGFR inhibitor drugs.  Comparison of cellular targeting efficacies reveals the most targeted inhibitors for EGFR-, ABL1- and BRAF(V600E)-driven cell growth, and demonstrates that the best targeted agents combine high biochem. potency with good selectivity.  For ABL1 inhibitors, we computationally deduce optimized kinase profiles for use in a next generation of drugs.  Our study shows the power of combining biochem. and cellular profiling data in the evaluation of kinase inhibitor drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVetYWQk4-rVg90H21EOLACvtfcHk0lhS_bpobfPtBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKjurnL&md5=3bbedb8c0a1c7f724f4cde734c38668d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0092146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0092146%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BDoornmalen%26aufirst%3DA.%2BM.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DTanizawa%26aufirst%3DY.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DYoshino%26aufirst%3DK.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26atitle%3DComparison%2520of%2520the%2520Cancer%2520Gene%2520Targeting%2520and%2520Biochemical%2520Selectivities%2520of%2520All%2520Targeted%2520Kinase%2520Inhibitors%2520Approved%2520for%2520Clinical%2520Use%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D3%26doi%3D10.1371%2Fjournal.pone.0092146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molica, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib: A Review of Efficacy and Safety</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.2174/1568009617666171002142659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.2174%2F1568009617666171002142659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28969556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=847-856&issue=9&author=F.+Massaroauthor=M.+Molicaauthor=M.+Breccia&title=Ponatinib%3A+A+Review+of+Efficacy+and+Safety&doi=10.2174%2F1568009617666171002142659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib: A Review of Efficacy and Safety</span></div><div class="casAuthors">Massaro, Fulvio; Molica, Matteo; Breccia, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">847-856</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I mutation.  In different trials this drug showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 mutations.  For this reason, ponatinib is currently indicated for the treatment of chronic myeloid leukemia (CML) in every phase of disease resistant and/or intolerant to dasatinib and nilotinib and for whom imatinib is not indicated anymore or for patients with T315I mutation.  The drug is also indicated for Ph+ acute lymphoblastic leukemia (ALL).  Ponatinib was temporarily suspended in 2013 for the occurrence of cardiovascular thrombotic events.  Since then, different investigators analyzed baseline characteristics of patient candidates for ponatinib, esp. cardiovascular profile, in order to describe general management recommendations in this setting.  In this review, clin. trials data about the use of ponatinib in CML and Ph+ ALL patients will be discussed.  It will be focused also about the safety and tolerability profile of the drug and future perspectives of employment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorPMsOjRTIyrVg90H21EOLACvtfcHk0lhS_bpobfPtBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWjsLrM&md5=78a025a9f4d42947fe3e194192810245</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1568009617666171002142659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666171002142659%26sid%3Dliteratum%253Aachs%26aulast%3DMassaro%26aufirst%3DF.%26aulast%3DMolica%26aufirst%3DM.%26aulast%3DBreccia%26aufirst%3DM.%26atitle%3DPonatinib%253A%2520A%2520Review%2520of%2520Efficacy%2520and%2520Safety%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2018%26volume%3D18%26issue%3D9%26spage%3D847%26epage%3D856%26doi%3D10.2174%2F1568009617666171002142659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&issue=1&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lgtIFWvKrvv_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26issue%3D1%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming EML4–ALK Fusion Gene in Non-Small-Cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span> (<span class="NLM_issue">7153</span>),  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&issue=7153&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+Transforming+EML4%E2%80%93ALK+Fusion+Gene+in+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lgtIFWvKrvv_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520EML4%25E2%2580%2593ALK%2520Fusion%2520Gene%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26issue%3D7153%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dubé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&issue=18&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28PF-02341066%29%2C+a+Potent+and+Selective+Dual+Inhibitor+of+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lgoktRJYmCInA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Dual%2520Inhibitor%2520of%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D18%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tursi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span> <span> </span><span class="NLM_article-title">First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">2167</span>– <span class="NLM_lpage">2177</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1408440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25470694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2167-2177&issue=23&author=B.+J.+Solomonauthor=T.+Mokauthor=D.-W.+Kimauthor=Y.-L.+Wuauthor=K.+Nakagawaauthor=T.+Mekhailauthor=E.+Felipauthor=F.+Cappuzzoauthor=J.+Paoliniauthor=T.+Usariauthor=S.+Iyerauthor=A.+Reismanauthor=K.+D.+Wilnerauthor=J.+Tursiauthor=F.+Blackhall&title=First-Line+Crizotinib+versus+Chemotherapy+in+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1408440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span></div><div class="casAuthors">Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2167-2177/1-2167-2177/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with std. chemotherapy as first-line treatment for advanced ALK-pos. non-small-cell lung cancer (NSCLC) is unknown.  METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-pos. nonsquamous NSCLC who had received no previous systemic treatment for advanced disease.  Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive i.v. chemotherapy (pemetrexed, 500 mg per square meter of bodysurface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per mL per min) every 3 wk for up to six cycles.  Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy.  The primary end point was progression-free survival as assessed by independent radiol. review.  RESULTS Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 mo vs. 7.0 mo; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001).  Objective response rates were 74% and 45 %, resp. (P<0.001).  Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-yr survival was 84% with crizotinib and 79% with chemotherapy.  The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite.  As compared with chemotherapy, crizotinib was assocd. with greater redn. in lung cancer symptoms and greater improvement in quality of life.  CONCLUSIONS Crizotinib was superior to std. first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7N7XM7ywBLVg90H21EOLACvtfcHk0lgoktRJYmCInA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D&md5=afd3c75ef95aff5c0fa12b6b7e22b46a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408440%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPaolini%26aufirst%3DJ.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DReisman%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DTursi%26aufirst%3DJ.%26aulast%3DBlackhall%26aufirst%3DF.%26atitle%3DFirst-Line%2520Crizotinib%2520versus%2520Chemotherapy%2520in%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D23%26spage%3D2167%26epage%3D2177%26doi%3D10.1056%2FNEJMoa1408440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curran, M. P.</span></span> <span> </span><span class="NLM_article-title">Crizotinib</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.2165/11207680-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.2165%2F11207680-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=22191798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC38XislWntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=99-107&issue=1&author=M.+P.+Curran&title=Crizotinib&doi=10.2165%2F11207680-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib: in locally advanced or metastatic non-small cell lung cancer</span></div><div class="casAuthors">Curran, Monique P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Crizotinib is an inhibitor of receptor tyrosine kinases (including anaplastic lymphoma kinase [ALK]).  Oral crizotinib 250 mg twice daily was assocd. with clin. meaningful response rates in two non-comparative trials (phase I and phase II) in patients with locally advanced or metastatic ALK-pos. non-small cell lung cancer (NSCLC).  In the phase I trial (median duration of treatment of 32 wk) and phase II trial (median duration of treatment of 22 wk), the objective response rate in crizotinib recipients was 61% and 50%, resp., and the median duration of response was 48.1 and 41.9 wk, resp.  Responses were rapid, with the majority of patients achieving an objective response within the first 8 wk of treatment.  Crizotinib was generally well tolerated, with most adverse reactions being grade 1 or 2.  The most commonly reported treatment-related adverse reactions were vision disorder, gastrointestinal disorders and edema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLnnvG1FnetbVg90H21EOLACvtfcHk0lhhYGZwxpP9Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XislWntb4%253D&md5=2943c2176e47f1af9ae1762f21e8f873</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2165%2F11207680-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11207680-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCurran%26aufirst%3DM.%2BP.%26atitle%3DCrizotinib%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26issue%3D1%26spage%3D99%26epage%3D107%26doi%3D10.2165%2F11207680-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&issue=18&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+Mutations+in+Lung+Cancer+That+Confer+Resistance+to+ALK+Inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lhhYGZwxpP9Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Mutations%2520in%2520Lung%2520Cancer%2520That%2520Confer%2520Resistance%2520to%2520ALK%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D18%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10927</span>– <span class="NLM_lpage">10954</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00446</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00446" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10927-10954&issue=24&author=X.+Kongauthor=P.+Panauthor=H.+Sunauthor=H.+Xiaauthor=X.+Wangauthor=Y.+Liauthor=T.+Hou&title=Drug+Discovery+Targeting+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.9b00446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Kong, Xiaotian; Pan, Peichen; Sun, Huiyong; Xia, Hongguang; Wang, Xuwen; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10927-10954</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, esp. anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas.  Currently, five small-mol. inhibitors of ALK, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, have been approved by the U.S.  Food and Drug Administration (FDA) against ALK-pos. NSCLCs.  Novel type-I1/2 and type-II ALK inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported.  Moreover, the "proteolysis targeting chimera" (PROTAC) technique has been successfully applied in developing ALK degraders, which opened a new avenue for targeted ALK therapies.  This review provides an overview of the physiol. and biol. functions of ALK, the discovery and development of drugs targeting ALK by focusing on their chemotypes, activity, selectivity, and resistance as well as potential therapeutic strategies to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LmONQduM_bVg90H21EOLACvtfcHk0lh6AgujLTYS-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E&md5=6c9aadf015cba2f11b2c2f747eea3eec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DDrug%2520Discovery%2520Targeting%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954%26doi%3D10.1021%2Facs.jmedchem.9b00446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK) Inhibitors in the Treatment of ALK-Driven Lung Cancers</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.phrs.2017.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28077299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=343-356&author=R.+Roskoski&title=Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+in+the+Treatment+of+ALK-Driven+Lung+Cancers&doi=10.1016%2Fj.phrs.2017.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">343-356</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase is expressed in two-thirds of the anaplastic large-cell lymphomas as an NPM-ALK fusion protein.  Physiol. ALK is a receptor protein-tyrosine kinase within the insulin receptor superfamily of proteins that participates in nervous system development.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The amino-terminal portions of the ALK fusion proteins result in dimerization and subsequent activation of the ALK protein kinase domain that plays a key role in the pathogenesis of various tumors.  Downstream signaling from the ALK fusion protein leads to the activation of the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathways.  Moreover, nearly two dozen ALK activating mutations are involved in the pathogenesis of childhood neuroblastomas.  The occurrence of oncogenic ALK-fusion proteins, particularly in non-small cell lung cancer, has fostered considerable interest in the development of ALK inhibitors.  Crizotinib was the first such inhibitor approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer in 2011.  The median time for the emergence of crizotinib drug resistance is 10.5 mo after the initiation of therapy.  Such resistance prompted the development of second-generation drugs including ceritinib and alectinib, which are approved for the treatment of non-small cell lung cancer.  Unlike the single gatekeeper mutation that occurs in drug-resistant epidermal growth factor receptor in lung cancer, nearly a dozen different mutations in the catalytic domain of ALK fusion proteins have been discovered that result in crizotinib resistance.  Crizotinib, ceritinib, and alectinib form a complex within the front cleft between the small and large lobes of an inactive ALK protein-kinase domain with a compact activation segment.  These drugs are classified as type I1/2 B inhibitors because they bind to an inactive enzyme and they do not extend past the gatekeeper into the back pocket of the drug binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq0rrYNRqutrVg90H21EOLACvtfcHk0lh6AgujLTYS-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D&md5=49200353921714b975e564df79631578</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520ALK-Driven%2520Lung%2520Cancers%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D117%26spage%3D343%26epage%3D356%26doi%3D10.1016%2Fj.phrs.2017.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kain, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwak-Tapp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span> <span> </span><span class="NLM_article-title">Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&issue=4&author=S.-H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-Generation+Sequencing+Reveals+a+Novel+NSCLC+ALK+F1174V+Mutation+and+Confirms+ALK+G1202R+Mutation+Confers+High-Level+Resistance+to+Alectinib+%28CH5424802%2FRO5424802%29+in+ALK-Rearranged+NSCLC+Patients+Who+Progressed+on+Crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-Generation%2520Sequencing%2520Reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520Mutation%2520and%2520Confirms%2520ALK%2520G1202R%2520Mutation%2520Confers%2520High-Level%2520Resistance%2520to%2520Alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-Rearranged%2520NSCLC%2520Patients%2520Who%2520Progressed%2520on%2520Crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies to Overcome Crizotinib Resistance in Non-Small Cell Lung Cancers Harboring the Fusion Oncogene EML4-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&issue=18&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+Strategies+to+Overcome+Crizotinib+Resistance+in+Non-Small+Cell+Lung+Cancers+Harboring+the+Fusion+Oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0lhyabN16pxlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Strategies%2520to%2520Overcome%2520Crizotinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancers%2520Harboring%2520the%2520Fusion%2520Oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D18%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodack, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezwada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span> <span> </span><span class="NLM_article-title">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccell.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26144315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=70-81&issue=1&author=H.+Y.+Zouauthor=L.+Fribouletauthor=D.+P.+Kodackauthor=L.+D.+Engstromauthor=Q.+Liauthor=M.+Westauthor=R.+W.+Tangauthor=H.+Wangauthor=K.+Tsaparikosauthor=J.+Wangauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=D.+M.+Dinhauthor=H.+Lamauthor=J.+L.+Lamauthor=S.+Yamazakiauthor=W.+Huauthor=B.+Patelauthor=D.+Bezwadaauthor=R.+L.+Friasauthor=E.+Lifshitsauthor=S.+Mahmoodauthor=J.+F.+Gainorauthor=T.+Affolterauthor=P.+B.+Lappinauthor=H.+Gukasyanauthor=N.+Leeauthor=S.+Dengauthor=R.+K.+Jainauthor=T.+W.+Johnsonauthor=A.+T.+Shawauthor=V.+R.+Fantinauthor=T.+Smeal&title=PF-06463922%2C+an+ALK%2FROS1+Inhibitor%2C+Overcomes+Resistance+to+First+and+Second+Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1016%2Fj.ccell.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zou, Helen Y.; Friboulet, Luc; Kodack, David P.; Engstrom, Lars D.; Li, Qiuhua; West, Melissa; Tang, Ruth W.; Wang, Hui; Tsaparikos, Konstantinos; Wang, Jinwei; Timofeevski, Sergei; Katayama, Ryohei; Dinh, Dac M.; Lam, Hieu; Lam, Justine L.; Yamazaki, Shinji; Hu, Wenyue; Patel, Bhushankumar; Bezwada, Divya; Frias, Rosa L.; Lifshits, Eugene; Mahmood, Sidra; Gainor, Justin F.; Affolter, Timothy; Lappin, Patrick B.; Gukasyan, Hovhannes; Lee, Nathan; Deng, Shibing; Jain, Rakesh K.; Johnson, Ted W.; Shaw, Alice T.; Fantin, Valeria R.; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-81</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We report the preclin. evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.  Compared with other clin. available ALK inhibitors, PF-06463922 displayed superior potency against all known clin. acquired ALK mutations, including the highly resistant G1202R mutant.  Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner.  Finally, PF-06463922 demonstrated high selectivity and safety margins in a variety of preclin. studies.  These results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clin. available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jseXrLwlSLVg90H21EOLACvtfcHk0lhyabN16pxlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E&md5=5bd2b7be6086f607b33b2255ad350486</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKodack%26aufirst%3DD.%2BP.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DBezwada%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DGukasyan%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DPF-06463922%252C%2520an%2520ALK%252FROS1%2520Inhibitor%252C%2520Overcomes%2520Resistance%2520to%2520First%2520and%2520Second%2520Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D1%26spage%3D70%26epage%3D81%26doi%3D10.1016%2Fj.ccell.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorlatinib, Y.</span></span> <span> </span><span class="NLM_article-title">First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1041-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-018-1041-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30604291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=93-98&issue=1&author=Y.+Syedauthor=Y.+Lorlatinib&title=First+Global+Approval&doi=10.1007%2Fs40265-018-1041-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lorlatinib is an oral small mol. inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Based on results from a phase I/II trial, lorlatinib received approval in Japan in Sept. 2018 and in the USA in Nov. 2018 for the treatment of ALK-pos. NSCLC.  This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU4Wwiia48VbVg90H21EOLACvtfcHk0lhyabN16pxlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D&md5=f041ba0200e2d607bb2a014884455990</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1041-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1041-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%26aulast%3DLorlatinib%26aufirst%3DY.%26atitle%3DFirst%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D1%26spage%3D93%26epage%3D98%26doi%3D10.1007%2Fs40265-018-1041-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhgOY6L3SGf3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span> <span> </span><span class="NLM_article-title">Trk Receptors: Roles in Neuronal Signal Transduction</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.72.121801.161629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1146%2Fannurev.biochem.72.121801.161629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12676795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=609-642&issue=1&author=E.+J.+Huangauthor=L.+F.+Reichardt&title=Trk+Receptors%3A+Roles+in+Neuronal+Signal+Transduction&doi=10.1146%2Fannurev.biochem.72.121801.161629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Trk receptors: roles in neuronal signal transduction</span></div><div class="casAuthors">Huang, Eric J.; Reichardt, Louis F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">609-642</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Trk receptors are a family of 3 receptor tyrosine kinases, each of which can be activated by ≥1 of 4 neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).  Neurotrophin signaling through these receptors regulates cell survival, proliferation, the fate of neural precursors, axon and dendrite growth and patterning, and the expression and activity of functionally important proteins, such as ion channels and neurotransmitter receptors.  In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity.  The cytoplasmic domains of Trk receptors contain several sites of tyrosine phosphorylation that recruit intermediates in intracellular signaling cascades.  As a result, Trk receptor signaling activates several small G proteins, including Ras, Rap-1, and the Cdc-42-Rac-Rho family, as well as pathways regulated by MAP kinase, PI 3-kinase and phospholipase-C-γ (PLC-γ).  Trk receptor activation has different consequences in different cells, and the specificity of downstream Trk receptor-mediated signaling is controlled through expression of intermediates in these signaling pathways and membrane trafficking that regulates localization of different signaling constituents.  Perhaps the most fascinating aspect of Trk receptor-mediated signaling is its interplay with signaling promoted by the pan-neurotrophin receptor p75NTR.  P75NTR activates a distinct set of signaling pathways within cells that are in some instances synergistic and in other instances antagonistic to those activated by Trk receptors.  Several of these are proapoptotic but are suppressed by Trk receptor-initiated signaling.  P75NTR also influences the conformations of Trk receptors; this modifies ligand-binding specificity and affinity with important developmental consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH3Pdvfi72LVg90H21EOLACvtfcHk0ljTODtea75hcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSgtbo%253D&md5=939bf60802da0a203c2e0d8585e28dd9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.72.121801.161629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.72.121801.161629%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DE.%2BJ.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26atitle%3DTrk%2520Receptors%253A%2520Roles%2520in%2520Neuronal%2520Signal%2520Transduction%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2003%26volume%3D72%26issue%3D1%26spage%3D609%26epage%3D642%26doi%3D10.1146%2Fannurev.biochem.72.121801.161629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnavi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25527197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=25-34&issue=1&author=A.+Vaishnaviauthor=A.+T.+Leauthor=R.+C.+Doebele&title=TRKing+Down+an+Old+Oncogene+in+a+New+Era+of+Targeted+Therapy&doi=10.1158%2F2159-8290.CD-14-0765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">TRKing Down an Old Oncogene in a New Era of Targeted Therapy</span></div><div class="casAuthors">Vaishnavi, Aria; Le, Anh T.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date.  These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago.  However, no drug has yet been approved by the FDA for cancers harboring this oncogene.  This review will discuss the biol. of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets.  Significance: Precision oncol. approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples.  Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types.  The scientific rationale for the targeting of the TRK oncogene family will be discussed here.  Cancer Discov; 5(1); 25-34. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUH4ooHY0TbVg90H21EOLACvtfcHk0ljTODtea75hcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCntbw%253D&md5=02103d46d85b6dc948dba58d32ffba9f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0765%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTRKing%2520Down%2520an%2520Old%2520Oncogene%2520in%2520a%2520New%2520Era%2520of%2520Targeted%2520Therapy%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D1%26spage%3D25%26epage%3D34%26doi%3D10.1158%2F2159-8290.CD-14-0765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkaniga, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaganti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-y.</span></span> <span> </span><span class="NLM_article-title">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1731</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1731-1760&issue=4&author=W.+Yanauthor=N.+R.+Lakkanigaauthor=F.+Carlomagnoauthor=M.+Santoroauthor=N.+Q.+McDonaldauthor=F.+Lvauthor=N.+Gunagantiauthor=B.+Frettauthor=H.-y.+Li&title=Insights+into+Current+Tropomyosin+Receptor+Kinase+%28TRK%29+Inhibitors%3A+Development+and+Clinical+Application&doi=10.1021%2Facs.jmedchem.8b01092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span></div><div class="casAuthors">Yan, Wei; Lakkaniga, Naga Rajiv; Carlomagno, Francesca; Santoro, Massimo; McDonald, Neil Q.; Lv, Fengping; Gunaganti, Naresh; Frett, Brendan; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1731-1760</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib.  Annually, it is estd. that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement.  In this Perspective, we discuss current development and clin. applications for TRK precision medicine by providing the following: (1) the biol. background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and anal. of their cocrystal structures, (3) an overview of TRK clin. trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwUthQyJEzFrVg90H21EOLACvtfcHk0ljTODtea75hcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO&md5=5ce2f8d295cf46f84b46f5890dad0160</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01092%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DLakkaniga%26aufirst%3DN.%2BR.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DGunaganti%26aufirst%3DN.%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.-y.%26atitle%3DInsights%2520into%2520Current%2520Tropomyosin%2520Receptor%2520Kinase%2520%2528TRK%2529%2520Inhibitors%253A%2520Development%2520and%2520Clinical%2520Application%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1731%26epage%3D1760%26doi%3D10.1021%2Facs.jmedchem.8b01092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larotrectinib, J.</span></span> <span> </span><span class="NLM_article-title">First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1044-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-018-1044-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30635837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=201-206&issue=2&author=L.+Scottauthor=J.+Larotrectinib&title=First+Global+Approval&doi=10.1007%2Fs40265-018-1044-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib: First Global Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-206</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (Vitrakvi) is an orally administered, small mol., highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncol. in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbor neurotrophic receptor tyrosine kinase (NTRK) gene fusions.  In Nov. 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.  A registration application for the use of larotrectinib in pediatric and adult patients with locally advanced or metastatic solid tumors with NTRK gene fusion proteins has been submitted in the EU.  This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and pediatric patients with solid tumors that have NTRK gene fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMpwdBG0H7ELVg90H21EOLACvtfcHk0lgeio3Q2yrtcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D&md5=8c3d442665ece609cc09422052903696</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1044-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1044-x%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%26aulast%3DLarotrectinib%26aufirst%3DJ.%26atitle%3DFirst%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D2%26spage%3D201%26epage%3D206%26doi%3D10.1007%2Fs40265-018-1044-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">628</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&issue=4&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.-M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan%E2%80%93TRK%2C+ROS1%2C+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0lgeio3Q2yrtcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan%25E2%2580%2593TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D4%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Entrectinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01177-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-019-01177-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31372957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1477-1483&issue=13&author=Z.+T.+Al-Salamaauthor=S.+J.+Keam&title=Entrectinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01177-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib: First Global Approval</span></div><div class="casAuthors">Al-Salama Zaina T; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1477-1483</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Entrectinib (Rozlytrek(®)) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment of various solid tumours harbouring NTRK1/2/3 or ROS1 gene fusions.  In June 2019, entrectinib received its first global approval in Japan, for the treatment of adult and paediatric patients with NTRK fusion-positive, advanced or recurrent solid tumours and is under regulatory review for the treatment of adult patients with ROS1-positive non-small cell lung cancer (NSCLC).  Entrectinib is also under regulatory review in the USA (PDUFA date 18 August 2019) and EU [Priority Medicines (PRIME) designation] for NTRK-positive solid tumours and ROS1-positive NSCLC.  This article summarizes the milestones in the development of entrectinib leading to this first global approval for solid tumours in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqIyGZmvQlpEkUaC_kzhvyfW6udTcc2eYJNfM2Yche0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D&md5=750c86d20c43273cf07f505988ac8dbd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01177-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01177-y%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DEntrectinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D13%26spage%3D1477%26epage%3D1483%26doi%3D10.1007%2Fs40265-019-01177-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/s41571-018-0113-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41571-018-0113-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30333516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=731-747&issue=12&author=E.+Coccoauthor=M.+Scaltritiauthor=A.+Drilon&title=NTRK+Fusion-Positive+Cancers+and+TRK+Inhibitor+Therapy&doi=10.1038%2Fs41571-018-0113-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK fusion-positive cancers and TRK inhibitor therapy</span></div><div class="casAuthors">Cocco, Emiliano; Scaltriti, Maurizio; Drilon, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, resp.) are oncogenic drivers of various adult and paediatric tumor types.  These fusions can be detected in the clinic using a variety of methods, including tumor DNA and RNA sequencing and plasma cell-free DNA profiling.  The treatment of patients with NTRK fusion-pos. cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is assocd. with high response rates (>75%), regardless of tumor histol.  First-generation TRK inhibitors are well tolerated by most patients, with toxicity profiles characterized by occasional off-tumor, on-target adverse events (attributable to TRK inhibition in non-malignant tissues).  Despite durable disease control in many patients, advanced-stage NTRK fusion-pos. cancers eventually become refractory to TRK inhibition; resistance can be mediated by the acquisition of NTRK kinase domain mutations.  Fortunately, certain resistance mutations can be overcome by second-generation TRK inhibitors, including LOXO-195 and TPX-0005 that are being explored in clin. trials.  In this Review, we discuss the biol. of NTRK fusions, strategies to target these drivers in the treatment-naive and acquired-resistance disease settings, and the unique safety profile of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2tGShkjX-5LVg90H21EOLACvtfcHk0lgT1_XXfiWpww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO&md5=fbc1f5b0de3614008f1b1f1e2e6167ce</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fs41571-018-0113-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-018-0113-0%26sid%3Dliteratum%253Aachs%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DNTRK%2520Fusion-Positive%2520Cancers%2520and%2520TRK%2520Inhibitor%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26issue%3D12%26spage%3D731%26epage%3D747%26doi%3D10.1038%2Fs41571-018-0113-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisafulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rospo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-15-0940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=26546295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36-44&issue=1&author=M.+Russoauthor=S.+Misaleauthor=G.+Weiauthor=G.+Siravegnaauthor=G.+Crisafulliauthor=L.+Lazzariauthor=G.+Cortiauthor=G.+Rospoauthor=L.+Novaraauthor=B.+Mussolinauthor=A.+Bartoliniauthor=N.+Camauthor=R.+Patelauthor=S.+Yanauthor=R.+Shoemakerauthor=R.+Wildauthor=F.+Di+Nicolantonioauthor=A.+S.+Bianchiauthor=G.+Liauthor=S.+Sienaauthor=A.+Bardelli&title=Acquired+Resistance+to+the+TRK+Inhibitor+Entrectinib+in+Colorectal+Cancer&doi=10.1158%2F2159-8290.CD-15-0940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span></div><div class="casAuthors">Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Bianchi, Andrea Sartore; Li, Gang; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clin. testing in colorectal cancer and other tumor types.  A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance.  To characterize the mol. bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed.  Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C.  Biochem. and pharmacol. anal. in multiple preclin. models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib.  These findings can be immediately exploited to design next-generation TRKA inhibitors.  Significance: We provide proof of principle that analyses of xenopatients (avatar) and liq. biopsies allow the identification of drug resistance mechanisms in parallel with clin. treatment of an individual patient.  We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Unyh1xjaoLVg90H21EOLACvtfcHk0lgT1_XXfiWpww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D&md5=5baa54a784e355b6afa50336b2708052</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0940%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DCrisafulli%26aufirst%3DG.%26aulast%3DLazzari%26aufirst%3DL.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DRospo%26aufirst%3DG.%26aulast%3DNovara%26aufirst%3DL.%26aulast%3DMussolin%26aufirst%3DB.%26aulast%3DBartolini%26aufirst%3DA.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DAcquired%2520Resistance%2520to%2520the%2520TRK%2520Inhibitor%2520Entrectinib%2520in%2520Colorectal%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D1%26spage%3D36%26epage%3D44%26doi%3D10.1158%2F2159-8290.CD-15-0940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&issue=9&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.-I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+Next-Generation+TRK+Kinase+Inhibitor+Overcomes+Acquired+Resistance+to+Prior+TRK+Kinase+Inhibition+in+Patients+with+TRK+Fusion-Positive+Solid+Tumors&doi=10.1158%2F2159-8290.CD-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. ©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0lhAq6ZCzZELTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520Next-Generation%2520TRK%2520Kinase%2520Inhibitor%2520Overcomes%2520Acquired%2520Resistance%2520to%2520Prior%2520TRK%2520Kinase%2520Inhibition%2520in%2520Patients%2520with%2520TRK%2520Fusion-Positive%2520Solid%2520Tumors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D9%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.CD-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&issue=10&author=A.+Drilonauthor=S.+I.+Ouauthor=B.+C.+Choauthor=D.+W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.+J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+Is+a+Next-Generation+ROS1%2FTRK%2FALK+Inhibitor+That+Potently+Inhibits+ROS1%2FTRK%2FALK+Solvent-Front+Mutations&doi=10.1158%2F2159-8290.CD-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0lithv5yK5K0lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520Is%2520a%2520Next-Generation%2520ROS1%252FTRK%252FALK%2520Inhibitor%2520That%2520Potently%2520Inhibits%2520ROS1%252FTRK%252FALK%2520Solvent-Front%2520Mutations%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D10%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.CD-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khozin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helms, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Hakim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2436</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-14-3157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25754348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2436-2439&issue=11&author=S.+Khozinauthor=G.+M.+Blumenthalauthor=L.+Zhangauthor=S.+Tangauthor=M.+Browerauthor=E.+Foxauthor=W.+Helmsauthor=R.+Leongauthor=P.+Songauthor=Y.+Panauthor=Q.+Liuauthor=P.+Zhaoauthor=H.+Zhaoauthor=D.+Luauthor=Z.+Tangauthor=A.+Al+Hakimauthor=K.+Boydauthor=P.+Keeganauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+Approval%3A+Ceritinib+for+the+Treatment+of+Metastatic+Anaplastic+Lymphoma+Kinase-Positive+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-14-3157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Khozin, Sean; Blumenthal, Gideon M.; Zhang, Lijun; Tang, Shenghui; Brower, Margaret; Fox, Emily; Helms, Whitney; Leong, Ruby; Song, Pengfei; Pan, Yuzhuo; Liu, Qi; Zhao, Ping; Zhao, Hong; Lu, Donghao; Tang, Zhe; Al Hakim, Ali; Boyd, Karen; Keegan, Patricia; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2436-2439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Apr. 29, 2014, the FDA granted accelerated approval to ceritinib (ZYKADIA; Novartis Pharmaceuticals Corporation), a breakthrough therapy-designated drug, for the treatment of patients with anaplastic lymphoma kinase (ALK)-pos., metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The approval was based on a single-arm multicenter trial enrolling 163 patients with metastatic ALK-pos. NSCLC who had disease progression on (91%) or intolerance to crizotinib.  Patients received ceritinib at a starting dose of 750 mg orally once daily.  The objective response rate (ORR) by a blinded independent review committee was 44% (95% CI, 36-52), and the median duration of response (DOR) was 7.1 mo.  The ORR by investigator assessment was similar.  Safety was evaluated in 255 patients.  The most common adverse reactions and lab. abnormalities included diarrhea (86%), nausea (80%), increased alanine transaminase (80%), increased aspartate transaminase (75%), vomiting (60%), increased glucose (49%), and increased lipase (28%).  Although 74% of patients required at least one dose redn. or interruption due to adverse reactions, the discontinuation rate due to adverse reactions was low (10%).  With this safety profile, the benefit-risk anal. was considered favorable because of the clin. meaningful ORR and DOR.  Clin Cancer Res; 21(11); 2436-9. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoopHbie8F3MLVg90H21EOLACvtfcHk0lithv5yK5K0lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D&md5=0b83c696c11bdc5281cdae60a8b0bf50</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3157%26sid%3Dliteratum%253Aachs%26aulast%3DKhozin%26aufirst%3DS.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DBrower%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DHelms%26aufirst%3DW.%26aulast%3DLeong%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DAl%2BHakim%26aufirst%3DA.%26aulast%3DBoyd%26aufirst%3DK.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%253A%2520Ceritinib%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D11%26spage%3D2436%26epage%3D2439%26doi%3D10.1158%2F1078-0432.CCR-14-3157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-014-0251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24980964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1285-1291&issue=11&author=S.+Dhillonauthor=M.+Clark&title=Ceritinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita; Clark, Madeleine</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1285-1291</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ceritinib is an oral anaplastic lymphoma kinase (ALK) inhibitor developed by Novartis for the treatment of tumors characterised by genetic abnormalities in ALK.  ALK is a member of the insulin receptor family of tyrosine kinases that can become oncogenic when fused to other proteins.  Ceritinib has been approved in the US under 'Breakthrough Therapy' designation for the second-line treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Regulatory submissions have also been made in the EU and other countries.  Phase III development is ongoing worldwide to evaluate ceritinib both as a first- and second-line therapy for ALK-pos. NSCLC.  This article summarizes the milestones in the development of ceritinib leading to this first approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1rTUW_DPL7Vg90H21EOLACvtfcHk0liR7l6yTpucPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK&md5=ec44e05bf8556567826c3eb7f5dbd5dc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0251-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DM.%26atitle%3DCeritinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D11%26spage%3D1285%26epage%3D1291%26doi%3D10.1007%2Fs40265-014-0251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&issue=14&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0liR7l6yTpucPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D14%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerwen, S. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span> <span> </span><span class="NLM_article-title">Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1535-7163.MCT-18-0877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30381447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1els7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=470-481&issue=2&author=J.+C.+M.+Uitdehaagauthor=J.+J.+Kooijmanauthor=J.+de+Roosauthor=M.+B.+W.+Prinsenauthor=J.+Dylusauthor=N.+Willemsen-Seegersauthor=Y.+Kawaseauthor=M.+Sawaauthor=J.+de+Manauthor=S.+J.+C.+van+Gerwenauthor=R.+C.+Buijsmanauthor=G.+J.+R.+Zaman&title=Combined+Cellular+and+Biochemical+Profiling+to+Identify+Predictive+Drug+Response+Biomarkers+for+Kinase+Inhibitors+Approved+for+Clinical+Use+between+2013+and+2017&doi=10.1158%2F1535-7163.MCT-18-0877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; Kooijman, Jeffrey J.; De Roos, Jeroen A. D. M.; Prinsen, Martine B. W.; Dylus, Jelle; Willemsen-Seegers, Nicole; Kawase, Yusuke; Sawa, Masaaki; De Man, Jos; Van Gerwen, Suzanne J. C.; Buijsman, Rogier C.; Zamad, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">470-481</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Kinase inhibitors form the largest class of precision medicine.  From 2013 to 2017, 17 kinase inhibitors have been approved, with 8 different mechanisms.  We present a comprehensive profiling study of all 17 inhibitors on a biochem. assay panel of 280 kinases and proliferation assays of 108 cancer cell lines.  Drug responses of the cell lines were related to the presence of frequently recurring point mutations, insertions, deletions, and amplifications in 15 well-known oncogenes and tumor-suppressor genes.  In addn., drug responses were correlated with basal gene expression levels with a focus on 383 clin. actionable genes.  Cell lines harboring actionable mutations defined in the FDA labels, such as mutant BRAF(V600E) for cobimetinib, or ALK gene translocation for ALK inhibitors, are generally 10 times more sensitive compared with wild-type cell lines.  This sensitivity window is more narrow for markers that failed to meet endpoints in clin. trials, for instance CDKN2A loss for CDK4/6 inhibitors (2.7-fold) and KRAS mutation for cobimetinib (2.3-fold).  Our data underscore the rationale of a no. of recently opened clin. trials, such as ibrutinib in ERBB2- or ERBB4-expressing cancers.  We propose and validate new response biomarkers, such as mutation in FBXW7 or SMAD4 for EGFR and HER2 inhibitors, ETV4 and ETV5 expression for MEK inhibitors, and JAK3 expression for ALK inhibitors.  Potentially, these new markers could be combined to improve response rates.  This comprehensive overview of biochem. and cellular selectivities of approved kinase inhibitor drugs provides a rich resource for drug repurposing, basket trial design, and basic cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd-nMoDtTIj7Vg90H21EOLACvtfcHk0ljvRJVzTFRzuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1els7g%253D&md5=309b9e50321428f3f66eab7da09293f6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0877%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%2BM.%26aulast%3DKooijman%26aufirst%3DJ.%2BJ.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%2BW.%26aulast%3DDylus%26aufirst%3DJ.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DSawa%26aufirst%3DM.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3Dvan%2BGerwen%26aufirst%3DS.%2BJ.%2BC.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26atitle%3DCombined%2520Cellular%2520and%2520Biochemical%2520Profiling%2520to%2520Identify%2520Predictive%2520Drug%2520Response%2520Biomarkers%2520for%2520Kinase%2520Inhibitors%2520Approved%2520for%2520Clinical%2520Use%2520between%25202013%2520and%25202017%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26issue%3D2%26spage%3D470%26epage%3D481%26doi%3D10.1158%2F1535-7163.MCT-18-0877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squillace, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadworny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miret, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5527</span>– <span class="NLM_lpage">5538</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-16-0569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=27780853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5527-5538&issue=22&author=S.+Zhangauthor=R.+Anjumauthor=R.+Squillaceauthor=S.+Nadwornyauthor=T.+Zhouauthor=J.+Keatsauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=D.+Millerauthor=Y.+Songauthor=L.+Eichingerauthor=L.+Moranauthor=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=Y.+Wangauthor=Q.+Mohemmadauthor=H.+G.+Jangauthor=E.+Yeauthor=N.+Narasimhanauthor=F.+Wangauthor=J.+Miretauthor=X.+Zhuauthor=T.+Clacksonauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=V.+M.+Rivera&title=The+Potent+ALK+Inhibitor+Brigatinib+%28AP26113%29+Overcomes+Mechanisms+of+Resistance+to+First-+and+Second-Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1158%2F1078-0432.CCR-16-0569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zhang, Sen; Anjum, Rana; Squillace, Rachel; Nadworny, Sara; Zhou, Tianjun; Keats, Jeff; Ning, Yaoyu; Wardwell, Scott D.; Miller, David; Song, Youngchul; Eichinger, Lindsey; Moran, Lauren; Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Wang, Yihan; Mohemmad, Qurish; Jang, Hyun Gyung; Ye, Emily; Narasimhan, Narayana; Wang, Frank; Miret, Juan; Zhu, Xiaotian; Clackson, Tim; Dalgarno, David; Shakespeare, William C.; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5527-5538</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain.  Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified.  Here, we report the structure and first comprehensive preclin. evaluation of the next-generation ALK TKI brigatinib.  Exptl. Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib.  The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines.  The brigatinib-ALK co-structure was detd.  Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases.  Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib.  Superior efficacy of brigatinib was also obsd. in mice with ALK+ tumors implanted s.c. or intracranially.  Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clin. achievable concns.  Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R.  The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.  Conclusions: Brigatinib is a highly potent and selective ALK inhibitor.  These findings provide the mol. basis for the promising activity being obsd. in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clin. trials.  Clin Cancer Res; 22(22); 5527-38. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwQUn_qLy7bVg90H21EOLACvtfcHk0ljvRJVzTFRzuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O&md5=1ece23bf36e807562023d0b814c990c7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0569%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DSquillace%26aufirst%3DR.%26aulast%3DNadworny%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEichinger%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMohemmad%26aufirst%3DQ.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DYe%26aufirst%3DE.%26aulast%3DNarasimhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMiret%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DThe%2520Potent%2520ALK%2520Inhibitor%2520Brigatinib%2520%2528AP26113%2529%2520Overcomes%2520Mechanisms%2520of%2520Resistance%2520to%2520First-%2520and%2520Second-Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D22%26spage%3D5527%26epage%3D5538%26doi%3D10.1158%2F1078-0432.CCR-16-0569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK: Precision Medicine Takes on Drug Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-16-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28122866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=137-155&issue=2&author=J.+J.+Linauthor=G.+J.+Rielyauthor=A.+T.+Shaw&title=Targeting+ALK%3A+Precision+Medicine+Takes+on+Drug+Resistance&doi=10.1158%2F2159-8290.CD-16-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK: Precision Medicine Takes on Drug Resistance</span></div><div class="casAuthors">Lin, Jessica J.; Riely, Gregory J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-155</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a validated mol. target in several ALK-rearranged malignancies, including non-small cell lung cancer.  However, the clin. benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance.  Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic.  In this review, we summarize the current successes and challenges of targeting ALK.  Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance.  This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms.  Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome.  Cancer Discov; 7(2); 137-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmMz7s4fYu7Vg90H21EOLACvtfcHk0liMXMKjrYwUjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D&md5=6f7d5358d13c75b215b0d1e6ce8ac8ff</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1123%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTargeting%2520ALK%253A%2520Precision%2520Medicine%2520Takes%2520on%2520Drug%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D2%26spage%3D137%26epage%3D155%26doi%3D10.1158%2F2159-8290.CD-16-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brigatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0776-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs40265-017-0776-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28597393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1131-1135&issue=10&author=A.+Markham&title=Brigatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0776-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Brigatinib (ALUNBRIG) is a small mol. antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company).  In Apr. 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-pos. metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants.  This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCYwTukZCLVg90H21EOLACvtfcHk0liMXMKjrYwUjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL&md5=c03f9d61e8e8fd4187d47ee207452f31</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0776-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0776-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrigatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26issue%3D10%26spage%3D1131%26epage%3D1135%26doi%3D10.1007%2Fs40265-017-0776-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&issue=3&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0liMXMKjrYwUjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26issue%3D3%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">ERBB Receptors and Cancer: the Complexity of Targeted Inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&issue=5&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+Receptors+and+Cancer%3A+the+Complexity+of+Targeted+Inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lirccDL28K9NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520Receptors%2520and%2520Cancer%253A%2520the%2520Complexity%2520of%2520Targeted%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26issue%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. E.</span></span> <span> </span><span class="NLM_article-title">Mutations of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer-Search and Ddestroy</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2005.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ejca.2005.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=16364841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&issue=1&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+Epidermal+Growth+Factor+Receptor+in+Non-Small+Cell+Lung+Cancer-Search+and+Ddestroy&doi=10.1016%2Fj.ejca.2005.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy</span></div><div class="casAuthors">Chan, S. K.; Gullick, W. J.; Hill, M. E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase, by the small mol. drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer.  However, it is now apparent that only a subset of patients responds to such treatment.  Two publications in early 2004 reported the presence of activating mutations in the EGFR tyrosine kinase gene conferring exquisite sensitivity to these drugs.  Several publications have since reported prospective data consistent with this finding.  This brief review summarizes the mutation data from 15 such studies in terms of mutation frequency by clinicopathol. features and correlation with response to tyrosine kinase inhibition.  A new paradigm for the routine detection of such mutations is needed to facilitate patient selection for treatment and further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2iKbYyg0gqbVg90H21EOLACvtfcHk0lirccDL28K9NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL&md5=01e38085f3beed6636d5e3979d4b9c5a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer-Search%2520and%2520Ddestroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26issue%3D1%26spage%3D17%26epage%3D23%26doi%3D10.1016%2Fj.ejca.2005.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span> <span> </span><span class="NLM_article-title">EGFR Antagonists in Cancer Treatment</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0707704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=18337605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&issue=11&author=F.+Ciardielloauthor=G.+Tortora&title=EGFR+Antagonists+in+Cancer+Treatment&doi=10.1056%2FNEJMra0707704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antagonists in cancer treatment</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1160-1174</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on epidermal growth factor receptor (EGFR) in human carcinogenesis, development of EGFR antagonists for anticancer therapy, and clin. efficacy of EGFR antagonists in human cancers.  Predicting the response to anti-EGFR drugs and future directions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNHvRENSffLVg90H21EOLACvtfcHk0lirccDL28K9NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D&md5=2834999545fd643c6f727d80d357134d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520Antagonists%2520in%2520Cancer%2520Treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26issue%3D11%26spage%3D1160%26epage%3D1174%26doi%3D10.1056%2FNEJMra0707704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0liT697diwKKGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&issue=6&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+Mutation+in+EGFR+Kinase+Causes+Drug+Resistance+by+Increasing+the+Affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liT697diwKKGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520Mutation%2520in%2520EGFR%2520Kinase%2520Causes%2520Drug%2520Resistance%2520by%2520Increasing%2520the%2520Affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D6%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S Resistance Mutations in NSCLC: Current Developments in Medicinal Chemistry</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1002/med.21488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fmed.21488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29377179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=1550-1581&issue=5&author=X.+Luauthor=L.+Yuauthor=Z.+Zhangauthor=X.+Renauthor=J.+B.+Smaillauthor=K.+Ding&title=Targeting+EGFRL858R%2FT790M+and+EGFRL858R%2FT790M%2FC797S+Resistance+Mutations+in+NSCLC%3A+Current+Developments+in+Medicinal+Chemistry&doi=10.1002%2Fmed.21488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry</span></div><div class="casAuthors">Lu, Xiaoyun; Yu, Lei; Zhang, Zhang; Ren, Xiaomei; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1550-1581</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Both the first-generation reversible epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib and the second-generation covalent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib have significantly improved the survival of non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations.  However, a secondary EGFRT790M mutation leads to the clin. acquired resistance to the first- and second-generation EGFR-TKIs drugs.  A no. of the third-generation wild-type sparing EGFR inhibitors, for example, WZ4002, CO1686, AZD9291, HM61713, EGF816, ASP8173, and PF0674775, have been developed, among which AZD9291 has been approved by US FDA for the treatment of NSCLC patients with EGFRT790M.  More recently, a tertiary EGFRC797S mutation was reported as the dominant resistance mechanism to the third-generation irreversible inhibitors.  It is highly desirable to develop the fourth-generation EGFR inhibitors.  This review summarizes the mechanisms of acquired resistance and the latest medicinal chem. advances on the third- and fourth-generation EGFR inhibitors, with special attention being paid to the allosteric and reversible inhibitors combating the tertiary EGFRC797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNK_1c8SI0qbVg90H21EOLACvtfcHk0lgr8RuqiodLsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVyqu73P&md5=71288118ca1d9eaab6d07b056bb5ab56</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fmed.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21488%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DTargeting%2520EGFRL858R%252FT790M%2520and%2520EGFRL858R%252FT790M%252FC797S%2520Resistance%2520Mutations%2520in%2520NSCLC%253A%2520Current%2520Developments%2520in%2520Medicinal%2520Chemistry%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581%26doi%3D10.1002%2Fmed.21488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): a Randomised, Open-Label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&issue=11&author=Y.+L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+Versus+Gefitinib+as+First-Line+Treatment+for+Patients+with+EGFR-Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28ARCHER+1050%29%3A+a+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0lgr8RuqiodLsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520EGFR-Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ARCHER%25201050%2529%253A%2520a%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5530</span>– <span class="NLM_lpage">5537</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-2571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-10-2571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21775534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5530-5537&issue=17&author=G.+R.+Oxnardauthor=M.+E.+Arcilaauthor=J.+Chmieleckiauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=New+Strategies+in+Overcoming+Acquired+Resistance+to+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+in+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-10-2571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Arcila, Maria E.; Chmielecki, Juliann; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5530-5537</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The management of non-small cell lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in epidermal growth factor receptor (EGFR) are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKI).  In these patients, acquired resistance to EGFR-TKI develops after a median of 10 to 14 mo, at which time the current std. practice is to switch to conventional cytotoxic chemotherapy.  Several possible mechanisms for acquired resistance have been identified, the most common being the development of an EGFR T790M gatekeeper mutation in more than 50% of cases.  In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies.  Clin Cancer Res; 17(17); 5530-7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqYmPYYBThNLVg90H21EOLACvtfcHk0ljhNpyRWGPZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtLnN&md5=209a41173563ee3776e020c0dacdd465</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2571%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNew%2520Strategies%2520in%2520Overcoming%2520Acquired%2520Resistance%2520to%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26issue%3D17%26spage%3D5530%26epage%3D5537%26doi%3D10.1158%2F1078-0432.CCR-10-2571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Strategies for Overcoming Resistance to EGFR Family Tyrosine Kinase Inhibitors</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2011.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ctrv.2011.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21367530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFGisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=456-464&issue=6&author=G.+Giacconeauthor=Y.+Wang&title=Strategies+for+Overcoming+Resistance+to+EGFR+Family+Tyrosine+Kinase+Inhibitors&doi=10.1016%2Fj.ctrv.2011.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors</span></div><div class="casAuthors">Giaccone, Giuseppe; Wang, Yisong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">456-464</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib have been incorporated into treatment paradigms for patients with advanced non-small cell lung cancer.  These agents are particularly effective in a subset of patients whose tumors harbor activating epidermal growth factor receptor mutations.  However, most patients do not respond to these tyrosine kinase inhibitors, and those who do will eventually acquire resistance that typically results from a secondary epidermal growth factor receptor mutation (e.g., T790M), mesenchymal-epithelial transition factor amplification, or activation of other signaling pathways.  For patients whose tumors have wild-type epidermal growth factor receptor, there are several known mechanisms of initial resistance (e.g., Kirsten rat sarcoma viral oncogene homolog mutations) but these do not account for all cases, suggesting that unknown mechanisms also contribute.  To potentially overcome the issue of resistance, next-generation tyrosine kinase inhibitors are being developed, which irreversibly block multiple epidermal growth factor receptor family members (e.g., afatinib [BIBW 2992] and PF-00299804) and/or vascular endothelial growth factor receptor pathways (e.g., BMS-690514 and XL647).  In addn., drugs that block parallel signaling pathways or signaling mols. downstream of the epidermal growth factor receptor, such as the insulin-like growth factor-1 receptor and the mammalian target of rapamycin, are undergoing clin. evaluation.  As drug resistance appears to be pleomorphic, combinations of drugs or drugs with multiple targets may be more effective in circumventing resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomHSJ2bX3NArVg90H21EOLACvtfcHk0ljhNpyRWGPZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFGisb4%253D&md5=f2f0779828bf000585c03bebf6ce9c76</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2011.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2011.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DStrategies%2520for%2520Overcoming%2520Resistance%2520to%2520EGFR%2520Family%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2011%26volume%3D37%26issue%3D6%26spage%3D456%26epage%3D464%26doi%3D10.1016%2Fj.ctrv.2011.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragane, N.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Acquired Resistance to Afatinib Clarified with Liquid Biopsy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e0209384</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0209384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1371%2Fjournal.pone.0209384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30550608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlGjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&issue=12&author=T.+Nakamuraauthor=C.+Nakashimaauthor=K.+Komiyaauthor=K.+Kiteraauthor=M.+Hiraiauthor=S.+Kimuraauthor=N.+Aragane&title=Mechanisms+of+Acquired+Resistance+to+Afatinib+Clarified+with+Liquid+Biopsy&doi=10.1371%2Fjournal.pone.0209384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to afatinib clarified with liquid biopsy</span></div><div class="casAuthors">Nakamura, Tomomi; Nakashima, Chiho; Komiya, Kazutoshi; Kitera, Kazuki; Hirai, Mitsuharu; Kimura, Shinya; Aragane, Naoko</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0209384</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Although mechanisms of acquired resistance to 1st and 3rd generation EGFR-TKI continue to be elucidated, there have been few clin. investigations into the mechanisms of acquired resistance to the 2nd generation EGFR-TKI afatinib.  We analyzed data from 20 patients with advanced lung adenocarcinoma who acquired resistance to afatinib, including resistance during EGFR-TKI re-challenge.  We examd. EGFR T790M and C797S mutations, BRAF V600E mutation, and MET amplification with the MBP-QP method and with droplet digital PCR using ctDNA and re-biopsy samples obtained before and after afatinib treatment.  Just before afatinib treatment, 15 of the 20 patients were T790M neg. and five were pos.  Among the T790M neg. patients, 40.0% (6/15) became pos. at the time of PD under afatinib.  In patients pos. for T790M, changes in T790M allele frequency were correlated with afatinib treatment efficacy.  C797S was not detected in any patients just before afatinib treatment, but it appeared after treatment in three patients, although with very low allele frequency.  Two of these three patients, although pos. for both C797S and T790M, achieved PR to osimertinib.  However, PFS of these patients was somewhat shorter than that of patients pos. for T790M only.  BRAF V600E was detected in one patient at PD under afatinib.  MET amplification was not detected in this study.  T790M is assocd. with acquired resistance to afatinib, as with 1st generation EGFR-TKI, but with somewhat lower frequency.  The influence of C797S on resistance to afatinib is less than that of T790M, but C797S might cause shorter PFS under osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWFck7DSCdLVg90H21EOLACvtfcHk0ljhNpyRWGPZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlGjtbc%253D&md5=9121d85daf0996334730f58bcf0a329c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0209384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0209384%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DC.%26aulast%3DKomiya%26aufirst%3DK.%26aulast%3DKitera%26aufirst%3DK.%26aulast%3DHirai%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DAragane%26aufirst%3DN.%26atitle%3DMechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Afatinib%2520Clarified%2520with%2520Liquid%2520Biopsy%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0209384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors Against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span> (<span class="NLM_issue">7276</span>),  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+Against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgk8aYS9T7MUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520Against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Red Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgk8aYS9T7MUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&issue=20&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+That+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lhHYtT5ZnJjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520That%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Proteome-Wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1388</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.chembiol.2017.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28965727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1388-1400&issue=11&author=S.+Niessenauthor=M.+M.+Dixauthor=S.+Barbasauthor=Z.+E.+Potterauthor=S.+Luauthor=O.+Brodskyauthor=S.+Plankenauthor=D.+Behennaauthor=C.+Almadenauthor=K.+S.+Gajiwalaauthor=K.+Ryanauthor=R.+Ferreauthor=M.+R.+Lazearauthor=M.+M.+Haywardauthor=J.+C.+Kathauthor=B.+F.+Cravatt&title=Proteome-Wide+Map+of+Targets+of+T790M-EGFR-Directed+Covalent+Inhibitors&doi=10.1016%2Fj.chembiol.2017.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">proteome-wide map of targets of t790m-egfr-directed covalent inhibitors</span></div><div class="casAuthors">Niessen, Sherry; Dix, Melissa M.; Barbas, Sabrina; Potter, Zachary E.; Lu, Shuyan; Brodsky, Oleg; Planken, Simon; Behenna, Douglas; Almaden, Chau; Gajiwala, Ketan S.; Ryan, Kevin; Ferre, RoseAnn; Lazear, Michael R.; Hayward, Matthew M.; Kath, John C.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1388-1400.e7</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancers that have kinase-activating epidermal growth factor receptor (EGFR) mutations are highly responsive to first- and second-generation EGFR inhibitors.  However, these patients often relapse due to a secondary, drug-resistant mutation in EGFR whereby the gatekeeper threonine is converted to methionine (T790M).  Several third-generation EGFR inhibitors have been developed that irreversibly inactivate T790M-EGFR while sparing wild-type EGFR, thus reducing epithelium-based toxicities.  Using chem. proteomics, we show here that individual T790M-EGFR inhibitors exhibit strikingly distinct off-target profiles in human cells.  The FDA-approved drug osimertinib (AZD9291), in particular, was found to covalently modify cathepsins in cell and animal models, which correlated with lysosomal accumulation of the drug.  Our findings thus show how chem. proteomics can be used to differentiate covalent kinase inhibitors based on global selectivity profiles in living systems and identify specific off-targets of these inhibitors that may affect drug activity and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP837IUk45tLVg90H21EOLACvtfcHk0lhHYtT5ZnJjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrnL&md5=dc2db6d29932ffdb991027ba272bd149</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DBarbas%26aufirst%3DS.%26aulast%3DPotter%26aufirst%3DZ.%2BE.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DLazear%26aufirst%3DM.%2BR.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DProteome-Wide%2520Map%2520of%2520Targets%2520of%2520T790M-EGFR-Directed%2520Covalent%2520Inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D1388%26epage%3D1400%26doi%3D10.1016%2Fj.chembiol.2017.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niiro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. A.</span></span> <span> </span><span class="NLM_article-title">Regulation of B-Cell Fate by Antigen-Receptor Signals</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1038/nri955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnri955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=12461567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFKnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=945-956&issue=12&author=H.+Niiroauthor=E.+A.+Clark&title=Regulation+of+B-Cell+Fate+by+Antigen-Receptor+Signals&doi=10.1038%2Fnri955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Decision making in the Immune System: Regulation of B-cell fate by antigen-receptor signals</span></div><div class="casAuthors">Niiro, Hiroaki; Clark, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent evidence indicates that B cells are instructed continuously by B-cell receptor (BCR) signals to make crucial cell-fate decisions at several checkpoints during their development.  Targeted disruption of BCR signaling components leads to distinct blocks in B-cell maturation, which indicates that key kinases and adaptors fine-tune BCR signaling to direct appropriate cell fates.  Recent progress in unravelling the mol. mechanisms of the BCR signaling pathways has helped to clarify how BCR signals regulate the proliferation, survival and apoptosis of developing B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Rvo57viTPbVg90H21EOLACvtfcHk0lhI0ieu2dgOvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFKnu7k%253D&md5=067cedc0cf02eaa7984509776bb34e9e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnri955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri955%26sid%3Dliteratum%253Aachs%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DE.%2BA.%26atitle%3DRegulation%2520of%2520B-Cell%2520Fate%2520by%2520Antigen-Receptor%2520Signals%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2002%26volume%3D2%26issue%3D12%26spage%3D945%26epage%3D956%26doi%3D10.1038%2Fnri955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of B-Cell Lymphoma Pathogenesis</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1038/nrc1589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc1589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15803153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=251-262&issue=4&author=R.+K%C3%BCppers&title=Mechanisms+of+B-Cell+Lymphoma+Pathogenesis&doi=10.1038%2Fnrc1589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of B-cell lymphoma pathogenesis</span></div><div class="casAuthors">Kueppers, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosomal translocations involving the Ig loci are a hallmark of many types of B-cell lymphoma.  Other factors, however, also have important roles in the pathogenesis of B-cell malignancies.  Most B-cell lymphomas depend on the expression of a B-cell receptor (BCR) for survival, and in several B-cell malignancies antigen activation of lymphoma cells through BCR signaling seems to be an important factor for lymphoma pathogenesis.  Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJru-Lq2OdbVg90H21EOLACvtfcHk0lhI0ieu2dgOvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D&md5=c8451de36e49f59432a4cee00419f97d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fnrc1589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1589%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCppers%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520B-Cell%2520Lymphoma%2520Pathogenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26issue%3D4%26spage%3D251%26epage%3D262%26doi%3D10.1038%2Fnrc1589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal
Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s Tyrosine Kinase in B Cells and Malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&issue=1&author=S.+Pal%0ASinghauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B+Cells+and+Malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2eYIQkfPQ639F7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B%2520Cells%2520and%2520Malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s Tyrosine Kinase in B Cell Malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&issue=4&author=R.+W.+Hendriksauthor=S.+Yuvarajauthor=L.+P.+Kil&title=Targeting+Bruton%E2%80%99s+Tyrosine+Kinase+in+B+Cell+Malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0lgWSDwDZLRAww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%2BP.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B%2520Cell%2520Malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D4%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The Development of Bruton’s Tyrosine Kinase (BTK) Inhibitors From 2012 to 2017: A Mini-Review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+Development+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+From+2012+to+2017%3A+A+Mini-Review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0lgWSDwDZLRAww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520Development%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520From%25202012%2520to%25202017%253A%2520A%2520Mini-Review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&issue=1&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0liCrJlzLU7zhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D1%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&issue=6&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-Cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0liCrJlzLU7zhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-Cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D6%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&issue=1&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0liiafrgONlc9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D1%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapatka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppert, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steggerda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span> <span> </span><span class="NLM_article-title">Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1056%2FNEJMoa1400029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=24869598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2286-2294&issue=24&author=J.+A.+Woyachauthor=R.+R.+Furmanauthor=T.-M.+Liuauthor=H.+G.+Ozerauthor=M.+Zapatkaauthor=A.+S.+Ruppertauthor=L.+Xueauthor=D.+H.-H.+Liauthor=S.+M.+Steggerdaauthor=M.+Verseleauthor=S.+S.+Daveauthor=J.+Zhangauthor=A.+S.+Yilmazauthor=S.+M.+Jaglowskiauthor=K.+A.+Blumauthor=A.+Lozanskiauthor=G.+Lozanskiauthor=D.+F.+Jamesauthor=J.+C.+Barrientosauthor=P.+Lichterauthor=S.+Stilgenbauerauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=A.+J.+Johnsonauthor=J.+C.+Byrd&title=Resistance+Mechanisms+for+the+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+Ibrutinib&doi=10.1056%2FNEJMoa1400029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib</span></div><div class="casAuthors">Woyach, Jennifer A.; Furman, Richard R.; Liu, Ta-Ming; Ozer, Hatice Gulcin; Zapatka, Marc; Ruppert, Amy S.; Xue, Ling; Li, Daniel Hsieh-Hsin; Steggerda, Susanne M.; Versele, Matthias; Dave, Sandeep S.; Zhang, Jenny; Yilmaz, Ayse Selen; Jaglowski, Samantha M.; Blum, Kristie A.; Lozanski, Arletta; Lozanski, Gerard; James, Danelle F.; Barrientos, Jacqueline C.; Lichter, Peter; Stilgenbauer, Stephan; Buggy, Joseph J.; Chang, Betty Y.; Johnson, Amy J.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2286-2294, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).  Resistance to irreversible kinase inhibitors and resistance assocd. with BTK inhibition have not been characterized.  Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important.  We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance.  Methods: We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy.  We then performed functional anal. of identified mutations.  In addn., we performed Ion Torrent sequencing for identified resistance mutations on samples from nine patients with prolonged lymphocytosis.  Results: We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLCγ2 in two patients.  Functional anal. showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib.  The R665W and L845F mutations in PLCγ2 are both potentially gain-of-function mutations that lead to autonomous B-cell-receptor activity.  These mutations were not found in any of the patients with prolonged lymphocytosis who were taking ibrutinib.  Conclusions: Resistance to the irreversible BTK inhibitor ibrutinib often involves mutation of a cysteine residue where ibrutinib binding occurs.  This finding, combined with two addnl. mutations in PLCγ2 that are immediately downstream of BTK, underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrutinib in CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpktSKmZODIjLVg90H21EOLACvtfcHk0liiafrgONlc9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ&md5=9eaf9f3ed7518c264b413ef4fe826985</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400029%26sid%3Dliteratum%253Aachs%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DT.-M.%26aulast%3DOzer%26aufirst%3DH.%2BG.%26aulast%3DZapatka%26aufirst%3DM.%26aulast%3DRuppert%26aufirst%3DA.%2BS.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%2BH.-H.%26aulast%3DSteggerda%26aufirst%3DS.%2BM.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DDave%26aufirst%3DS.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYilmaz%26aufirst%3DA.%2BS.%26aulast%3DJaglowski%26aufirst%3DS.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DLozanski%26aufirst%3DA.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DLichter%26aufirst%3DP.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DResistance%2520Mechanisms%2520for%2520the%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D24%26spage%3D2286%26epage%3D2294%26doi%3D10.1056%2FNEJMoa1400029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Liberto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blecua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen-Kiang, S.</span></span> <span> </span><span class="NLM_article-title">Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-14-0098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25082755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1022-1035&issue=9&author=D.+Chironauthor=M.+Di+Libertoauthor=P.+Martinauthor=X.+Huangauthor=J.+Sharmanauthor=P.+Blecuaauthor=S.+Mathewauthor=P.+Vijayauthor=K.+Engauthor=S.+Aliauthor=A.+Johnsonauthor=B.+Changauthor=S.+Elyauthor=O.+Elementoauthor=C.+E.+Masonauthor=J.+P.+Leonardauthor=S.+Chen-Kiang&title=Cell-Cycle+Reprogramming+for+PI3K+Inhibition+Overrides+a+Relapse-Specific+C481S+BTK+Mutation+Revealed+by+Longitudinal+Functional+Genomics+in+Mantle+Cell+Lymphoma&doi=10.1158%2F2159-8290.CD-14-0098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma</span></div><div class="casAuthors">Chiron, David; Di Liberto, Maurizio; Martin, Peter; Huang, Xiangao; Sharman, Jeff; Blecua, Pedro; Mathew, Susan; Vijay, Priyanka; Eng, Ken; Ali, Siraj; Johnson, Amy; Chang, Betty; Ely, Scott; Elemento, Olivier; Mason, Christopher E.; Leonard, John P.; Chen-Kiang, Selina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1022-1035</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Longitudinal anal. of MCL tumors identified the relapse-specific BTKC481S mutation and provided evidence that targeting CDK4 overcomes ibrutinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76gjvFtJiRrVg90H21EOLACvtfcHk0ljh-dtwyKbjpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur7E&md5=5257fed997f3484db60a49c7e30ed0f1</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0098%26sid%3Dliteratum%253Aachs%26aulast%3DChiron%26aufirst%3DD.%26aulast%3DDi%2BLiberto%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DSharman%26aufirst%3DJ.%26aulast%3DBlecua%26aufirst%3DP.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DVijay%26aufirst%3DP.%26aulast%3DEng%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DEly%26aufirst%3DS.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DMason%26aufirst%3DC.%2BE.%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DCell-Cycle%2520Reprogramming%2520for%2520PI3K%2520Inhibition%2520Overrides%2520a%2520Relapse-Specific%2520C481S%2520BTK%2520Mutation%2520Revealed%2520by%2520Longitudinal%2520Functional%2520Genomics%2520in%2520Mantle%2520Cell%2520Lymphoma%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1022%26epage%3D1035%26doi%3D10.1158%2F2159-8290.CD-14-0098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bond, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK in CLL: Beyond Ibrutinib</span>. <i>Curr. Hematol. Malig. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1007/s11899-019-00512-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1007%2Fs11899-019-00512-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31028669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fpslygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=197-205&issue=3&author=D.+A.+Bondauthor=J.+A.+Woyach&title=Targeting+BTK+in+CLL%3A+Beyond+Ibrutinib&doi=10.1007%2Fs11899-019-00512-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK in CLL: Beyond Ibrutinib</span></div><div class="casAuthors">Bond David A; Woyach Jennifer A</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance.  In this review, we summarize the emerging data for alternative BTKi.  RECENT FINDINGS:  Second-generation BTKi include acalabrutinib, zanubrutinib, and tirabrutinib which offer greater BTK selectivity.  While these agents may limit off-target toxicity, they do not overcome common mechanisms of ibrutinib resistance.  Reversible BTKi including vecabrutinib and LOXO-305 inhibit BTK in the presence of C481S mutation, and non-selective reversible BTKi, including ARQ-531, may retain activity despite mutations within PLCG2.  Early-phase studies are underway to establish the clinical efficacy and toxicity of these agents.  A randomized trial of ibrutinib versus acalabrutinib is ongoing, and acalabrutinib may be an option for ibrutinib-intolerant patients.  Results from ongoing trials of alternate BTKi will help to define their role in CLL therapy as single agents or in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ28N5K1jZXbmZyxfu64m4ffW6udTcc2eYl3bq1Xm3xELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fpslygsw%253D%253D&md5=4b0f317b8fd4818220d906d889450158</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs11899-019-00512-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-019-00512-0%26sid%3Dliteratum%253Aachs%26aulast%3DBond%26aufirst%3DD.%2BA.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520BTK%2520in%2520CLL%253A%2520Beyond%2520Ibrutinib%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D197%26epage%3D205%26doi%3D10.1007%2Fs11899-019-00512-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhowski, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettl, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddocks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andritsos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapalombella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eathiraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadessa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1300</span>– <span class="NLM_lpage">1315</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-1409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-17-1409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30093506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1300-1315&issue=10&author=S.+D.+Reiffauthor=R.+Mantelauthor=L.+L.+Smithauthor=J.+T.+Greeneauthor=E.+M.+Muhowskiauthor=C.+A.+Fabianauthor=V.+M.+Goettlauthor=M.+Tranauthor=B.+K.+Harringtonauthor=K.+A.+Rogersauthor=F.+T.+Awanauthor=K.+Maddocksauthor=L.+Andritsosauthor=A.+M.+Lehmanauthor=D.+Sampathauthor=R.+Lapalombellaauthor=S.+Eathirajauthor=G.+Abbadessaauthor=B.+Schwartzauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+A.+Woyach&title=The+BTK+Inhibitor+ARQ+531+Targets+Ibrutinib-Resistant+CLL+and+Richter+Transformation&doi=10.1158%2F2159-8290.CD-17-1409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation</span></div><div class="casAuthors">Reiff, Sean D.; Mantel, Rose; Smith, Lisa L.; Greene, J. T.; Muhowski, Elizabeth M.; Fabian, Catherine A.; Goettl, Virginia M.; Tran, Minh; Harrington, Bonnie K.; Rogers, Kerry A.; Awan, Farrukh T.; Maddocks, Kami; Andritsos, Leslie; Lehman, Amy M.; Sampath, Deepa; Lapalombella, Rosa; Eathiraj, Sudharshan; Abbadessa, Giovanni; Schwartz, Brian; Johnson, Amy J.; Byrd, John C.; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1300-1315</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematol. malignancies, including chronic lymphocytic leukemia (CLL).  Here, we describe preclin. investigations of ARQ 531, a potent, reversible inhibitor of BTK with addnl. activity against Src family kinases and kinases related to ERK signaling.  We hypothesized that targeting addnl. kinases would improve global inhibition of signaling pathways, producing more robust responses.  In vitro treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B-cell receptor (BCR) signaling, viability, migration, CD40 and CD86 expression, and NF-κB gene transcription.  In vivo, ARQ 531 was found to increase survival over ibrutinib in a murine Eμ-TCL1 engraftment model of CLL and a murine Eμ-MYC/TCL1 engraftment model resembling Richter transformation.  Addnl., ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCΓ 2 mutants, which facilitate clin. resistance to ibrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPG67bk_6NSrVg90H21EOLACvtfcHk0ljh-dtwyKbjpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLo%253D&md5=3b968f070e3c9a0995abe6b8ddd58c47</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-1409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-1409%26sid%3Dliteratum%253Aachs%26aulast%3DReiff%26aufirst%3DS.%2BD.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DGreene%26aufirst%3DJ.%2BT.%26aulast%3DMuhowski%26aufirst%3DE.%2BM.%26aulast%3DFabian%26aufirst%3DC.%2BA.%26aulast%3DGoettl%26aufirst%3DV.%2BM.%26aulast%3DTran%26aufirst%3DM.%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DRogers%26aufirst%3DK.%2BA.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DMaddocks%26aufirst%3DK.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLapalombella%26aufirst%3DR.%26aulast%3DEathiraj%26aufirst%3DS.%26aulast%3DAbbadessa%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520BTK%2520Inhibitor%2520ARQ%2520531%2520Targets%2520Ibrutinib-Resistant%2520CLL%2520and%2520Richter%2520Transformation%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D10%26spage%3D1300%26epage%3D1315%26doi%3D10.1158%2F2159-8290.CD-17-1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&issue=6&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+Potent%2C+Selective%2C+and+Noncovalent+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+in+Early+Clinical+Development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0liVwjPq4WAF7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Noncovalent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D6%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhowski, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">Noncovalent Inhibition of C481S Bruton Tyrosine Kinase by GDC-0853: A New Treatment Strategy for Ibrutinib-Resistant CLL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-809020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2017-10-809020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30018078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=1039-1049&issue=10&author=S.+D.+Reiffauthor=E.+M.+Muhowskiauthor=D.+Guinnauthor=A.+Lehmanauthor=C.+A.+Fabianauthor=C.+Cheneyauthor=R.+Mantelauthor=L.+Smithauthor=A.+J.+Johnsonauthor=W.+B.+Youngauthor=A.+R.+Johnsonauthor=L.+Liuauthor=J.+C.+Byrdauthor=J.+A.+Woyach&title=Noncovalent+Inhibition+of+C481S+Bruton+Tyrosine+Kinase+by+GDC-0853%3A+A+New+Treatment+Strategy+for+Ibrutinib-Resistant+CLL&doi=10.1182%2Fblood-2017-10-809020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent inhibition of C481S Bruton tyrosinekinase by GDC-0853: A new treatment strategy foribrutinib-resistant CLL</span></div><div class="casAuthors">Reiff, Sean D.; Muhowski, Elizabeth M.; Guinn, Daphne; Lehman, Amy; Fabian, Catherine A.; Cheney, Carolyn; Mantel, Rose; Smith, Lisa; Johnson, Amy J.; Young, Wendy B.; Johnson, Adam R.; Liu, Lichuan; Byrd, John C.; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The clin. success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as aneffective strategy for treating hematol. malignancies, including chronic lymphocyticleukemia (CLL).  Despite ibrutinib's ability to produce durable remissions in patients, acquiredresistance can develop, mostly commonly by mutation of C481 of BTK in theibrutinib binding site.  Here, we characterize a novel BTK inhibitor, GDC-0853, to evaluateits preclin. efficacy in ibrutinib-naive and ibrutinib-resistant CLL.  GDC-0853 is uniqueamong reported BTK inhibitors in that it does not rely upon covalent reaction with C481 tostabilize its occupancy within BTK's ATP binding site.  As with ibrutinib,GDC-0853 potently reduces B-cell receptor signaling, viability, NF-κB-dependent transcription,activation, and migration in treatment na.ovrddot.ive CLL cells.  We found that GDC-0853also inhibits the most commonly reported ibrutinib-resistant BTK mutant (C481S) both in abiochem. enzyme activity assay and in a stably transfected 293T cell line and maintainscytotoxicity against patient CLL cells harboring C481S BTK mutations.  Addnl., GDC-0853 does not inhibit endothelial growth factor receptor or ITK, 2 alternative targets ofibrutinib that are likely responsible for some adverse events and may reduce the efficacy of ibrutinib-antibodycombinations, resp.  Our results using GDC-0853 indicate that noncovalent, selective BTK inhibition may beeffective in CLL either as monotherapy or in combination with therapeutic antibodies, esp. among the emergingpopulation of patients with acquired resistance to ibrutinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLuDzLD7FMb7Vg90H21EOLACvtfcHk0lhB1QbhQhVX_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL&md5=f867a4ef8469fb2db96eb45c481a7b76</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-809020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-809020%26sid%3Dliteratum%253Aachs%26aulast%3DReiff%26aufirst%3DS.%2BD.%26aulast%3DMuhowski%26aufirst%3DE.%2BM.%26aulast%3DGuinn%26aufirst%3DD.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DFabian%26aufirst%3DC.%2BA.%26aulast%3DCheney%26aufirst%3DC.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DNoncovalent%2520Inhibition%2520of%2520C481S%2520Bruton%2520Tyrosine%2520Kinase%2520by%2520GDC-0853%253A%2520A%2520New%2520Treatment%2520Strategy%2520for%2520Ibrutinib-Resistant%2520CLL%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3D10%26spage%3D1039%26epage%3D1049%26doi%3D10.1182%2Fblood-2017-10-809020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00480</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00480" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2897-2907&issue=10&author=A.+R.+Johnsonauthor=P.+B.+Kohliauthor=A.+Katewaauthor=E.+Gogolauthor=L.+D.+Belmontauthor=R.+Choyauthor=E.+Penuelauthor=L.+Burtonauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+F.+Ortwineauthor=K.+Bowmanauthor=Y.+Frankeauthor=C.+Tamauthor=A.+Estevezauthor=K.+Mortaraauthor=J.+Wuauthor=H.+Liauthor=M.+Linauthor=P.+Bergeronauthor=J.+J.+Crawfordauthor=W.+B.+Young&title=Battling+Btk+Mutants+With+Noncovalent+Inhibitors+That+Overcome+Cys481+and+Thr474+Mutations&doi=10.1021%2Facschembio.6b00480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span></div><div class="casAuthors">Johnson, Adam R.; Kohli, Pawan Bir; Katewa, Arna; Gogol, Emily; Belmont, Lisa D.; Choy, Regina; Penuel, Elicia; Burton, Luciana; Eigenbrot, Charles; Yu, Christine; Ortwine, Daniel F.; Bowman, Krista; Franke, Yvonne; Tam, Christine; Estevez, Alberto; Mortara, Kyle; Wu, Jiansheng; Li, Hong; Lin, May; Bergeron, Philippe; Crawford, James J.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2897-2907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown impressive clin. efficacy in a range of B-cell malignancies, however acquired resistance has emerged and second generation therapies are now being sought.  Ibrutinib is a covalent, irreversible inhibitor that modifies Cys481 in the ATP binding site of Btk and renders the enzyme inactive, thereby blocking B-cell receptor signal transduction.  Not surprisingly, Cys481 is the most commonly mutated Btk residue in cases of acquired resistance to ibrutinib.  Mutations at other sites, including Thr474, a gatekeeper residue, have also been detected.  Herein the authors describe noncovalent Btk inhibitors that differ from covalent inhibitors like ibrutinib in that they do not interact with Cys481, they potently inhibit the ibrutinib-resistant Btk C481S mutant in vitro and in cells, and they are exquisitely selective for Btk.  Noncovalent inhibitors such as GNE-431 also show excellent potency against the C481R, T474I, and T474M mutants.  X-ray crystallog. anal. of Btk provides insight into the unique mode of binding of these inhibitors that explains their high selectivity for Btk and their retained activity against mutant forms of Btk.  This class of noncovalent Btk inhibitors may provide a treatment option to patients, esp. those who have acquired resistance to ibrutinib by mutation of Cys481 or Thr474.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkuzaMmxhJ67Vg90H21EOLACvtfcHk0lhB1QbhQhVX_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E&md5=1e0458160f967ed01c259751cc2118e1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00480%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DBattling%2520Btk%2520Mutants%2520With%2520Noncovalent%2520Inhibitors%2520That%2520Overcome%2520Cys481%2520and%2520Thr474%2520Mutations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3D2897%26epage%3D2907%26doi%3D10.1021%2Facschembio.6b00480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0liK6DO6LSEv5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalsy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-15-0399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25934077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=713-722&issue=7&author=Z.+Piotrowskaauthor=M.+J.+Niederstauthor=C.+A.+Karlovichauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=M.+Mino-Kenudsonauthor=L.+Fultonauthor=A.+N.+Hataauthor=E.+L.+Lockermanauthor=A.+Kalsyauthor=S.+Digumarthyauthor=A.+Muzikanskyauthor=M.+Raponiauthor=A.+R.+Garciaauthor=H.+E.+Mulveyauthor=M.+K.+Parksauthor=R.+H.+DiCeccaauthor=D.+Dias-Santagataauthor=A.+J.+Iafrateauthor=A.+T.+Shawauthor=A.+R.+Allenauthor=J.+A.+Engelmanauthor=L.+V.+Sequist&title=Heterogeneity+Underlies+the+Emergence+of+EGFR+T790+Wild-Type+Clones+Following+Treatment+of+T790M-Positive+Cancers+with+a+Third-Generation+EGFR+Inhibitor&doi=10.1158%2F2159-8290.CD-15-0399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor</span></div><div class="casAuthors">Piotrowska, Zofia; Niederst, Matthew J.; Karlovich, Chris A.; Wakelee, Heather A.; Neal, Joel W.; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N.; Lockerman, Elizabeth L.; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Raponi, Mitch; Garcia, Angel R.; Mulvey, Hillary E.; Parks, Melissa K.; DiCecca, Richard H.; Dias-Santagata, Dora; Iafrate, A. John; Shaw, Alice T.; Allen, Andrew R.; Engelman, Jeffrey A.; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance.  We biopsied patients at rociletinib progression to explore resistance mechanisms.  Among 12 patients with T790M-pos. cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies.  Two T790-wild-type cancers underwent small cell lung cancer transformation; three T790M-pos. cancers acquired EGFR amplification.  We documented T790-wild-type and T790M-pos. clones coexisting within a single pre-rociletinib biopsy.  The pretreatment fraction of T790M-pos. cells affected response to rociletinib.  Longitudinal circulating tumor DNA (ctDNA) anal. revealed an increase in plasma EGFR-activating mutation, and T790M heralded rociletinib resistance in some patients, whereas in others the activating mutation increased but T790M remained suppressed.  Together, these findings demonstrate the role of tumor heterogeneity when therapies targeting a singular resistance mechanism are used.  To further improve outcomes, combination regimens that also target T790-wild-type clones are required.  Significance: This report documents that half of T790M-pos. EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance.  We show that tumor heterogeneity has important clin. implications and that plasma ctDNA analyses can sometimes predict emerging resistance mechanisms.  Cancer Discov; 5(7); 713-22. ©2015 AACR.  See related commentary by Ichihara and Lovly, p. 694.  This article is highlighted in the In This Issue feature, p.  681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4z_KYM4-R7Vg90H21EOLACvtfcHk0liK6DO6LSEv5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjsLnF&md5=6512fff2abf24f5bef615a70b0f89c56</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0399%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DParks%26aufirst%3DM.%2BK.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DHeterogeneity%2520Underlies%2520the%2520Emergence%2520of%2520EGFR%2520T790%2520Wild-Type%2520Clones%2520Following%2520Treatment%2520of%2520T790M-Positive%2520Cancers%2520with%2520a%2520Third-Generation%2520EGFR%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D7%26spage%3D713%26epage%3D722%26doi%3D10.1158%2F2159-8290.CD-15-0399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&issue=17&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+Allelic+Context+of+the+C797S+Mutation+Acquired+upon+Treatment+with+Third-Generation+EGFR+Inhibitors+Impacts+Sensitivity+to+Subsequent+Treatment+Strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0lhwZImqX0NXNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Allelic%2520Context%2520of%2520the%2520C797S%2520Mutation%2520Acquired%2520upon%2520Treatment%2520with%2520Third-Generation%2520EGFR%2520Inhibitors%2520Impacts%2520Sensitivity%2520to%2520Subsequent%2520Treatment%2520Strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors Against C797S Resistance in Non-Small-Cell Lung Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&issue=10&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+Progress+of+Small-Molecule+Epidermal+Growth+Factor+Receptor+%28EGFR%29+Inhibitors+Against+C797S+Resistance+in+Non-Small-Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lhwZImqX0NXNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520Progress%2520of%2520Small-Molecule%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Inhibitors%2520Against%2520C797S%2520Resistance%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+Boseauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+Dobelauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtmullerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+Selective+and+Rigidify%3A+The+Discovery+Path+toward+a+Next+Generation+of+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lhwZImqX0NXNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DBose%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DDobel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520Selective%2520and%2520Rigidify%253A%2520The%2520Discovery%2520Path%2520toward%2520a%2520Next%2520Generation%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4293</span>– <span class="NLM_lpage">4305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4293-4305&issue=8&author=D.+E.+Heppnerauthor=M.+Guntherauthor=F.+Wittlingerauthor=S.+A.+Lauferauthor=M.+J.+Eck&title=Structural+Basis+for+EGFR+Mutant+Inhibition+by+Trisubstituted+Imidazole+Inhibitors&doi=10.1021%2Facs.jmedchem.0c00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors</span></div><div class="casAuthors">Heppner, David E.; Gunther, Marcel; Wittlinger, Florian; Laufer, Stefan A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4293-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy.  Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism.  To dissect the mol. basis for their activity, we detd. the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallog.  These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the "αC-helix out" inactive state.  Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant.  Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHNY-o4bNl6bVg90H21EOLACvtfcHk0lhBaXwTkU47eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D&md5=0ee498e9de51374ad9a049d7ffd9fa24</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DWittlinger%26aufirst%3DF.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructural%2520Basis%2520for%2520EGFR%2520Mutant%2520Inhibition%2520by%2520Trisubstituted%2520Imidazole%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305%26doi%3D10.1021%2Facs.jmedchem.0c00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant EGFR(L858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&issue=15&author=J.+Shenauthor=T.+Zhangauthor=S.+J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.+H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-Based+Design+of+5-Methylpyrimidopyridone+Derivatives+as+New+Wild-Type+Sparing+Inhibitors+of+the+Epidermal+Growth+Factor+Receptor+Triple+Mutant+EGFR%28L858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0lhBaXwTkU47eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-Based%2520Design%2520of%25205-Methylpyrimidopyridone%2520Derivatives%2520as%2520New%2520Wild-Type%2520Sparing%2520Inhibitors%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Triple%2520Mutant%2520EGFR%2528L858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">New Promise and Opportunities for Allosteric Kinase Inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1002/anie.201914525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fanie.201914525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=32313322" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=X.+Luauthor=J.+B.+Smaillauthor=K.+Ding&title=New+Promise+and+Opportunities+for+Allosteric+Kinase+Inhibitors&doi=10.1002%2Fanie.201914525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fanie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201914525%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DNew%2520Promise%2520and%2520Opportunities%2520for%2520Allosteric%2520Kinase%2520Inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26doi%3D10.1002%2Fanie.201914525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Emergence of Allosteric Drug-Resistance Mutations: New Challenges for Allosteric Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.drudis.2019.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31634592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=177-184&issue=1&author=S.+Luauthor=Y.+Qiuauthor=D.+Niauthor=X.+Heauthor=J.+Puauthor=J.+Zhang&title=Emergence+of+Allosteric+Drug-Resistance+Mutations%3A+New+Challenges+for+Allosteric+Drug+Discovery&doi=10.1016%2Fj.drudis.2019.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery</span></div><div class="casAuthors">Lu, Shaoyong; Qiu, Yuran; Ni, Duan; He, Xinheng; Pu, Jun; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allosteric drugs have several significant advantages over traditional orthosteric drugs, encompassing higher selectivity and lower toxicity.  Although allosteric drugs have potential advantages as therapeutic agents to treat human diseases, allosteric drug-resistance mutations still occur, rendering these drugs ineffective.  Here, we review the emergence of allosteric drug-resistance mutations with an emphasis on examples covering clin. important therapeutic targets, including Breakpoint cluster region-Abelson tyrosine kinase (Bcr-Abl), Akt kinase [also called Protein Kinase B (PKB)], isocitrate dehydrogenase (IDH), MAPK/ERK kinase (MEK), and SRC homol. 2 domain-contg. phosphatase 2 (SHP2).  We also discuss challenges assocd. with tackling allosteric drug resistance and the possible strategies to overcome this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4a4rK610lLLVg90H21EOLACvtfcHk0ljwboKBuckJnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaqtr3I&md5=052d6b87051bd173ab692aa963bdd3ea</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DEmergence%2520of%2520Allosteric%2520Drug-Resistance%2520Mutations%253A%2520New%2520Challenges%2520for%2520Allosteric%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26issue%3D1%26spage%3D177%26epage%3D184%26doi%3D10.1016%2Fj.drudis.2019.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrián, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajpai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bcr–Abl by Combining Allosteric with ATP-Binding-Site Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span> (<span class="NLM_issue">7280</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nature08675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature08675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=20072125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=501-506&issue=7280&author=J.+Zhangauthor=F.+J.+Adri%C3%A1nauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+G.+Liauthor=R.+E.+Iacobauthor=T.+Simauthor=J.+Powersauthor=C.+Dierksauthor=F.+Sunauthor=G.-R.+Guoauthor=Q.+Dingauthor=B.+Okramauthor=Y.+Choiauthor=A.+Wojciechowskiauthor=X.+Dengauthor=G.+Liuauthor=G.+Fendrichauthor=A.+Straussauthor=N.+Vajpaiauthor=S.+Grzesiekauthor=T.+Tuntlandauthor=Y.+Liuauthor=B.+Bursulayaauthor=M.+Azamauthor=P.+W.+Manleyauthor=J.+R.+Engenauthor=G.+Q.+Daleyauthor=M.+Warmuthauthor=N.+S.+Gray&title=Targeting+Bcr%E2%80%93Abl+by+Combining+Allosteric+with+ATP-Binding-Site+Inhibitors&doi=10.1038%2Fnature08675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Adrian, Francisco J.; Jahnke, Wolfgang; Cowan-Jacob, Sandra W.; Li, Allen G.; Iacob, Roxana E.; Sim, Taebo; Powers, John; Dierks, Christine; Sun, Fangxian; Guo, Gui-Rong; Ding, Qiang; Okram, Barun; Choi, Yongmun; Wojciechowski, Amy; Deng, Xianming; Liu, Guoxun; Fendrich, Gabriele; Strauss, Andre; Vajpai, Navratna; Grzesiek, Stephan; Tuntland, Tove; Liu, Yi; Bursulaya, Badry; Azam, Mohammad; Manley, Paul W.; Engen, John R.; Daley, George Q.; Warmuth, Markus; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7280</span>),
    <span class="NLM_cas:pages">501-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In an effort to find new pharmacol. modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor.  Here, using soln. NMR, X-ray crystallog., mutagenesis and hydrogen exchange mass spectrometry, we show that GNF-2 binds to the myristate-binding site of Abl, leading to changes in the structural dynamics of the ATP-binding site.  GNF-5, an analog of GNF-2 with improved pharmacokinetic properties, when used in combination with the ATP-competitive inhibitors imatinib or nilotinib, suppressed the emergence of resistance mutations in vitro, displayed additive inhibitory activity in biochem. and cellular assays against T315I mutant human Bcr-Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bone-marrow transplantation model.  These results show that therapeutically relevant inhibition of Bcr-Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtkKFuTQx1LVg90H21EOLACvtfcHk0ljwboKBuckJnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D&md5=46c122384fa004d27865c77f4a9165b7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnature08675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08675%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAdri%25C3%25A1n%26aufirst%3DF.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DDierks%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DG.-R.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Bcr%25E2%2580%2593Abl%2520by%2520Combining%2520Allosteric%2520with%2520ATP-Binding-Site%2520Inhibitors%26jtitle%3DNature%26date%3D2010%26volume%3D463%26issue%3D7280%26spage%3D501%26epage%3D506%26doi%3D10.1038%2Fnature08675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonamici, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groell, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellé, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wylie, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8120</span>– <span class="NLM_lpage">8135</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKru7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8120-8135&issue=18&author=J.+Schoepferauthor=W.+Jahnkeauthor=G.+Berelliniauthor=S.+Buonamiciauthor=S.+Cotestaauthor=S.+W.+Cowan-Jacobauthor=S.+Doddauthor=P.+Drueckesauthor=D.+Fabbroauthor=T.+Gabrielauthor=J.-M.+Groellauthor=R.+M.+Grotzfeldauthor=A.+Q.+Hassanauthor=C.+Henryauthor=V.+Iyerauthor=D.+Jonesauthor=F.+Lombardoauthor=A.+Looauthor=P.+W.+Manleyauthor=X.+Pell%C3%A9author=G.+Rummelauthor=B.+Salemauthor=M.+Warmuthauthor=A.+A.+Wylieauthor=T.+Zollerauthor=A.+L.+Marzinzikauthor=P.+Furet&title=Discovery+of+Asciminib+%28ABL001%29%2C+an+Allosteric+Inhibitor+of+the+Tyrosine+Kinase+Activity+of+BCR-ABL1&doi=10.1021%2Facs.jmedchem.8b01040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1</span></div><div class="casAuthors">Schoepfer, Joseph; Jahnke, Wolfgang; Berellini, Giuliano; Buonamici, Silvia; Cotesta, Simona; Cowan-Jacob, Sandra W.; Dodd, Stephanie; Drueckes, Peter; Fabbro, Doriano; Gabriel, Tobias; Groell, Jean-Marc; Grotzfeld, Robert M.; Hassan, A. Quamrul; Henry, Chrystele; Iyer, Varsha; Jones, Darryl; Lombardo, Franco; Loo, Alice; Manley, Paul W.; Pelle, Xavier; Rummel, Gabriele; Salem, Bahaa; Warmuth, Markus; Wylie, Andrew A.; Zoller, Thomas; Marzinzik, Andreas L.; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8120-8135</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of asciminib I, an allosteric inhibitor of the BCR-ABL1 kinase for use in treating chronic myelogenous leukemia (CML), is delineated.  I binds to the myristate pocket of BCR-ABL1 and maintains activity against cancer cells possessing ATP-site mutations in BCR-ABL1 that render them resistant to tyrosine kinase inhibitors; cancer cells resistant to myristate-site mutations are likely to be susceptible to ATP-competitive inhibitors so that combinations of I and tyrosine kinase inhibitors should suppress the emergence of resistance.  Fragment-based screening using NMR and X-ray yielded ligands for the myristate pocket, while an NMR-based conformational assay guided the transformation of these inactive ligands into ABL1 inhibitors.  Further structure-based optimization for potency, physicochem., pharmacokinetic, and drug-like properties, culminated in I which is currently undergoing clin. studies in CML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIQbEIXXgRgbVg90H21EOLACvtfcHk0lhjRg1gBZIylA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKru7bN&md5=023a566cdf4faba6dfc05501b8b6a6ed</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01040%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DBerellini%26aufirst%3DG.%26aulast%3DBuonamici%26aufirst%3DS.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGroell%26aufirst%3DJ.-M.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DPell%25C3%25A9%26aufirst%3DX.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWylie%26aufirst%3DA.%2BA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Asciminib%2520%2528ABL001%2529%252C%2520an%2520Allosteric%2520Inhibitor%2520of%2520the%2520Tyrosine%2520Kinase%2520Activity%2520of%2520BCR-ABL1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D18%26spage%3D8120%26epage%3D8135%26doi%3D10.1021%2Facs.jmedchem.8b01040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wylie, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonamici, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanasse, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">The Allosteric Inhibitor ABL001 Enables Dual Targeting of BCR–ABL1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span> (<span class="NLM_issue">7647</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1038/nature21702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature21702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28329763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=733-737&issue=7647&author=A.+A.+Wylieauthor=J.+Schoepferauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+Looauthor=P.+Furetauthor=A.+L.+Marzinzikauthor=X.+Pelleauthor=J.+Donovanauthor=W.+Zhuauthor=S.+Buonamiciauthor=A.+Q.+Hassanauthor=F.+Lombardoauthor=V.+Iyerauthor=M.+Palmerauthor=G.+Berelliniauthor=S.+Doddauthor=S.+Thohanauthor=H.+Bitterauthor=S.+Branfordauthor=D.+M.+Rossauthor=T.+P.+Hughesauthor=L.+Petruzzelliauthor=K.+G.+Vanasseauthor=M.+Warmuthauthor=F.+Hofmannauthor=N.+J.+Keenauthor=W.+R.+Sellers&title=The+Allosteric+Inhibitor+ABL001+Enables+Dual+Targeting+of+BCR%E2%80%93ABL1&doi=10.1038%2Fnature21702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1</span></div><div class="casAuthors">Wylie, Andrew A.; Schoepfer, Joseph; Jahnke, Wolfgang; Cowan-Jacob, Sandra W.; Loo, Alice; Furet, Pascal; Marzinzik, Andreas L.; Pelle, Xavier; Donovan, Jerry; Zhu, Wenjing; Buonamici, Silvia; Hassan, A. Quamrul; Lombardo, Franco; Iyer, Varsha; Palmer, Michael; Berellini, Giuliano; Dodd, Stephanie; Thohan, Sanjeev; Bitter, Hans; Branford, Susan; Ross, David M.; Hughes, Timothy P.; Petruzzelli, Lilli; Vanasse, K. Gary; Warmuth, Markus; Hofmann, Francesco; Keen, Nicholas J.; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7647</span>),
    <span class="NLM_cas:pages">733-737</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is driven by the activity of the BCR-ABL1 fusion oncoprotein.  ABL1 kinase inhibitors have improved the clin. outcomes for patients with CML, with over 80% of patients treated with imatinib surviving for more than 10 years.  Second-generation ABL1 kinase inhibitors induce more potent mol. responses in both previously untreated and imatinib-resistant patients with CML.  Studies in patients with chronic-phase CML have shown that around 50% of patients who achieve and maintain undetectable BCR-ABL1 transcript levels for at least 2 years remain disease-free after the withdrawal of treatment.  Here we characterize ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clin. development testing in patients with CML and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia.  In contrast to catalytic-site ABL1 kinase inhibitors, ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation.  ABL001 and second-generation catalytic inhibitors have similar cellular potencies but distinct patterns of resistance mutations, with genetic barcoding studies revealing pre-existing clonal populations with no shared resistance between ABL001 and the catalytic inhibitor nilotinib.  Consistent with this profile, acquired resistance was obsd. with single-agent therapy in mice; however, the combination of ABL001 and nilotinib led to complete disease control and eradicated CML xenograft tumors without recurrence after the cessation of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreJ5YSS_wiS7Vg90H21EOLACvtfcHk0lgdScslwP-Oww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWntbc%253D&md5=20d00f222ab8d9387cb340a9531b8ba5</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnature21702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21702%26sid%3Dliteratum%253Aachs%26aulast%3DWylie%26aufirst%3DA.%2BA.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DPelle%26aufirst%3DX.%26aulast%3DDonovan%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBuonamici%26aufirst%3DS.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DBerellini%26aufirst%3DG.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DThohan%26aufirst%3DS.%26aulast%3DBitter%26aufirst%3DH.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DPetruzzelli%26aufirst%3DL.%26aulast%3DVanasse%26aufirst%3DK.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DThe%2520Allosteric%2520Inhibitor%2520ABL001%2520Enables%2520Dual%2520Targeting%2520of%2520BCR%25E2%2580%2593ABL1%26jtitle%3DNature%26date%3D2017%26volume%3D543%26issue%3D7647%26spage%3D733%26epage%3D737%26doi%3D10.1038%2Fnature21702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antelope, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabriskie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomicter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szankasi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayuela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2844</span>– <span class="NLM_lpage">2847</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fleu.2017.264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=28819281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWntL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=2844-2847&issue=12&author=W.+Qiangauthor=O.+Antelopeauthor=M.+S.+Zabriskieauthor=A.+D.+Pomicterauthor=N.+A.+Velloreauthor=P.+Szankasiauthor=D.+Reaauthor=J.+M.+Cayuelaauthor=T.+W.+Kelleyauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hare&title=Mechanisms+of+Resistance+to+the+BCR-ABL1+Allosteric+Inhibitor+Asciminib&doi=10.1038%2Fleu.2017.264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib</span></div><div class="casAuthors">Qiang, W.; Antelope, O.; Zabriskie, M. S.; Pomicter, A. D.; Vellore, N. A.; Szankasi, P.; Rea, D.; Cayuela, J. M.; Kelley, T. W.; Deininger, M. W.; O'Hare, T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2844-2847</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The development of asciminib (ABL001),1 a highly potent and specific ABL1/ABL2/BCR-ABL1 tyrosine kinase inhibitor (TKI) with an allosteric mechanism of action that culminated from research in academic and pharmaceutical industry labs. spanning more than a decade.  Currently in clin. trials for relapsed/refractory Philadelphia chromosome-pos. (Ph+) leukemia patients (ClinicalTrials.gov: NCT02081378), asciminib represents a major advance from the structurally related, prototype compds. GNF-2 and GNF-5.2,3,4 We investigated mechanisms of asciminib resistance and identified two major categories: (1) upregulation of the ABCG2 efflux pump, resulting in undetectable intracellular asciminib levels and (2) emergence of BCR-ABL1 mutations at the myristoyl-binding site and at a distant residue.  We generated five asciminib-resistant, BCR-ABL1-pos. cell lines by adapting to increasing concns. of asciminib (range: 20-10 000 nm): K562asciminib-R, LAMA84asciminib-R, KYO1asciminib-R, Ba/F3 BCR-ABL1asciminib-R and KCL-22asciminib-R cells (Supplementary Methods).  In K562asciminib-R cells, methanethiosulfonate-based cell proliferation assays demonstrated a ∼60-fold increase in asciminib IC50 compared to parental K562 cells, despite remaining sensitive to the ATP-competitive TKIs imatinib, nilotinib, dasatinib and ponatinib (Figure 1a; Supplementary Table S1).  Immunoblot anal. revealed similar results, showing marked restoration of BCR-ABL1 tyrosine kinase activity and downstream STAT5 tyrosine phosphorylation in the presence of asciminib but not ponatinib (Supplementary Figure S1a).  However, next-generation sequencing (NGS) and Sanger sequencing of the BCR-ABL1 kinase domain identified no mutations (Supplementary Table S2).5 To check for the possibility of reduced intracellular drug concns., asciminib levels were measured following treatment using a customized liq. chromatog.-mass spectrometry/mass spectrometry (LC-MS/MS) method.6 Asciminib was undetectable in K562asciminib-R cells, but present at substantial levels in parental K562 cells (Supplementary Figure S1b), with an inhibitor-based screen for potential involvement of efflux pumps (Supplementary Figure S1c) and anal. by qPCR and immunoblot (Figure 1b) all implicating ABCG2.  Cell proliferation expts. revealed that the ABCG2 inhibitor Ko143 (100 nm) restored asciminib effectiveness against K562asciminib-R cells but had no effect on the asciminib IC50 for K562 cells (Figure 1c).  Similar results were obtained for LAMA84asciminib-R (Supplementary Figure S2; Supplementary Table S1) and KYO1asciminib-R cells (Supplementary Figure S3; Supplementary Table S1).  Our findings support ABCG2-mediated efflux of asciminib as the major mechanism of resistance in these cell lines, warrant its profiling among patients with asciminib resistance in the clinic, and suggest that combining asciminib with an ABCG2 inhibitor could override resistance, though development of clin. ABCG2 inhibitors is at the investigational stage.7, 8 In contrast, mutation-based resistance mechanisms were obsd. in Ba/F3 BCR-ABL1asciminib-R and KCL-22asciminib-R cells.  In Ba/F3 BCR-ABL1asciminib-R cells, a>1000-fold increase in asciminib IC50 over Ba/F3 BCR-ABL1 cells was obsd., despite undiminished sensitivity to ATP-competitive TKIs (Figure 2a; Supplementary Table S1).  While immunoblot anal. demonstrated restored BCR-ABL1 signaling in Ba/F3 BCR-ABL1asciminib-R cells treated with asciminib (Supplementary Figure S4a), LC-MS/MS anal. showed similar amts. of asciminib in Ba/F3 BCR-ABL1 and Ba/F3 BCR-ABL1asciminib-R cells and there was no evidence of efflux pump involvement (Supplementary Figure S4b-e).  NGS and Sanger sequencing of the BCR-ABL1 kinase domain identified a novel BCR-ABL1C464W mutation (Supplementary Table S2), mol. modeling of which suggested that the bulky tryptophan residue impedes access of asciminib to the myristoyl-binding pocket, consistent with high-level resistance (Figure 2b).  While other BCR-ABL1 mutations within or near the myristoyl-binding pocket (for example, A337V; P465S; V468F) have been shown to confer asciminib resistance,1 this is the first report of BCR-ABL1C464W as an asciminib-resistant mutant.  KCL-22asciminib-R cells exhibited two mutations at similar allelic frequencies:9 BCR-ABL1M244V near the ATP-binding site and BCR-ABL1A337V in the myristoyl-binding pocket (Supplementary Table S2), and single-cell sorting followed by clonal sequencing revealed a BCR-ABL1M244V/A337V compd. mutation.10, 11 KCL-22asciminib-R cells were completely insensitive to asciminib (IC50: 10 000 nm as compared to 2.2 nm for parental KCL-22 cells), but remained sensitive to ATP-binding site TKIs (Figure 2c; Supplementary Figure S5a; Supplementary Table S1).  LC/MS-MS showed comparable intracellular asciminib levels in KCL-22asciminib-R and KCL-22 cells, and there was no evidence of either altered effectiveness of asciminib against KCL-22asciminib-R cells by inclusion of an efflux pump inhibitor or upregulation of an efflux pump by qPCR or ABCG2 immunoblot (Supplementary Figure S5b-e).  Sequencing of increasingly asciminib-resistant cells collected in the process of generating the final KCL-22asciminib-R cell line revealed a progression from BCR-ABL1A337V to BCR-ABL1M244V/A337V (Figure 2d).  The reported asciminib IC50 value of 702 nM for KCL-22A337V cells1 is consistent with the inability of this mutation alone to confer the high-level resistance obsd. in KCL-22asciminib-R cells.  The BCR-ABL1M244V/A337V compd. mutant confers high-level asciminib resistance but inclusion of clin. achievable concns. of imatinib lead to outgrowth of BCR-ABL1S229P/T315I at the expense of BCR-ABL1M244V/A337V (Supplementary Figure S6), highlighting a potential complication of addressing asciminib resistance by switching to or including an ATP-binding site TKI.  Taken together, our findings suggest that mechanisms of acquired resistance to the allosteric BCR-ABL1 inhibitor asciminib involve restoration of BCR-ABL1 signaling, due to either asciminib efflux or select BCR-ABL1 mutations.  It may be possible to override ABCG2-mediated drug efflux by dose escalation of asciminib.  The achievable clin. dose is estd. to be at least 1μm.12 Another possibility to circumvent this resistance mechanism is to design an allosteric inhibitor that is not a substrate for efflux pump(s).  While development of a next-generation allosteric inhibitor13 is possible, the potential for cross-resistant myristoyl-binding pocket mutations may be high, as those obsd. for asciminib to date completely block inhibitor access to the binding pocket.  Alternatively, myristoyl-binding site mutation-based resistance to asciminib could be countered with an ATP-binding site TKI, though such a mutation occurring in tandem with an addnl. kinase domain mutation could result in resistance to both types of inhibitor.  The strategy of simultaneously treating with asciminib and an ATP-binding site TKI (imatinib, nilotinib or dasatinib) to minimize opportunity for resistance is under clin. investigation.  Ponatinib, which has activity against the T315I mutant and reported potency as an ABCG2 inhibitor,14, 15 may also warrant consideration in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRMgO1FwXE47Vg90H21EOLACvtfcHk0lgdScslwP-Oww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWntL3F&md5=e769bc2091eebd5f0e838fa6cf18d749</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.264%26sid%3Dliteratum%253Aachs%26aulast%3DQiang%26aufirst%3DW.%26aulast%3DAntelope%26aufirst%3DO.%26aulast%3DZabriskie%26aufirst%3DM.%2BS.%26aulast%3DPomicter%26aufirst%3DA.%2BD.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3DSzankasi%26aufirst%3DP.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DCayuela%26aufirst%3DJ.%2BM.%26aulast%3DKelley%26aufirst%3DT.%2BW.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520the%2520BCR-ABL1%2520Allosteric%2520Inhibitor%2520Asciminib%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26issue%3D12%26spage%3D2844%26epage%3D2847%26doi%3D10.1038%2Fleu.2017.264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabriskie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage Stevens, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antelope, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Than, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomicter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szankasi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayuela, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1016%2Fj.ccell.2019.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31543464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=431-443&issue=4&author=C.+A.+Eideauthor=M.+S.+Zabriskieauthor=S.+L.+Savage+Stevensauthor=O.+Antelopeauthor=N.+A.+Velloreauthor=H.+Thanauthor=A.+R.+Schultzauthor=P.+Clairauthor=A.+D.+Bowlerauthor=A.+D.+Pomicterauthor=D.+Yanauthor=A.+V.+Seninaauthor=W.+Qiangauthor=T.+W.+Kelleyauthor=P.+Szankasiauthor=M.+C.+Heinrichauthor=J.+W.+Tynerauthor=D.+Reaauthor=J.-M.+Cayuelaauthor=D.-W.+Kimauthor=C.+E.+Tognonauthor=T.+O%E2%80%99Hareauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Combining+the+Allosteric+Inhibitor+Asciminib+with+Ponatinib+Suppresses+Emergence+of+and+Restores+Efficacy+against+Highly+Resistant+BCR-ABL1+Mutants&doi=10.1016%2Fj.ccell.2019.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants</span></div><div class="casAuthors">Eide, Christopher A.; Zabriskie, Matthew S.; Savage Stevens, Samantha L.; Antelope, Orlando; Vellore, Nadeem A.; Than, Hein; Schultz, Anna Reister; Clair, Phillip; Bowler, Amber D.; Pomicter, Anthony D.; Yan, Dongqing; Senina, Anna V.; Qiang, Wang; Kelley, Todd W.; Szankasi, Philippe; Heinrich, Michael C.; Tyner, Jeffrey W.; Rea, Delphine; Cayuela, Jean-Michel; Kim, Dong-Wook; Tognon, Cristina E.; O'Hare, Thomas; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-443.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-pos. (Ph+) leukemia is effectively managed with several approved drugs, including ponatinib for BCR-ABL1T315I-mutant disease.  However, therapy options are limited for patients with leukemic clones bearing multiple BCR-ABL1 mutations.  Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compd. mutants.  We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clin. isolates and cell lines.  Inclusion of asciminib restores ponatinib's effectiveness against currently untreatable compd. mutants at clin. achievable concns.  Our findings support combining asciminib with ponatinib as a treatment strategy for this molecularly defined group of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwcxeCHYx87Vg90H21EOLACvtfcHk0lh3YVCNvm0N5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M&md5=77fb1a5430c13932b2af244e8749e7ee</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DZabriskie%26aufirst%3DM.%2BS.%26aulast%3DSavage%2BStevens%26aufirst%3DS.%2BL.%26aulast%3DAntelope%26aufirst%3DO.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3DThan%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DA.%2BR.%26aulast%3DClair%26aufirst%3DP.%26aulast%3DBowler%26aufirst%3DA.%2BD.%26aulast%3DPomicter%26aufirst%3DA.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DSenina%26aufirst%3DA.%2BV.%26aulast%3DQiang%26aufirst%3DW.%26aulast%3DKelley%26aufirst%3DT.%2BW.%26aulast%3DSzankasi%26aufirst%3DP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DCayuela%26aufirst%3DJ.-M.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DCombining%2520the%2520Allosteric%2520Inhibitor%2520Asciminib%2520with%2520Ponatinib%2520Suppresses%2520Emergence%2520of%2520and%2520Restores%2520Efficacy%2520against%2520Highly%2520Resistant%2520BCR-ABL1%2520Mutants%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26issue%3D4%26spage%3D431%26epage%3D443%26doi%3D10.1016%2Fj.ccell.2019.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective Allosteric Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span> (<span class="NLM_issue">7605</span>),  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&issue=7605&author=Y.+Jiaauthor=C.-H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.-Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+Resistance+with+Mutant-Selective+Allosteric+Inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lh3YVCNvm0N5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520Resistance%2520with%2520Mutant-Selective%2520Allosteric%2520Inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26issue%3D7605%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&issue=7&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+J.+H.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Single+and+Dual+Targeting+of+Mutant+EGFR+with+an+Allosteric+Inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0lhwPhTmRRcLDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520Dual%2520Targeting%2520of%2520Mutant%2520EGFR%2520with%2520an%2520Allosteric%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_label">102. </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1549-1553&issue=11&author=D.+J.+H.+De+Clercqauthor=D.+E.+Heppnerauthor=C.+Toauthor=J.+Jangauthor=E.+Parkauthor=C.-H.+Yunauthor=M.+Mushajiangauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=D.+A.+Scottauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Discovery+and+Optimization+of+Dibenzodiazepinones+as+Allosteric+Mutant-Selective+EGFR+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102102.</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span></div><div class="casAuthors">De Clercq, Dries J. H.; Heppner, David E.; To, Ciric; Jang, Jaebong; Park, Eunyoung; Yun, Cai-Hong; Mushajiang, Mierzhati; Shin, Bo Hee; Gero, Thomas W.; Scott, David A.; Janne, Pasi A.; Eck, Michael J.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1549-1553</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors represent a promising new therapeutic strategy for targeting kinases harboring oncogenic driver mutations in cancers.  Here, we report the discovery, optimization, and structural characterization of allosteric mutant-selective EGFR inhibitors comprising a 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one scaffold.  Our structure-based medicinal chem. effort yielded an inhibitor (3) of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with an IC50 of ∼10 nM and high selectivity, as assessed by kinome profiling.  Further efforts to develop allosteric dibenzodiazepinone inhibitors may serve as the basis for new therapeutic options for targeting drug-resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyvHIT2KWY7Vg90H21EOLACvtfcHk0lhwPhTmRRcLDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM&md5=9d8771e7444fa58f06dff284f6f393da</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00381%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Dibenzodiazepinones%2520as%2520Allosteric%2520Mutant-Selective%2520EGFR%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1549%26epage%3D1553%26doi%3D10.1021%2Facsmedchemlett.9b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00848</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00848" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=240-249&issue=3&author=X.+Sunauthor=Y.+Rao&title=PROTACs+as+Potential+Therapeutic+Agents+for+Cancer+Drug+Resistance&doi=10.1021%2Facs.biochem.9b00848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance</span></div><div class="casAuthors">Sun, Xiuyun; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Cancer drug resistance has become the major problem facing current clin. treatment via different kinds of therapies.  Proteolysis targeting chimeras (PROTACs) as a novel and powerful strategy have attracted a great deal of attention both from academia and from industry for their sensitivity to drug-resistant targets relying on their unique characteristics compared to those of traditional inhibitors.  PROTACs exert their function by degrading the target protein instead of inhibiting targets.  Thus, different kinds of resistance could be conquered by PROTACs such as target mutation or overexpression.  Various resistant targets have been overcome by PROTACs, including AR, ER, BTK, BET, and BCR-ABL.  Though PROTACs have achieved some significant advances in combating drug resistance, more cases are needed to prove the efficiency of PROTACs in addressing the hurdle of resistance in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_hi9ENDVPLVg90H21EOLACvtfcHk0lhwPhTmRRcLDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP&md5=bb7d34974dcb22f73ce9ce60665c391f</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00848%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%2520as%2520Potential%2520Therapeutic%2520Agents%2520for%2520Cancer%2520Drug%2520Resistance%26jtitle%3DBiochemistry%26date%3D2020%26volume%3D59%26issue%3D3%26spage%3D240%26epage%3D249%26doi%3D10.1021%2Facs.biochem.9b00848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">When Kinases Meet PROTACs</span>. <i>Chin. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1002/cjoc.201800293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1002%2Fcjoc.201800293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Whs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=971-977&issue=10&author=L.+Tanauthor=N.+S.+Gray&title=When+Kinases+Meet+PROTACs&doi=10.1002%2Fcjoc.201800293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">When Kinases Meet PROTACs</span></div><div class="casAuthors">Tan, Li; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-977</span>CODEN:
                <span class="NLM_cas:coden">CJOCEV</span>;
        ISSN:<span class="NLM_cas:issn">1001-604X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Small mol. drugs targeting kinases have revolutionized treatment options for millions of patients worldwide, esp. in oncol.  These targeted treatments have less side effects because they inhibit a specific dysfunctional kinase usually with relatively narrow selectivity.  However, kinase inhibitors do have well-established liabilities, most prominently the emergence of drug resistance.  Moreover, the majority of kinases are multidomain and multifunctional proteins that in addn. to their enzymic activity have scaffolding and other roles, and inhibitors seldom address these alternative functions.  Recently, small mol. mediated targeted protein degrdn. emerged as a new pharmacol. strategy.  The majority of small mol. degraders are bispecific mols. called proteolysis targeting chimeras (PROTACs), and their mechanism of action is based on simultaneous recruitment of the target of interest and an E3 ligase, resulting in target polyubiquitination and eventual destruction by the proteasome.  Over the last couple of years, PROTAC strategy has been developed and validated for a range of targets, including kinases.  Here, we introduce the targeted protein degrdn. strategy, provide an overview of representative kinase PROTACs, and describe design rationales, efficacy and specificity.  We also discuss their potential advantages, as well as comment on some of the limitations of this emerging pharmacol. modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSq2mWe6GuL7Vg90H21EOLACvtfcHk0lgU0Zckn1DgUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Whs7nO&md5=62bdc9ad20001b4f9a2167bc695757fe</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fcjoc.201800293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcjoc.201800293%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DWhen%2520Kinases%2520Meet%2520PROTACs%26jtitle%3DChin.%2520J.%2520Chem.%26date%3D2018%26volume%3D36%26issue%3D10%26spage%3D971%26epage%3D977%26doi%3D10.1002%2Fcjoc.201800293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTAC-Induced BTK Degradation as a Novel Ttherapy for Mutated BTK C481S Induced Ibrutinib-Resistant B-cell Malignancies</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1038/s41422-018-0055-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41422-018-0055-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=29875397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ektbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=779-781&issue=7&author=Y.+Sunauthor=X.+Zhaoauthor=N.+Dingauthor=H.+Gaoauthor=Y.+Wuauthor=Y.+Yangauthor=M.+Zhaoauthor=J.+Hwangauthor=Y.+Songauthor=W.+Liuauthor=Y.+Rao&title=PROTAC-Induced+BTK+Degradation+as+a+Novel+Ttherapy+for+Mutated+BTK+C481S+Induced+Ibrutinib-Resistant+B-cell+Malignancies&doi=10.1038%2Fs41422-018-0055-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies</span></div><div class="casAuthors">Sun, Yonghui; Zhao, Xingwang; Ding, Ning; Gao, Hongying; Wu, Yue; Yang, Yiqing; Zhao, Meng; Hwang, Jinseok; Song, Yuqin; Liu, Wanli; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-781</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In this study, for the first time, we report the development of BTK-targeting degraders using the PROTAC strategy.  These PROTACs could ef fi ciently degrade ibrutinib-sensitive BTK-WT (wild type).  More importantly, our newly designed PROTACs also significantly induced the degrdn. of ibrutinib resistant BTK-C481S (50% degrdn. efficiency at 30 nM).  Furthermore, our PROTAC mols. ef fi ciently inhibited cell proliferation and colony formation, while exhibited no obvious inhibition (>1000 nM) of ITK, EGFR, and TEC, which are major off-targets of ibrutinib.  These data demonstrate the strong potential for developing PROTAC-based therapeutic mols.  The results indicate that the PROTAC strategy (protein degrdn. instead of inhibition) could be adopted as a general and powerful therapeutic treatment for drug-resistant cancers in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_FLdaUP_HLVg90H21EOLACvtfcHk0lgU0Zckn1DgUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ektbzO&md5=1cca51ac76ecb3b491da0117b21271fb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fs41422-018-0055-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-018-0055-1%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTAC-Induced%2520BTK%2520Degradation%2520as%2520a%2520Novel%2520Ttherapy%2520for%2520Mutated%2520BTK%2520C481S%2520Induced%2520Ibrutinib-Resistant%2520B-cell%2520Malignancies%26jtitle%3DCell%2520Res.%26date%3D2018%26volume%3D28%26issue%3D7%26spage%3D779%26epage%3D781%26doi%3D10.1038%2Fs41422-018-0055-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Degradation of Bruton’s Tyrosine Kinase Mutants by PROTACs for Potential Treatment of Ibrutinib-Resistant non-Hodgkin Lymphomas</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2105</span>– <span class="NLM_lpage">2110</span>, <span class="refDoi"> DOI: 10.1038/s41375-019-0440-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41375-019-0440-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30858551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=2105-2110&issue=8&author=Y.+Sunauthor=N.+Dingauthor=Y.+Songauthor=Z.+Yangauthor=W.+Liuauthor=J.+Zhuauthor=Y.+Rao&title=Degradation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Mutants+by+PROTACs+for+Potential+Treatment+of+Ibrutinib-Resistant+non-Hodgkin+Lymphomas&doi=10.1038%2Fs41375-019-0440-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas</span></div><div class="casAuthors">Sun Yonghui; Yang Zimo; Rao Yu; Ding Ning; Song Yuqin; Zhu Jun; Liu Wanli</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2105-2110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF-dfST00W0BcfW6udTcc2ebH84UdTxJD8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D&md5=9d58ea99a2e3c695ee226e78431fce91</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41375-019-0440-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-019-0440-x%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDegradation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Mutants%2520by%2520PROTACs%2520for%2520Potential%2520Treatment%2520of%2520Ibrutinib-Resistant%2520non-Hodgkin%2520Lymphomas%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26issue%3D8%26spage%3D2105%26epage%3D2110%26doi%3D10.1038%2Fs41375-019-0440-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">3564</span>– <span class="NLM_lpage">3575</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3564-3575&issue=26&author=A.+D.+Buhimschiauthor=H.+A.+Armstrongauthor=M.+Toureauthor=S.+Jaime-Figueroaauthor=T.+L.+Chenauthor=A.+M.+Lehmanauthor=J.+A.+Woyachauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=C.+M.+Crews&title=Targeting+the+C481S+Ibrutinib-Resistance+Mutation+in+Bruton%E2%80%99s+Tyrosine+Kinase+Using+PROTAC-Mediated+Degradation&doi=10.1021%2Facs.biochem.8b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation</span></div><div class="casAuthors">Buhimschi, Alexandru D.; Armstrong, Haley A.; Toure, Momar; Jaime-Figueroa, Saul; Chen, Timothy L.; Lehman, Amy M.; Woyach, Jennifer A.; Johnson, Amy J.; Byrd, John C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3564-3575</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies.  Yet, more than 80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S).  Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist and these patients have poor outcomes.  To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degrdn. of both wild-type and C481S mutant BTK.  We selected a lead PROTAC, MT-802, from several candidates based on its potency to induce BTK knockdown.  MT-802 recruits BTK to the cereblon (CRBN) E3 ubiquitin ligase complex to trigger BTK ubiquitination and degrdn. via the proteasome.  MT-802 binds fewer off-target kinases than ibrutinib and retains equiv. potency (>99% degrdn. at nanomolar concns.) against wild-type and C481S BTK.  In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot.  Collectively, these data provide basis for further preclin. study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-ls5ps9FaLVg90H21EOLACvtfcHk0lh_c6IKeRSibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO&md5=bd27f09d041413c7bacb6d61fcb9a327</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00391%26sid%3Dliteratum%253Aachs%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DArmstrong%26aufirst%3DH.%2BA.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%2BL.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeting%2520the%2520C481S%2520Ibrutinib-Resistance%2520Mutation%2520in%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Using%2520PROTAC-Mediated%2520Degradation%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26issue%3D26%26spage%3D3564%26epage%3D3575%26doi%3D10.1021%2Facs.biochem.8b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-07-862953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1182%2Fblood-2018-07-862953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=30545835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlGjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2019&pages=952-961&issue=9&author=D.+Dobrovolskyauthor=E.+S.+Wangauthor=S.+Morrowauthor=C.+Leahyauthor=T.+Faustauthor=R.+P.+Nowakauthor=K.+A.+Donovanauthor=G.+Yangauthor=Z.+Liauthor=E.+S.+Fischerauthor=S.+P.+Treonauthor=D.+M.+Weinstockauthor=N.+S.+Gray&title=Bruton+Tyrosine+Kinase+Degradation+as+a+Therapeutic+Strategy+for+Cancer&doi=10.1182%2Fblood-2018-07-862953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase degradation as a therapeutic strategy for cancer</span></div><div class="casAuthors">Dobrovolsky, Dennis; Wang, Eric S.; Morrow, Sara; Leahy, Catharine; Faust, Tyler; Nowak, Radoslaw P.; Donovan, Katherine A.; Yang, Guang; Li, Zhengnian; Fischer, Eric S.; Treon, Steven P.; Weinstock, David M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">952-961</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies.  However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.  We hypothesized that small-mol.-induced BTK degrdn. may overcome some of the limitations of traditional enzymic inhibitors.  Here, we demonstrate that BTK degrdn. results in potent suppression of signaling and proliferation in cancer cells and that BTK degraders efficiently degrade C481S-BTK.  Moreover, we discovered DD-03-171, an optimized lead compd. that exhibits enhanced antiproliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading BTK, IKFZ1, and IKFZ3 as well as efficacy against patient-derived xenografts in vivo.  Thus, "triple degrdn." may be an effective therapeutic approach for treating MCL and overcoming ibrutinib resistance, thereby addressing a major unmet need in the treatment of MCL and other B-cell lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN4GLppunGArVg90H21EOLACvtfcHk0lh_c6IKeRSibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlGjtrY%253D&md5=ce7e48897378c2821d728daf6d9935d5</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-07-862953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-07-862953%26sid%3Dliteratum%253Aachs%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DMorrow%26aufirst%3DS.%26aulast%3DLeahy%26aufirst%3DC.%26aulast%3DFaust%26aufirst%3DT.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Degradation%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Cancer%26jtitle%3DBlood%26date%3D2019%26volume%3D133%26issue%3D9%26spage%3D952%26epage%3D961%26doi%3D10.1182%2Fblood-2018-07-862953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk Inhibition Suppresses B Cell- and Myeloid Cell-Mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&issue=1&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+Inhibition+Suppresses+B+Cell-+and+Myeloid+Cell-Mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0li1cTN10o0m_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520and%2520Myeloid%2520Cell-Mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26issue%3D1%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9281</span>– <span class="NLM_lpage">9298</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01264</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVantrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9281-9298&issue=20&author=Q.+Zhaoauthor=C.+Renauthor=L.+Liuauthor=J.+Chenauthor=Y.+Shaoauthor=N.+Sunauthor=R.+Sunauthor=Y.+Kongauthor=X.+Dingauthor=X.+Zhangauthor=Y.+Xuauthor=B.+Yangauthor=Q.+Yinauthor=X.+Yangauthor=B.+Jiang&title=Discovery+of+SIAIS178+as+an+Effective+BCR-ABL+Degrader+by+Recruiting+Von+Hippel-Lindau+%28VHL%29+E3+Ubiquitin+Ligase&doi=10.1021%2Facs.jmedchem.9b01264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase</span></div><div class="casAuthors">Zhao, Quanju; Ren, Chaowei; Liu, Linyi; Chen, Jinju; Shao, Yubao; Sun, Ning; Sun, Renhong; Kong, Ying; Ding, Xinyu; Zhang, Xianfang; Xu, Youwei; Yang, Bei; Yin, Qianqian; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9281-9298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oncogenic fusion protein BCR-ABL is the driving force of leukemogenesis in chronic myeloid leukemia (CML).  Despite great progress for CML treatment through application of tyrosine kinase inhibitors (TKIs) against BCR-ABL, long-term drug administration and clin. resistance continue to be an issue.  Herein, we described the design, synthesis, and evaluation of novel proteolysis-targeting chimeric (PROTAC) small mols. targeting BCR-ABL which connect dasatinib and VHL E3 ubiquitin ligase ligand by extensive optimization of linkers.  Our efforts have yielded SIAIS178 (19), which induces proper interaction between BCR-ABL and VHL ligase leading to effective degrdn. of BCR-ABL protein, achieves significant growth inhibition of BCR-ABL+ leukemic cells in vitro, and induces substantial tumor regression against K562 xenograft tumors in vivo.  In addn., SIAIS178 also degrades several clin. relevant resistance-conferring mutations.  Our data indicate that SIAIS178 as efficacious BCR-ABL degrader warrants extensive further investigation for the treatment of BCR-ABL+ leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLBFfujSx6ZbVg90H21EOLACvtfcHk0li1cTN10o0m_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVantrnN&md5=50ace274dbc6ef3931f86504a1be93a7</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01264%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520SIAIS178%2520as%2520an%2520Effective%2520BCR-ABL%2520Degrader%2520by%2520Recruiting%2520Von%2520Hippel-Lindau%2520%2528VHL%2529%2520E3%2520Ubiquitin%2520Ligase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D20%26spage%3D9281%26epage%3D9298%26doi%3D10.1021%2Facs.jmedchem.9b01264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs: Great Opportunities for Academia and Industry</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">64</span>, <span class="refDoi"> DOI: 10.1038/s41392-019-0101-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41392-019-0101-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31885879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=64&author=X.+Sunauthor=H.+Gaoauthor=Y.+Yangauthor=M.+Heauthor=Y.+Wuauthor=Y.+Songauthor=Y.+Tongauthor=Y.+Rao&title=PROTACs%3A+Great+Opportunities+for+Academia+and+Industry&doi=10.1038%2Fs41392-019-0101-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: great opportunities for academia and industry</span></div><div class="casAuthors">Sun Xiuyun; Gao Hongying; Yang Yiqing; He Ming; Wu Yue; Song Yugang; Tong Yan; Rao Yu; Sun Xiuyun; Gao Hongying; Yang Yiqing; Rao Yu</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although many kinds of therapies are applied in the clinic, drug-resistance is a major and unavoidable problem.  Another disturbing statistic is the limited number of drug targets, which are presently only 20-25% of all protein targets that are currently being studied.  Moreover, the focus of current explorations of targets are their enzymatic functions, which ignores the functions from their scaffold moiety.  As a promising and appealing technology, PROteolysis TArgeting Chimeras (PROTACs) have attracted great attention both from academia and industry for finding available approaches to solve the above problems.  PROTACs regulate protein function by degrading target proteins instead of inhibiting them, providing more sensitivity to drug-resistant targets and a greater chance to affect the nonenzymatic functions.  PROTACs have been proven to show better selectivity compared to classic inhibitors.  PROTACs can be described as a chemical knockdown approach with rapidity and reversibility, which presents new and different biology compared to other gene editing tools by avoiding misinterpretations that arise from potential genetic compensation and/or spontaneous mutations.  PRTOACs have been widely explored throughout the world and have outperformed not only in cancer diseases, but also in immune disorders, viral infections and neurodegenerative diseases.  Although PROTACs present a very promising and powerful approach for crossing the hurdles of present drug discovery and tool development in biology, more efforts are needed to gain to get deeper insight into the efficacy and safety of PROTACs in the clinic.  More target binders and more E3 ligases applicable for developing PROTACs are waiting for exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQretvERU2xT-_Q9URG6Dx8fW6udTcc2eYHRaEv1S36dbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D&md5=7d9545a21e3a78cededf2977a31e8f7d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fs41392-019-0101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-019-0101-6%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%253A%2520Great%2520Opportunities%2520for%2520Academia%2520and%2520Industry%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2019%26volume%3D4%26spage%3D64%26doi%3D10.1038%2Fs41392-019-0101-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation: Expanding the Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&issue=12&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+Protein+Degradation%3A+Expanding+the+Toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0lh3do52xFQQ-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%253A%2520Expanding%2520the%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26issue%3D12%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leischner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illert, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bubnoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span> <span> </span><span class="NLM_article-title">The Secondary FLT3-ITD F691L Mutation Induces Resistance to AC220 in FLT3-ITD<sup>+</sup> AML But Retains in Vitro Sensitivity to PKC412 and Sunitinib</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1416</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1038%2Fleu.2013.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=23392356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1416-1418&issue=6&author=C.+Albersauthor=H.+Leischnerauthor=M.+Verbeekauthor=C.+Yuauthor=A.+L.+Illertauthor=C.+Peschelauthor=N.+von+Bubnoffauthor=J.+Duyster&title=The+Secondary+FLT3-ITD+F691L+Mutation+Induces+Resistance+to+AC220+in+FLT3-ITD%2B+AML+But+Retains+in+Vitro+Sensitivity+to+PKC412+and+Sunitinib&doi=10.1038%2Fleu.2013.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib</span></div><div class="casAuthors">Albers, C.; Leischner, H.; Verbeek, M.; Yu, C.; Illert, A. L.; Peschel, C.; von Bubnoff, N.; Duyster, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1416-1418</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This paper discusses a secondary FLT3 internal tandem duplication (FLT3-ITD) mutation in a 48-yr-old female patient with FLT3-ITD+ acute myeloid leukemia (AML) mediating resistance to the FLT3 inhibitor AC220 but retains in vitro sensitivity to PKC412 and sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR7iOLeeWO5bVg90H21EOLACvtfcHk0li4bWtDs9fK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFektb4%253D&md5=83b22218f5bac1e80c24f3fd60f35114</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.14%26sid%3Dliteratum%253Aachs%26aulast%3DAlbers%26aufirst%3DC.%26aulast%3DLeischner%26aufirst%3DH.%26aulast%3DVerbeek%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DThe%2520Secondary%2520FLT3-ITD%2520F691L%2520Mutation%2520Induces%2520Resistance%2520to%2520AC220%2520in%2520FLT3-ITD%252B%2520AML%2520But%2520Retains%2520in%2520Vitro%2520Sensitivity%2520to%2520PKC412%2520and%2520Sunitinib%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26issue%3D6%26spage%3D1416%26epage%3D1418%26doi%3D10.1038%2Fleu.2013.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koryotowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leversha, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMatteo, R. P.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4190</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&issue=11&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+Resistance+to+Imatinib+in+Gastrointestinal+Stromal+Tumor+Occurs+Through+Secondary+Gene+Mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0li4bWtDs9fK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520Resistance%2520to%2520Imatinib%2520in%2520Gastrointestinal%2520Stromal%2520Tumor%2520Occurs%2520Through%2520Secondary%2520Gene%2520Mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYY','PDB','2HYY'); return false;">PDB: 2HYY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3','PDB','3IK3'); return false;">PDB: 3IK3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ANS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ANS','PDB','4ANS'); return false;">PDB: 4ANS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLJ','PDB','4CLJ'); return false;">PDB: 4CLJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YNE','PDB','4YNE'); return false;">PDB: 4YNE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKC','PDB','4MKC'); return false;">PDB: 4MKC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MX8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MX8','PDB','6MX8'); return false;">PDB: 6MX8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5P','PDB','4G5P'); return false;">PDB: 4G5P</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY','PDB','2ITY'); return false;">PDB: 2ITY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E4F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E4F','PDB','6E4F'); return false;">PDB: 6E4F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI','PDB','5VFI'); return false;">PDB: 5VFI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J','PDB','5P9J'); return false;">PDB: 5P9J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B','PDB','6S9B'); return false;">PDB: 6S9B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FEE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FEE','PDB','5FEE'); return false;">PDB: 5FEE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D','PDB','6S9D'); return false;">PDB: 6S9D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JRJ','PDB','6JRJ'); return false;">PDB: 6JRJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MO4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MO4','PDB','5MO4'); return false;">PDB: 5MO4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DUK','PDB','6DUK'); return false;">PDB: 6DUK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i17"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00507">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_00186"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00507?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00507</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Approved SMKIs including chemical structures, targets, indications, companies, and registered years (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00507/suppl_file/jm0c00507_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00507/suppl_file/jm0c00507_si_001.pdf">jm0c00507_si_001.pdf (174.51 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00507&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00507%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00507" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f6573fd13d30","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
